<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.science.org/doi/10.1126/science.abm0811');</script>

        <script> var body_html = '<body > <div > <div > <div > <div > <div > <div > <div > <div > <div > <div > <span >Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header > <div ><div ><div ><div ><div ><div ><div ><a ><div >science</div></a></div></div><div ><div ><a ><div >science advances</div></a></div></div><div ><div ><a ><div >science immunology</div></a></div></div><div ><div ><a ><div >science robotics</div></a></div></div><div ><div ><a ><div >science signaling</div></a></div></div><div ><div ><a ><div >science translational medicine</div></a></div></div><div ><div ><a ><div >science partner journals</div></a></div></div></div></div></div></div></div> <div > <div > <div > <div > <div ><div ><div ><label >Searching:</label><div ><div ><div >Anywhere<a >Science</a><a >Science Advances</a><a >Science Immunology</a><a >Science Robotics</a><a >Science Signaling</a><a >Science Translational Medicine</a></div></div></div></div><div > <a ><u>Advanced Search</u></a> </div></div></div> </div> </div> </div> <div > <div > <div > <h6 >Trending Terms:</h6> <ul > <li > <a >covid-19</a> </li> <li > <a >climate</a> </li> <li > <a >science policy</a> </li> <li > <a >genome editing</a> </li> <li > <a >batteries</a> </li> </ul> </div> </div> </div> </div> </header><div ><div ><div > <div > <div > <ul > <li > <a >Current Issue</a> </li> <li > <a >First release papers</a> </li> <li > <a >Archive</a> </li> <li > <div > <a >About</a> <div > <a >About Science</a> <a >Mission Scope</a> <a >Editors Advisory Boards</a> <a >Editorial Policies</a> <a >Information for Authors</a> <a >Information for Reviewers</a> <a >Journal Metrics</a> <a >Staff</a> <a >Contact Us</a> </div> </div> </li> </ul> </div> <div > <ul > <li > <a >Submit manuscript</a> </li> <li > <div > <a >More</a> </div> </li> </ul> </div> </div> <a >GET OUR E-ALERTS</a> </div></div></div> <main > <div ><div ><div ><div ><div > <div ><a >Home</a><a >Science</a><a >First Release</a>Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants</div><div >Back To First Release</div> </div> <article ><section ><header><div ><div ><div ><div >OPEN ACCESS</div><div >Research Article</div></div><div ><div > <div >Share on</div> </div></div></div><h1 >Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants</h1><div >Catherine J. Reynolds https://orcid.org/0000-0002-1371-653X, Joseph M. Gibbons https://orcid.org/0000-0002-7238-2381, Corinna Pade https://orcid.org/0000-0003-0626-2346, Kai-Min Lin https://orcid.org/0000-0003-2109-1530, Diana Munoz Sandoval https://orcid.org/0000-0001-8350-3989, Franziska Pieper https://orcid.org/0000-0002-4857-0518, David K. Butler https://orcid.org/0000-0003-1882-8159, … Show All … , Siyi Liu https://orcid.org/0000-0003-0206-9661, Ashley D. Otter https://orcid.org/0000-0002-8317-9194, George Joy https://orcid.org/0000-0003-1467-5490, Katia Menacho https://orcid.org/0000-0001-5183-5655, Marianna Fontana https://orcid.org/0000-0002-9233-9831, Angelique Smit https://orcid.org/0000-0002-2144-1249, Beatrix Kele https://orcid.org/0000-0003-1273-7299, Teresa Cutino-Moguel https://orcid.org/0000-0002-1726-4278, Mala K. Maini https://orcid.org/0000-0001-6384-1462, Mahdad Noursadeghi https://orcid.org/0000-0002-4774-0853, COVIDsortium Immune Correlates Network‡, Tim Brooks https://orcid.org/0000-0002-3783-1284, Amanda Semper https://orcid.org/0000-0003-3656-1363, Charlotte Manisty https://orcid.org/0000-0003-0245-7090, Thomas A. Treibel https://orcid.org/0000-0003-1560-7414, James C. Moon https://orcid.org/0000-0001-8071-1491, Áine McKnight https://orcid.org/0000-0002-8113-817X, Daniel M. Altmann https://orcid.org/0000-0002-2436-6192, and Rosemary J. Boyton https://orcid.org/0000-0002-5608-0797 [email protected] Show Fewer</div><div >Science • 2 Dec 2021 • First Release • DOI: 10.1126/science.abm0811</div><div ><div > <div > <a ><div ><div ><h6>PREVIOUS ARTICLE</h6><div>Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain</div></div></div>Previous</a><a ><div ><div ><h6>NEXT ARTICLE</h6><div>Visualizing broken symmetry and topological defects in a quantum Hall ferromagnet</div></div></div>Next</a> </div> </div></div></div></header><div ><div ><section ><h2 >Abstract</h2><div >The impact of initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOC) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection+two vaccine doses), S1 antibody, memory B cells and heterologous neutralization of B.1.351, P.1 and B.1.617.2 plateaued, while B.1.1.7 neutralization and spike T cell responses increased. Serology using Wuhan Hu-1 spike receptor binding domain poorly predicted neutralizing immunity against VOCs. Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over 5-months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.</div></section></div></div></section><section ><div ><div >After experiencing &gt;18 months of the COVID-19 pandemic, immunological analysis has shifted to issues of response durability, boosting, and mitigation against future variants of concern (VOC). In doing so we confront viral and population heterogeneities that affect immunity and future protection (<a ><i>1</i></a>–<a ><i>4</i></a>). Individuals are either immunologically naïve to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or have been infected with either the original Wuhan Hu-1 strain or one of the alpha to delta variants of concern (VOC; which we will refer to by full Pango lineage terms). Infection-naïve individuals, those infected by ancestral SARS-CoV-2 Wuhan Hu-1 or a VOC may have received different numbers of vaccine doses. Thus, there is a spectrum of individuals spanning the immunologically naïve to those who have experienced one, two, three exposures (and four with boosting) to homologous or heterologous spike sequences. The challenge is to understand whether different antigen exposure combinations are associated with the same quality, quantity and durability of immunity, and ability to cross-protect against other VOCs.</div><div >Using a cohort of UK healthcare workers (HCW) for which we have extensive, longitudinal, clinical, transcriptomic, and immunologic characterization (<a ><i>5</i></a>–<a ><i>10</i></a>)<i>,</i> we address these questions by immunological comparison of BNT162b2 (Pfizer-BioNTech vaccine) vaccinees, with or without infection. We and others have shown the boosting effect of prior infection by the Wuhan Hu-1 strain on the response to vaccination with homologous spike (<a ><i>8</i></a>, <a ><i>9</i></a>, <a ><i>11</i></a>–<a ><i>14</i></a>), and others are decoding changes in immune programming between first and second dose (<a ><i>15</i></a>)<i>.</i> We compared the impact of prior infection with Wuhan Hu-1 or B.1.1.7. (alpha VOC) in the context of vaccination on T and memory B cell (MBC) responses, cross-neutralization against VOC, durability of immunity and susceptibility to B.1.617.2 (delta VOC) breakthrough infection. We considered the extent to which first encounter with spike sequence shapes subsequent response features to explore the possible effect of immune imprinting or ‘original antigenic sin’ (<a ><i>16</i></a>–<a ><i>18</i></a>).</div><section ><h2>B and T cell immunity after three homologous antigen exposures</h2><div >We analyzed this longitudinal vaccine cohort (<i>n</i> = 51) at 20d (interquartile range, IQR 7) after receiving a second BNT162b2 dose (fig. S1 and table S1). Twenty-five HCW were infected with SARS-CoV-2 approximately synchronous and coincident with peak transmission in London in March 2020 (6). At one year, nucleoprotein (N) antibody (Ab) responses had waned but were still positive (anti-N Ab expressed as a cut-off index of ≥1.0 were classified as positive), 16% having fallen to sub-threshold levels (<a >Fig. 1A</a>). Two (2/25, 8%) HCW appeared to have been reinfected (increase in N) and two (2/26, 8%) newly infected (positive N having been previously negative) among the previously uninfected cohort (<a >Fig. 1A</a>). T cell responses to N were sustained at 1 year in the majority of prior infected individuals (22/24, 92%) (fig. S2). All prior infected HCW with positive anti-S1 receptor binding domain (RBD) responses at 16-18 weeks had sustained responses at 28-30 weeks (22/24, 92%), which substantially enhanced following single dose vaccination (36-fold increase in Ab titer) (<a >Fig. 1B</a>). This response plateaued (only increased a further 1.4-fold) following second dose vaccination (third antigen exposure). The prior infected HCW (2/24, 8%) with unrecordable anti-S1 RBD responses at 16-18 and 28-30 weeks showed a 155-fold increase anti-S1 response following second dose vaccination, demonstrating the benefit of a third antigen exposure in poor Ab responders (<a ><i>19</i></a>, <a ><i>20</i></a>)<i>.</i> Infection-naïve HCW made incrementally increased Ab responses following first and second dose vaccination, achieving about half the Ab titer of their previously infected counterparts 20 days after second vaccine dose (<a >Fig. 1B</a>).</div><div >T cell responses to spike mapped epitope peptide (MEP) pool (table S2) increased following second dose vaccination in prior infected individuals (i.e., third exposure to antigen) (<i>P</i> = 0.0294; <a >Fig. 1C</a>). T cell responses following two dose vaccination in infection-naïve HCW achieved similar levels to those seen at 16-18 weeks after natural SARS-CoV-2 infection. However, there were fewer non-responders (2/23, 9%) in double vaccinated infection-naïve individuals compared with (5/25, 20%) 16-18 weeks after natural infection.</div><div >Infection-naïve individuals showed incremental increases in neutralizing Ab (nAb) to authentic Wuhan Hu-1 virus and VOCs following first and second vaccination, the largest fold increase occurring after the second vaccine dose (Wuhan Hu-1,123-fold; B.1.1.7, 589-fold; B.1.351, 445-fold; P.1, 1765-fold; and B.1.617.2, 39-fold increase). There was a wider heterogeneity of nAb response to B.1.351, P.1 and B.1.617.2 VOCs compared to B.1.1.7 and Wuhan Hu-1 (<a >Fig. 1D</a>). Individuals who had experienced SARS-CoV-2 infection prior to vaccination also showed the largest fold nAb increase on second antigen exposure (i.e., after first vaccine dose) (Wuhan Hu-1, 27-fold; B.1.1.7, 52-fold; B.1.351, 65-fold; P.1, 63-fold; and B.1.617.2, 20-fold increase) (<a >Fig. 1E</a>). In contrast, nAb responses against Wuhan Hu-1 and VOCs B.1.351, P.1 and B.1.617.2 plateaued or decreased between the second and third antigen exposure. This was not the case for nAb responses against Wuhan Hu-1 and B.1.1.7, which increased 6-fold and 23-fold respectively between the second and third antigen exposure (<a >Fig. 1E</a>). The potency of nAb response after third antigen exposure varied depending on the VOC being neutralized. Prior infected HCW who made a low nAb IC50 after the first vaccine dose caught up following the second vaccine dose (i.e., third antigen exposure). Heterologous neutralizing IC50s were lower than those against homologous Wuhan Hu-1 and at risk of falling below a threshold for protection as levels wane (<a ><i>21</i></a>, <a ><i>22</i></a>) (1F, S3).</div><div >There was a positive correlation between S1 RBD binding Ab and neutralization (IC50), with previously infected individuals showing higher nAb IC50 and S1 RBD binding (<a >Fig. 1G</a>). Wuhan-Hu-1 sequence specific S1 RBD binding correlated less well with nAb IC50 against VOCs B.1.351, P.1 and B.1.617.2, especially for infection-naïve, double vaccinated HCW. To establish if this was due to different sequences in the VOC RBD, the relationship between VOC RBD binding titers and neutralization was explored. There was positive correlation between the Roche S1 RBD and VOC RBD specific binding (fig. S4). The weaker correlations between VOC nAb titers and VOC RBD binding indicate that antibodies targeting regions outside of RBD may contribute to neutralization and therefore the binding titer is not predictive of neutralization (<a >Fig. 1H</a>). For example, a two-dose vaccinated HCW with an S1 RBD (Wuhan Hu-1) binding titer of 2950 U/ml, considered strongly positive, showed divergent neutralization of VOCs, with IC50s of: Wuhan Hu-1, 6,071, B.1.1.7, 1,037; B.1.351, 301; P.1, 560 and B.1.617.2 zero 20d after second dose vaccination that all fell to undetectable 18 weeks later. This individual was later infected by B.1.617.2. Thus, S1 serology data using the Wuhan Hu-1 S1 RBD and VOC sequence is an unreliable marker for neutralization potency against VOCs.</div><div >For infection-naïve subjects, frequency of S1 specific MBC 20d after first-dose vaccination was lower compared to 16-18 weeks after infection. On the other hand, MBCs were amplified in previously infected HCWs to a level similar to that seen following two doses of vaccine (<a >Fig. 1I</a>). As expected from the S1 RBD binding Ab and nAb responses, MBC responses plateaued, with no further enhancement following a third antigen exposure (i.e., double vaccinated previously infected HCW) (<a >Fig. 1, I and J</a>). For infection-naïve HCW, the MBC frequency for specificity to S1 containing the N501Y, E484K and K417N B.1.351 mutations was lower after one vaccine dose (<a >Fig. 1K</a>, left panel). After two (two dose vaccination or single dose vaccination and prior infection) or three antigen exposures (two dose vaccination and prior infection), the MBC response is maintained whether stimulated by S1 or S1 containing mutations found in B.1.351 and B.1.617.2 (<a >Fig. 1K</a>, middle and right panels). There was a high frequency of MBC able to recognize S1 and S1 containing VOC specific mutations, but not always correlated well with a VOC specific nAb response (fig. S5). Authentic P.1 (<i>r</i> = 0.529, <i>P</i> = 0.0138) and B.1.617.2 (<i>r</i> = 0.548, <i>P</i> = 0.001) nAb responses of double vaccinated HCW with and without prior Wuhan Hu-1 infection positively correlated with the MBC frequency against S1 containing the B.1.617.2 specific mutations (fig. S5C).</div><div >Next, we examined the T cell response against VOCs B.1.1.7, B.1.351, P.1, B.1.617.2 peptide pools and Wuhan Hu-1 matched pools and individual peptides with substituted epitopes covering N501Y and D1118H (table S2 and <a >Fig. 2, A and B</a>). T cell responses in doubly vaccinated, infection-naïve individuals were variable. Previously infected doubly vaccinated individuals showed a significantly increased T cell response to B.1.1.7 (<i>P</i> = 0.0153) and B.1.617.2 (<i>P</i> = 0.0283) peptide pools and N501Y (<i>P</i> = 0.0156) variant peptide compared to the respective Wuhan Hu-1 pools and peptide (<a >Fig. 2B</a>). A cumulative increase in T cell response to the Wuhan Hu-1 spike MEP pool was observed as the number of antigen exposures increased (one to two exposures, <i>P</i> = 0.0003; two to three exposures, <i>P</i> = 0.0294; <a >Fig. 2C</a>). There was a similarly increased T cell response to the B.1.1.7 variant peptide pool (one to two exposures, <i>P</i> = 0.0008; two to three exposures, <i>P</i> = 0.0004; <a >Fig. 2E</a>) depending on number of antigen exposures, indicating a heteroclitic response to variant peptides (<a ><i>23</i></a>) (<a >Fig. 2, D and E</a>).</div></section><section ><h2>VOC mutation alters T cell effector program</h2><div >Immunization of transgenic mice expressing human HLADRB1*0401 were used to see if any of the variant peptides behave as an altered peptide ligand (APL), eliciting a differential T cell program (<a ><i>9</i></a>). <i>In silico</i> analysis of P.1 variant peptides indicated that the majority are not predicted to bind to common HLAII alleles found in the UK population (table S3). The N501Y mutation is predicted to change from strong to weak binding to HLADRB1*0401. IFNγ T cell responses in mice primed with Wuhan-Hu-1 peptide pool were ablated for the 501Y variant peptide (found in the B.1.1.7, B.1.351 and P.1 VOCs (<a >Fig. 2F</a>) when presented by HLA-DRB1*0401 (<i>n</i> = 7, <i>P</i> = 0.006). Altered CD4 recognition of the N501Y mutation merits further attention as it is a frequent replacement among reported sequences, comprising a convergent mutational signature shared by alpha, beta and gamma lineages (<a ><i>24</i></a>–<a ><i>26</i></a>)<i>.</i> Thus far the lack of T cell responses to 501Y has been described in terms of absence of CD8 recognition (<a ><i>27</i></a>)<i>.</i> Our transcriptomic analysis showed an absence of immune effector response to the variant peptide, although induction of the regulatory T cell (Treg) transcription factor, FOXP3, did occur, indicating that the variant peptide may exert an APL effect on T cell function, switching from effector to regulatory (<a >Fig. 2G</a>). This was further confirmed by qPCR for IRF4 and by CD4 expression of FoxP3 protein, indicating that mutant epitopes may subvert T cell activation into a regulatory program (<a >Fig. 2, G to I</a>).</div><div >Mice were primed with either B.1.617.2 or Wuhan Hu-1 matched specific peptide pools. In each case, T cells responded on challenge to the pool with which they were primed and not to the heterologous panel (<i>P</i> = 0.0022; <a >Fig. 2J</a>). That is, the T cell repertoire distinguishes VOC mutations, specifically recognizing the B.1.617.2 epitopes. <i>In silico</i> analysis of the B.1.617.2 variant peptides indicated that the majority are predicted to bind one or more of the common HLAII alleles found in the UK population (table S4). The D950N mutation is predicted to change from HLADRB1*0401 binding from weak to strong. T cell responses after priming with B.1.617.2 peptide pool were present for the D950N variant peptide, but not after priming with the Wuhan Hu-1 pool (<i>P</i> = 0.0022; <a >Fig. 2J</a>).</div></section><section ><h2>Heterologous B.1.1.7 infection shapes subsequent immunity</h2><div >We then looked at the impact of infection with B.1.1.7 during the second wave on immune responses in individuals given vaccine expressing Wuhan Hu-1 spike. For this part of the study, an additional 358 HCWs were followed up at 55-57 weeks after recruitment into the study (fig. S1). Of these, 63 had been infected with SARS-CoV-2 during the first Wuhan Hu-1 wave. Fifty-three of previously uninfected HCW (53/296, 18%) were identified by virtue of longitudinal N serology (from baseline to 16-18, 28-30, 42, 54, and 55-57 weeks) as having been newly infected during the B.1.1.7 s wave. Thirty-six (68%) were doubly vaccinated and eight (15%) unvaccinated at the time of follow up (fig. S1 and tables S5 and S6). Five previously infected HCW were reinfected (5/63, 8%) during the second wave. S1 IgG titers were measured at 55-57 weeks (fig. S6B). The median date of a positive SARS-CoV-2 PCR test was December 28<sup>th</sup>, 2020 (IQR, 22d). The B.1.1.7 VOC accounted for 94.7% of SARS-CoV-2 infections in central London in the two weeks leading up to January 2<sup>nd</sup>, 202 (<a ><i>28</i></a>); we thus made the starting assumption that for the majority of HCW infected during the second wave, the infecting strain was B.1.1.7. To support this, we compared the Wuhan Hu-1 and B.1.1.7 nAb IC50 results for unvaccinated (<i>n</i> = 24 and 8), single dose (<i>n</i> = 25 and 9), and two dose vaccinated (<i>n</i> = 24 and 34), HCW infected during the first and second UK waves by Wuhan Hu-1 and B.1.1.7 respectively (fig. S7). In unvaccinated HCWs, those infected during the first wave (fig. S7A, LHS) made nAb IC50 responses against Wuhan Hu-1, but negligible or no nAb IC50 response against B.1.1.7 (<i>P</i> &lt; 0.0001). In contrast, HCW infected as B.1.1.7 peaked (fig. S7A, RHS) made similar nAb IC50 against B.1.1.7 and Wuhan Hu-1 live virus. In Wuhan Hu-1 infected HCW, the Wuhan Hu-1 and B.1.1.7 nAb IC50 increased and remained significantly different after one (<i>P</i> &lt; 0.0001) and two (<i>P</i> &lt; 0.0001) dose vaccination, but the differential between them decreased (<a >Fig. 3F</a> and fig. S7, B and C).</div><div >We set out to investigate the impact of heterologous antigen exposure with B.1.1.7. A confounder in assessing comparative post-vaccination immunity between first wave (Wuhan-Hu-1) infected and second wave (B.1.1.7) infected HCW is that they differ with respect to the infecting strain and in the time interval between infection and vaccination. We hypothesized that observed differences in immunity may relate to recall differences between heterologous spike sequences – immune imprinting (<a ><i>16</i></a>–<a ><i>18</i></a>), and/or to differences in affinity maturation of the Ab repertoire with time from initial infection. Somatic hypermutation and breadth of neutralizing response is known to improve with time from infection (<a ><i>29</i></a>–<a ><i>31</i></a>), but also, there may be intrinsic differences between the breadth and hierarchy of neutralizing responses primed by different variants (<a ><i>32</i></a>). We initially compared nAb profiles for neutralization of Wuhan Hu-1 and VOC alpha to delta at a similar number of weeks after PCR confirmed SARS-CoV-2 infection with Wuhan Hu-1 during the first wave and B.1.1.7 during the second wave (all HCW unvaccinated). This data supports the contention that there are qualitatively and quantitatively differential patterns, even matching for timepoint (fig. S9).</div><div >After a single vaccine dose, infection-naïve HCW made a similar S1 RBD response to that seen in infection with B.1.1.7. Those HCW that were infected by Wuhan Hu-1 12 months earlier made a 3.9-fold higher S1-RBD response than those infected more recently by the B.1.1.7 variant (<i>P</i> = 0.004; <a >Fig. 3A</a>). After two vaccine doses, HCW infected during March 2020 by Wuhan Hu-1 (<i>n</i> = 70), having had three homologous antigen exposures, made a 1.5-fold higher S1-RBD response than those encountering three antigen exposures, with one of these being heterologous B.1.1.7 (<i>n</i> = 36, <i>P</i> = 0.0188; <a >Fig. 3A</a>). The B.1.1.7 infected two dose vaccinated HCW made a similar S1-RBD response to two-dose infection-naïve vaccinees. Infection-naïve vacccinees made a 1.8-fold lower response compared to the Wuhan Hu-1 prior infected group (<i>n</i> = 241, <i>P</i> &lt; 0.0001; <a >Fig. 3A</a>). The indication is that the phenomenon of enhanced vaccine responses by infection, which has been reproducibly described by us and others (<a ><i>8</i></a>, <a ><i>9</i></a>, <a ><i>11</i></a>–<a ><i>14</i></a>), is less effective if the infection involves heterologous spike from a VOC.</div><div >After two vaccine doses, individuals infected during the Wuhan Hu-1 wave made a higher T cell response to the B.1.1.7 peptide pool than those infected during the B.1.1.7 wave (<i>P</i> = 0.0412), arguing for stronger T cell priming in those with three homologous exposures (<a >Fig. 3, B to D</a>).</div><div >We next considered the effect of B.1.1.7 infection in single and double vaccination. In two dose vaccinated individuals, B.1.1.7 infection resulted in a different hierarchy of nAb IC50 responses against VOC compared to after Wuhan Hu-1 infection: Wuhan Hu-1&gt;B.1.1.7&gt;B.1.351&gt;P.1&gt;B.1.617.2. In the context of heterologous B.1.1.7 infection and two dose vaccination, the hierarchy changed to B.1.1.7&gt;Wuhan Hu-1&gt;B.1.617.2&gt;P.1&gt;B.1.351 (<a >Fig. 3, E and F</a>). This indicates a process of selective discriminative heterologous imprinting following exposure to B.1.1.7 infection (<a >Fig. 3, E and F</a>, and fig. S8). As predicted for immune imprinting by SARS-CoV-2 variants, first encounter imparts a differential subsequent pattern (<a ><i>16</i></a>–<a ><i>18</i></a>).</div><div >To better understand the relationship between differential nAb IC50 and S1 RBD binding we correlated the two. First we compared the impact of 2 homologous antigen exposures (either 2 dose vaccination [blue, infection-naive] or prior Wuhan Hu-1 infection followed by single-dose vaccination [red, Wuhan Hu-1]) to heterologous exposure through B.1.1.7 infection (single dose vaccination and B.1.1.7 infection [green, B.1.1.7]). Double dose vaccinated infection-naïve HCW (blue) achieved higher neutralization against authentic Wuhan Hu-1 live virus than those with heterologous infection by B.1.1.7 and single-dose vaccination (green) (<i>P</i> = 0.0036; <a >Fig. 3G</a> and fig. S10A). Individuals infected by B.1.1.7 and single-dose vaccinated (green) made higher nAb IC50 against B.1.1.7 compared to two dose infection-naïve HCW (<i>P</i> &lt; 0.0001) (blue) and Wuhan Hu-1 prior infected single-dose vaccinated HCW (<i>P</i> &lt; 0.0001) (red) (<a >Fig. 3G</a> and fig. S10A). Furthermore, neutralization IC50 of B.1.351 live virus was less potent following heterologous B.1.1.7 infection and single dose vaccination (green) (<i>P</i> = 0.0001; <a >Fig. 3G</a> and fig. S10A). Following 3 antigen encounters, the impact of heterologous exposure becomes more pronounced. HCW with heterologous infection with B.1.1.7 (green) rather than Wuhan Hu-1 (red) had substantially lower neutralization against authentic Wuhan Hu-1 (<i>P</i> &lt; 0.0001), B.1.351 (<i>P</i> &lt; 0.0001) and P.1 (<i>P</i> = 0.0616) live virus (fig. S10B). Furthermore, double vaccinated HCW with a history of heterologous infection by B.1.1.7 had lower nAb IC50 against B.1.351 than infection-naïve double vaccinated HCW (<i>P</i> = 0.0007; fig. S10B). In contrast, double dose vaccinated HCW with a history of heterologous infection with B.1.1.7 (green) had higher nAb IC50 against B.1.617.2 than infection-naïve double vaccinated HCW (<i>P</i> &lt; 0.0001; fig. S10B). Thus, neutralization potency achieved was dependent on number of antigen encounters and the presence or absence of heterologous exposure. Ab neutralization is a widely accepted correlate of protection (COP), estimated at a nAb IC50 of &gt;15, and S1 RBD binding an accessible and accepted marker of this (<a ><i>22</i></a>). Our data here show that S1 RBD and VOC S1 RBD titers are not a reliable COP for VOC, especially in the context of selective discriminative heterologous exposure during infection with B.1.1.7. In HCW with heterologous B.1.1.7 exposure, the nAb IC50 of B1.351 was significantly reduced (<i>P</i> &lt; 0.0001) and B.1.617.2 significantly increased (<i>P</i> = 0.0025) when compared to HCW with homologous Wuhan Hu-1 infection.</div></section><section ><h2>Differential longitudinal immunity after heterologous infection</h2><div >Next, we considered relative durability of immunity following 3 dose homologous (Wuhan Hu-1 infection plus vaccination) and heterologous (B.1.1.7 infection plus vaccination) antigen compared to two dose vaccinated infection-naïve individuals. S1 RBD Ab levels declined as the number of weeks post second dose increased in both infection-naïve (<i>r</i> = 0.545; <i>P</i> &lt; 0.0001) and prior infected (<i>r</i> = 0.537; <i>P</i> &lt; 0.0001) HCW (<a >Fig. 4, A and B</a>, and tables S1 and S5 to S9). Following a third vaccine dose the S1 RBD binding increased in all three groups to a similar level (<a >Fig. 4C</a>). B.1.1.7 infection (green circles) compared with Wuhan Hu-1 infection (red circles) was associated with lower nAb IC50 against Wuhan Hu-1 (<i>P</i> &lt; 0.0001) and B.1.351 (<i>P</i> &lt; 0.0001) VOC initially at (10d-8 weeks after vaccination) and P.1 (<i>P</i> = 0.0020) 8 weeks later (12-22 weeks after vaccination), indicating differential nAb responses over time depend on the VOC (<a >Fig. 4D</a>). Double vaccinated infection-naïve HCW were at a lower starting value for nAb IC50 against B.1.617.2 compared to B.1.1.7 (<i>P</i> &lt; 0.0001) and Wuhan Hu-1 (<i>P</i> = 0.0462) infected HCW (<a >Fig. 3H</a> and fig. S10B). The nAb IC50 against authentic Wuhan Hu-1 and all four VOC (B.1.1.7, B.1.351, P.1, and B.1.617.2) fell differentially depending on the VOC being neutralized and SARS-CoV-2 infection history (<a >Fig. 4E</a>).</div><div >In two dose vaccinated infection-naïve HCW, nAb IC50 against authentic Wuhan Hu-1 and all four of the VOCs fell significantly over 18 weeks (Wuhan Hu-1, 26-fold, <i>P</i> &lt; 0.0001; B.1.1.7, 18-fold, <i>P</i> &lt; 0.0001; B.1.351, 29-fold, <i>P</i> &lt; 0.0001; P.1. 26-fold, <i>P</i> &lt; 0.0001; B.1.617.2 233-fold, <i>P</i> &lt; 0.0001). This was most marked for B.1.617.2 live virus neutralization where by 21 weeks after the second dose it was zero for 21/27 (78%) of HCW tested (median 0, IQR 0, <i>n</i> = 27) (<a >Fig. 4E</a>). For two dose vaccinated prior Wuhan Hu-1 infected HCW, there was a significantly and less pronounced fall in nAb IC50 against authentic Wuhan Hu-1 and three of the VOCs over 18 weeks (Wuhan Hu-1, 5-fold, <i>P</i> = 0.0003; B.1.1.7, 7-fold, <i>P</i> &lt; 0.0001; B.1.351, 4-fold, <i>P</i> = 0.0042; P.1. 10-fold, <i>P</i> = 0.0003). By contrast, in the presence of heterologous infection with B.1.1.7 and two dose vaccination, nAb IC50 fell significantly over 18 weeks for some variants (Wuhan Hu-1, 6-fold, <i>P</i> = 0.0002; B.1.1.7 13-fold, <i>P</i> &lt; 0.0001; P.1 7-fold, <i>P</i> &lt; 0.0001; and B.1.617.2 41-fold, <i>P</i> &lt; 0.0001) while nAb IC50 against B.1.351 did not (<i>P</i> = 0.4304).</div><div >T cell responses against spike MEP pool 21 weeks after the second dose were higher in two dose vaccinated HCW that were infected with B.1.1.7 than two dose vaccinated infection-naïve HCW (<i>P</i> = 0.0304; <a >Fig. 4F</a>).</div><div >MBC frequencies against the Wuhan Hu-1 S1 and S1 containing the B.1.617.2 mutations were equivalent twenty-one weeks after second dose vaccination (<a >Fig. 4G</a>). Two dose vaccinated B.1.1.7 infected HCW made higher frequency responses against S1 containing the B.1.617.2 mutations than two dose vaccinated infection-naïve HCW (<i>P</i> = 0.0138; <a >Fig. 4H</a>). MBC frequencies in two dose vaccinated infection-naïve HCW fell over 18 weeks (<i>n</i> = 11, <i>P</i> = 0.0098) while those from Wuhan Hu-1 prior infected HCW were sustained (<i>n</i> = 4; <a >Fig. 4I</a>).</div></section><section ><h2>Immune parameters associated with B.1.617.2 breakthrough infection</h2><div >At the time of the 71-72 and 83-84 week recruitments B.1.617.2 VOC infections accounted for 97.8% and 99.9% of UK SARS-CoV-2 infections respectively (<a ><i>26</i></a>)<i>.</i> We identified 6/80 (8%) and 14/74 (19%) B.1.617.2 breakthrough infections in the double vaccinated HCW. Ten were previously infection-naïve, four had prior Wuhan Hu-1 infection and six were infected by B.1.1.7 (tables S8 and S10). PCR positive confirmed B.1.617.2 breakthrough infections occurred in the context of S1 RBD Ab levels ranging 1,110 to 29,308 U/ml (median = 9,010, IQR 13,650) 2-3 weeks after the second vaccine dose. We evaluated the S1 RBD, nAb, T cell and MBC data in these double vaccinated HCW before (purple circle) and after (lilac circle) their B.1.617.2 breakthrough infection (fig. S11, A to J). Analysis showed that both prior infected and infection-naïve HCW making S1 RBD Ab responses (20d post second dose) of over 1,100 U/ml had become infected and breakthrough infection was not specifically associated with being a low responder (fig. S11, A and B). Relatively potent nAb IC50 at 20d after second vaccine dose had fallen 12 weeks later. This fall was more pronounced in the infection-naïve double vaccinated HCW (fig. S11, D and E). For B.1.617.2 the nAb IC50 fell to zero in two dose vaccinated infection-naïve HCW (fig. S11, D and G). B.1.617.2 breakthrough infections have been linked to low nAb responses (<a ><i>33</i></a>). Current estimates for COP apply poorly in the case of B.1.617.2 (<a ><i>22</i></a>). In the cases reported here, breakthrough infections occurred in the face of good prior S1 RBD Ab titers, nAb IC50s and MBC frequency 20d after second vaccine dose, but responses fell in the subsequent 18 weeks especially in the infection naïve two dose vaccinated. Initial immune responses poorly predicted protection against B.1.617.2 breakthrough infection (fig. S11, A to J).</div></section><section ><h2>Discussion</h2><div >The new challenge in a world facing diverse VOC is to understand both cross-neutralization of these by first-generation spike vaccines, but also, how protective immunity is differentially shaped in those who have had infection by the different VOC (<a ><i>34</i></a>). These real-life issues of immune imprinting have implications for optimal design of second-generation variant spike vaccine boosters in parts of the world experiencing different VOCs, or in assessing heterogeneity in the quantity, quality, and durability of immune protection in those who have experienced different combinations of infecting and vaccinating sequences. Infection by B.1.1.7 had different features to Wuhan Hu-1 in terms of protection against VOC, evident in the response to infection and in the differential impact of vaccine-boosting previously described (<a ><i>8</i></a>, <a ><i>9</i></a>, <a ><i>11</i></a>–<a ><i>14</i></a>). Differential skewing of the immune repertoire may occur if the prime/boost is through B.1.1.7, since epitope modification at DY144 and N501Y changes the nAb repertoire (<a ><i>4</i></a>, <a ><i>35</i></a>). We found a differential hierarchy of cross-neutralization to VOC after natural infection, one or two vaccine doses, depending on the infecting strain. That different immune priming by B.1.1.7 is likely a consequence of heterologous virus per se and not of a shorter timespan for affinity maturation is supported by data from Israel, confirming that susceptibility grows with time and with declining Ab levels (<a ><i>36</i></a>). Vaccine programs currently use prototypic Wuhan Hu-1 sequence against a background of infection by different VOC predominating in different parts of the world. Decoding the differential breadth of VOC neutralizing response ensuing from diverse priming combinations will affect which variant spike sequences may best serve in second generation vaccines. This appears a more complex choice than simply opting for the most concerning variant at any given time. Since heterologous combinations can confer a diminished response against other variants, there may be a case for sticking with the Wuhan Hu-1 sequence in booster vaccinations in the first instance in the face of unknown future VOCs, or for improved efforts to define vaccines based on optimization of common, conserved, neutralizing epitopes (<a ><i>37</i></a>). In any case, the inference from this cohort is that populations infected during waves of different variants carry distinct immune memory, with implications for differential protection against future VOCs.</div></section><section ><h2>Methods summary</h2><div >Detailed materials and methods are reported in the supplementary materials. Recruitment of 731 HCW into the COVIDsortium cohort followed longitudinally with weekly self-reported symptom diaries, SARS-CoV-2 PCR, N and S1 RBD serology for 16-weeks from the start of the first UK wave has been described (<a ><i>5</i></a>–<a ><i>10</i></a>). This enabled a cross-sectional case controlled sub-study of 136 HCW recruited 16-18 weeks after the March 2020 UK lockdown that reported discordant neutralizing antibody and T cell responses in SARS-CoV-2 natural infection during the 1<sup>st</sup> wave (Wuhan Hu-1) (<a ><i>6</i></a>). A cross-sectional, case-controlled vaccine sub-study cohort of 51 HCW at 22d after first BNT162b2 dose described vaccine immunity in HCW with (<i>n</i> = 25) and without (<i>n</i> = 26) prior SARS-CoV-2 infection during the Wuhan Hu-1 wave (<a ><i>8</i></a>, <a ><i>9</i></a>). The current sub-study includes longitudinal follow-up of this previously published vaccine sub-study cohort (<i>n</i> = 51) at 20d (IQR, 7) after second BNT162b2 dose plus an additional 358 HCW, 53 of whom were infected with B.1.1.7 during the second UK wave. At 71-72 weeks, 80 2-dose vaccinated HCW were re-recruited 18-21 weeks after their second dose for longitudinal follow up of SARS-CoV-2 infection-naïve (<i>n</i> = 27) or prior-infected HCW infected during the Wuhan Hu-1 UK wave (<i>n</i> = 31) or the second B.1.1.7 UK wave (<i>n</i> = 22). At 83-84 weeks, 74 previously 2-dose vaccinated HCW were re-recruited 30-33 weeks after their second dose that were infection naïve (<i>n</i> = 30) or infected during the Wuhan Hu-1 (<i>n</i> = 18) or B.1.1.7 wave (<i>n</i> = 19). Sixty-seven (91%) were within a median of 18d (IQR, 12) after their third BNT162b2 dose. HCW with breakthrough infection by B.1.617.2 were identified by PCR and N serology. Peripheral blood mononuclear cells (PBMC) and serum samples were prepared and cryopreserved as previously described (<a ><i>6</i></a>, <a ><i>9</i></a>). Anti-nucleocapsid (COI ≥ 1.0, positive) and anti-spike antibody (≥0.8 U/ml, positive) detection Ab testing was conducted at UK Health Security Agency (UKHSA) using the Roche cobas<sup>®</sup>e801 analyser. Recombinant proteins were used in ELISAs looking at the VOC S1 RBD responses: SARS-CoV-2 Spike Glycoprotein (S1) RBD, SARS-CoV-2 (N501Y Mutant), (501Y.V2: K417N, E484K, N501Y), (B.1.1.28: K417T, E484K, N501Y) and (B.1.617.2: L452R, T478K) Spike Glycoprotein (S1) RBDs derived from Wuhan Hu-1, B.1.1.7, B.1.351, P.1 and B.1.617.2 VOC respectively. T cell experiments peptide panels included spike mapped epitope pool (MEP) comprised of a pool of eighteen 12-20mer peptide epitopes (<a ><i>6</i></a>, <a ><i>9</i></a>) and VOC pools contained peptides from the B.1.1.7, B.1.351, P.1 and B.1.617.2 sequences and their respective Wuhan Hu-1 sequence (table S2). IFNγ-T cell ELISpots and MBC ELISpots were performed as previously described (<a ><i>6</i></a>, <a ><i>9</i></a>). MBC ELISpot plates were coated with PBS, purified anti-human IgG MT91/145, SARS-CoV-2 S1 spike, E484K, K417N, N501Y spike or T19R, G142D, del 156-157, R158G, L452R, T478K, D614G, P681R spike. <i>In silico</i> predictions of HLA-DRB1/peptide-binding utilized NetMHCIIpan-4.0 (<a ><i>9</i></a>, <a ><i>38</i></a>, <a ><i>39</i></a>). Studies using HLAII transgenics (DRB1*0401) were performed as previously described (<a ><i>9</i></a>, <a ><i>40</i></a>, <a ><i>41</i></a>). For transcriptomic and flow cytometry analysis, mouse lymph node cells were cultured with no peptide, wild-type or variant N501Y peptides, then, at 24h, cells were harvested and lysed for RNA extraction or stained for flow cytometry. SARS-CoV-2 microneutralization assays were carried out as described previously using VeroE6 cells (<a ><i>6</i></a>, <a ><i>9</i></a>). Participant sera were incubated with 3x10<sup>4</sup> FFU SARS-CoV-2 (Wuhan Hu-1, B.1.1.7, B.1.351, P.1, or B.1617.2 isolates of SARS-CoV-2 live virus).</div></section><section ><h2>Acknowledgments</h2><div ><b>ACKNOWLEDGMENTS:</b> The authors thank HCW participants for participating in the study and the research teams involved in recruitment, obtaining consent, and sampling the HCW participants. The COVIDsortium Healthcare Workers bioresource is approved by the ethical committee of UK National Research Ethics Service (20/SC/0149) and registered on ClinicalTrials.gov (NCT04318314). The study conforms to the principles of the Helsinki Declaration, and all subjects provided written informed consent. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV Isolate EVA catalog code 026V-03883 was obtained from European Virus Archive Global. (EVAg), Charité - Universitätsmedizin Berlin. The SARS-CoV-2 B.1.1.7 isolate was obtained from NIBSC, thanks to the contribution of PHE Porton Down and Dr Simon Funnell. The nCoV19 isolate/UK ex South African/2021 lineage B.1.351 EVA catalog code 04V-04071 was obtained from EVAg, PHE Porton Down. P.1 and B.1.617.2 isolates were purchased from EVAg. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. <b>Funding</b>: RJB and DMA are supported by MRC (MR/S019553/1, MR/R02622X/1, MR/V036939/1, MR/W020610/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC (2019SRC015), NIHR EME Fast Track (NIHR134607), NIHR Long Covid (COV-LT2-0027), Innovate Uk (SBRI 10008614) and Horizon 2020 Marie Skłodowska-Curie Innovative Training Network (ITN) European Training Network (No 860325). ÁM is supported by MRC (MR/W020610/1), NIHR EME Fast Track (NIHR134607), Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomew’s Hospital Trust. The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Kenneth C Griffin, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with University College London and Queen Mary University of London. MKM is supported by UKRI/NIHR UK-CIC, Wellcome Trust Investigator Award (214191/Z/18/Z) and CRUK Immunology grant (26603). JCM, CM and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223​). TT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. <b>Author contributions:</b> R.J.B conceptualised and designed the study reported. R.J.B and D.M.A designed and supervised the T cell and B cell experiments. Á.M. designed and supervised the nAb experiments. T.B. and A.Se supervised S1 IgG and N IgG/IgM studies. D.MS., KM.L., F.P., and D.K.B. performed and analyzed T cell experiments. C.J.R. developed, performed and analyzed T cell, and memory B cell experiments. J.M.G. and C.P developed, performed and analyzed nAb experiments. A.D.O. performed and A.Se analyzed RBD and N antibody assays. T.B., C.M., Á.M., T.T., J.C.M., and M.N conceptualised and established the COVIDsortium HCW cohort. R.J.B, T.T., J.C.M., and C.M designed the vaccine sub-study cohort. G.J., K.M., M.F., A.S., C.M., T.A.T., and J.C.M. recruited HCW and collected samples. B.K. and T.C-M. helped with confirmation of sequence of viral isolates. C.J.R., D.MS., KM.L., F.P., S.L., and D.K.B. and COVIDsortium Investigators processed HCW samples. C.J.R., J.M.G., C.P., Á.M., D.M.A., and R.J.B. analyzed the data. C.J.R., J.M.G., C.P., C.M., T.T., J.C.M., M.K.M., A.Se., T.B., M.N., Á.M., D.M.A., and R.J.B. interpreted the data. R.J.B. and D.M.A wrote the manuscript with input from all the authors. All the authors reviewed and edited the manuscript and figures. <b>Competing interests:</b> R.J.B. and D.M.A. are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. <b>Data and materials availability:</b> All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV, B.1.351, P.1 and B.1.617.2 isolates were obtained under material agreements with European Virus Archive Global (EVAg), France. The SARS-CoV-2 B.1.1.7 isolate was obtained under a material agreement with the National Institute for Biological Standards and Control (NIBSC), UK. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section> </div></section><section ><div ><section ><h2>Supplementary Material</h2><section><h3>Summary</h3><div ><a >science.org/doi/10.1126/science.abm0811</a></div><div >Materials and Methods</div><div >Figs. S1 to S11</div><div >Tables S1 to S13</div><div >References (<a ><i>42</i></a>, <a ><i>43</i></a>)</div><div >Data Table S14</div><div >MDAR Reproducibility Checklist</div></section><section><h3>Resources</h3><div ><div ><div >File (science.abm0811_mdar_reproducibility_checklist.pdf)</div><div >Download</div></div><div ><div >File (science.abm0811_sm.pdf)</div><div >Download</div></div><div ><div >File (science.abm0811_table_s14.xlsx)</div><div >Download</div></div></div></section></section><section ><h2>References and Notes</h2><div ><div >1</div><div ><div ><div >D. A. Collier, I. A. T. M. Ferreira, P. Kotagiri, R. P. Datir, E. Y. Lim, E. Touizer, B. Meng, A. Abdullahi, CITIID-NIHR BioResource COVID-19 Collaboration, A. Elmer, N. Kingston, B. Graves, E. Le Gresley, D. Caputo, L. Bergamaschi, K. G. C. Smith, J. R. Bradley, L. Ceron-Gutierrez, P. Cortes-Acevedo, G. Barcenas-Morales, M. A. Linterman, L. E. McCoy, C. Davis, E. Thomson, P. A. Lyons, E. McKinney, R. Doffinger, M. Wills, R. K. Gupta, Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature <b>596</b>, 417–422 (2021).</div><div ><div>Crossref</div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >2</div><div ><div ><div >E. C. Wall, M. Wu, R. Harvey, G. Kelly, S. Warchal, C. Sawyer, R. Daniels, P. Hobson, E. Hatipoglu, Y. Ngai, S. Hussain, J. Nicod, R. Goldstone, K. Ambrose, S. Hindmarsh, R. Beale, A. Riddell, S. Gamblin, M. Howell, G. Kassiotis, V. Libri, B. Williams, C. Swanton, S. Gandhi, D. L. Bauer, Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet <b>397</b>, 2331–2333 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >3</div><div ><div ><div >D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, N. Kassis-Chikhani, D. Edriss, L. Belec, A. Seve, L. Courtellemont, H. Péré, L. Hocqueloux, S. Fafi-Kremer, T. Prazuck, H. Mouquet, T. Bruel, E. Simon-Lorière, F. A. Rey, O. Schwartz, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature <b>596</b>, 276–280 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >4</div><div ><div ><div >W. T. Harvey, A. M. Carabelli, B. Jackson, R. K. Gupta, E. C. Thomson, E. M. Harrison, C. Ludden, R. Reeve, A. Rambaut, S. J. Peacock, D. L. Robertson; COVID-19 Genomics UK (COG-UK) Consortium, SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. <b>19</b>, 409–424 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >5</div><div ><div ><div >T. A. Treibel, C. Manisty, M. Burton, Á. McKnight, J. Lambourne, J. B. Augusto, X. Couto-Parada, T. Cutino-Moguel, M. Noursadeghi, J. C. Moon, COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet <b>395</b>, 1608–1610 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >6</div><div ><div ><div >C. J. Reynolds, L. Swadling, J. M. Gibbons, C. Pade, M. P. Jensen, M. O. Diniz, N. M. Schmidt, D. K. Butler, O. E. Amin, S. N. L. Bailey, S. M. Murray, F. P. Pieper, S. Taylor, J. Jones, M. Jones, W. J. Lee, J. Rosenheim, A. Chandran, G. Joy, C. Di Genova, N. Temperton, J. Lambourne, T. Cutino-Moguel, M. Andiapen, M. Fontana, A. Smit, A. Semper, B. O’Brien, B. Chain, T. Brooks, C. Manisty, T. Treibel, J. C. Moon, M. Noursadeghi, D. M. Altmann, M. K. Maini, Á. McKnight, R. J. Boyton; COVIDsortium investigators; COVIDsortium immune correlates network, Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. <b>5</b>, eabf3698 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >7</div><div ><div ><div >C. Manisty, T. A. Treibel, M. Jensen, A. Semper, G. Joy, R. K. Gupta, T. Cutino-Moguel, M. Andiapen, J. Jones, S. Taylor, A. Otter, C. Pade, J. Gibbons, J. Lee, J. Bacon, S. Thomas, C. Moon, M. Jones, D. Williams, J. Lambourne, M. Fontana, D. M. Altmann, R. Boyton, M. Maini, A. McKnight, B. Chain, M. Noursadeghi, J. C. Moon, Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection. EBioMedicine <b>65</b>, 103259 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >8</div><div ><div ><div >C. Manisty, A. D. Otter, T. A. Treibel, Á. McKnight, D. M. Altmann, T. Brooks, M. Noursadeghi, R. J. Boyton, A. Semper, J. C. Moon, Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet <b>397</b>, 1057–1058 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >9</div><div ><div ><div >C. J. Reynolds, C. Pade, J. M. Gibbons, D. K. Butler, A. D. Otter, K. Menacho, M. Fontana, A. Smit, J. E. Sackville-West, T. Cutino-Moguel, M. K. Maini, B. Chain, M. Noursadeghi, ; UK COVIDsortium Immune Correlates Network, T. Brooks, A. Semper, C. Manisty, T. A. Treibel, J. C. Moon, UK COVIDsortium Investigators, A. M. Valdes, Á. McKnight, D. M. Altmann, R. Boyton, Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science <b>372</b>, eabh1282 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >10</div><div ><div ><div >R. K. Gupta, J. Rosenheim, L. C. Bell, A. Chandran, J. A. Guerra-Assuncao, G. Pollara, M. Whelan, J. Artico, G. Joy, H. Kurdi, D. M. Altmann, R. J. Boyton, M. K. Maini, A. McKnight, J. Lambourne, T. Cutino-Moguel, C. Manisty, T. A. Treibel, J. C. Moon, B. M. Chain, M. Noursadeghi, COVIDsortium Investigators, Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: A nested, case-control diagnostic accuracy study. Lancet Microbe <b>2</b>, e508–e517 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >11</div><div ><div ><div >F. Krammer, K. Srivastava, H. Alshammary, A. A. Amoako, M. H. Awawda, K. F. Beach, M. C. Bermúdez-González, D. A. Bielak, J. M. Carreño, R. L. Chernet, L. Q. Eaker, E. D. Ferreri, D. L. Floda, C. R. Gleason, J. Z. Hamburger, K. Jiang, G. Kleiner, D. Jurczyszak, J. C. Matthews, W. A. Mendez, I. Nabeel, L. C. F. Mulder, A. J. Raskin, K. T. Russo, A. T. Salimbangon, M. Saksena, A. S. Shin, G. Singh, L. A. Sominsky, D. Stadlbauer, A. Wajnberg, V. Simon, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. <b>384</b>, 1372–1374 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >12</div><div ><div ><div >L. Stamatatos, J. Czartoski, Y. H. Wan, L. J. Homad, V. Rubin, H. Glantz, M. Neradilek, E. Seydoux, M. F. Jennewein, A. J. MacCamy, J. Feng, G. Mize, S. C. De Rosa, A. Finzi, M. P. Lemos, K. W. Cohen, Z. Moodie, M. J. McElrath, A. T. McGuire, mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science <b>372</b>, eabg9175 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >13</div><div ><div ><div >R. R. Goel, S. A. Apostolidis, M. M. Painter, D. Mathew, A. Pattekar, O. Kuthuru, S. Gouma, P. Hicks, W. Meng, A. M. Rosenfeld, S. Dysinger, K. A. Lundgreen, L. Kuri-Cervantes, S. Adamski, A. Hicks, S. Korte, D. A. Oldridge, A. E. Baxter, J. R. Giles, M. E. Weirick, C. M. McAllister, J. Dougherty, S. Long, K. D’Andrea, J. T. Hamilton, M. R. Betts, E. T. Luning Prak, P. Bates, S. E. Hensley, A. R. Greenplate, E. J. Wherry, Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. Sci. Immunol. <b>6</b>, eabi6950 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >14</div><div ><div ><div >J. E. Ebinger, J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J. C. Prostko, E. C. Frias, J. L. Stewart, J. E. Van Eyk, J. G. Braun, S. Cheng, K. Sobhani, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. <b>27</b>, 981–984 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >15</div><div ><div ><div >P. S. Arunachalam, M. K. D. Scott, T. Hagan, C. Li, Y. Feng, F. Wimmers, L. Grigoryan, M. Trisal, V. V. Edara, L. Lai, S. E. Chang, A. Feng, S. Dhingra, M. Shah, A. S. Lee, S. Chinthrajah, S. B. Sindher, V. Mallajosyula, F. Gao, N. Sigal, S. Kowli, S. Gupta, K. Pellegrini, G. Tharp, S. Maysel-Auslender, S. Hamilton, H. Aoued, K. Hrusovsky, M. Roskey, S. E. Bosinger, H. T. Maecker, S. D. Boyd, M. M. Davis, P. J. Utz, M. S. Suthar, P. Khatri, K. C. Nadeau, B. Pulendran, Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature <b>596</b>, 410–416 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >16</div><div ><div ><div >A. Zhang, H. D. Stacey, C. E. Mullarkey, M. S. Miller, Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J. Immunol. <b>202</b>, 335–340 (2019).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >17</div><div ><div ><div >T. Aydillo, A. Rombauts, D. Stadlbauer, S. Aslam, G. Abelenda-Alonso, A. Escalera, F. Amanat, K. Jiang, F. Krammer, J. Carratala, A. García-Sastre, Immunological imprinting of the antibody response in COVID-19 patients. Nat. Commun. <b>12</b>, 3781 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >18</div><div ><div ><div >A. K. Wheatley, A. Fox, H. X. Tan, J. A. Juno, M. P. Davenport, K. Subbarao, S. J. Kent, Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. <b>42</b>, 956–959 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >19</div><div ><div ><div >N. Kamar, F. Abravanel, O. Marion, C. Couat, J. Izopet, A. Del Bello, Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. <b>385</b>, 661–662 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >20</div><div ><div ><div >A. Del Bello, F. Abravanel, O. Marion, C. Couat, L. Esposito, L. Lavayssière, J. Izopet, N. Kamar, Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am. J. Transplant. ajt.16775 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >21</div><div ><div ><div >D. M. Altmann, R. J. Boyton, R. Beale, Immunity to SARS-CoV-2 variants of concern. Science <b>371</b>, 1103–1104 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >22</div><div ><div ><div >D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. <b>27</b>, 1205–1211 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >23</div><div ><div ><div >A. M. Solinger, M. E. Ultee, E. Margoliash, R. H. Schwartz, T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J. Exp. Med. <b>150</b>, 830–848 (1979).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >24</div><div ><div ><div >D. P. Martin, S. Weaver, H. Tegally, J. E. San, S. D. Shank, E. Wilkinson, A. G. Lucaci, J. Giandhari, S. Naidoo, Y. Pillay, L. Singh, R. J. Lessells, R. K. Gupta, J. O. Wertheim, A. Nekturenko, B. Murrell, G. W. Harkins, P. Lemey, O. A. MacLean, D. L. Robertson, T. de Oliveira, S. L. Kosakovsky Pond; NGS-SA; COVID-19 Genomics UK (COG-UK), The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. Cell <b>184</b>, 5189–5200.e7 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >25</div><div ><div ><div >L. Lu, A. W. Chu, R. R. Zhang, W. M. Chan, J. D. Ip, H. W. Tsoi, L. L. Chen, J. P. Cai, D. C. Lung, A. R. Tam, Y. S. Yau, M. Y. Kwan, W. K. To, O. T. Tsang, L. L. Lee, H. Yi, T. C. Ip, R. W. Poon, G. K. Siu, B. W. Mok, V. C. Cheng, K. H. Chan, K. Y. Yuen, I. F. Hung, K. K. To, The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine <b>71</b>, 103544 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >26</div><div ><div ><div >GISAID, “Tracking of variants” (2021); <a >https://www.gisaid.org/hcov19-variants/</a></div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >27</div><div ><div ><div >T. M. Snyder, R. M. Gittelman, M. Klinger, D. H. May, E. J. Osborne, R. Taniguchi, H. J. Zahid, I. M. Kaplan, J. N. Dines, M. T. Noakes, R. Pandya, X. Chen, S. Elasady, E. Svejnoha, P. Ebert, M. W. Pesesky, P. De Almeida, H. O’Donnell, Q. DeGottardi, G. Keitany, J. Lu, A. Vong, R. Elyanow, P. Fields, J. Greissl, L. Baldo, S. Semprini, C. Cerchione, F. Nicolini, M. Mazza, O. M. Delmonte, K. Dobbs, R. Laguna-Goya, G. Carreño-Tarragona, S. Barrio, L. Imberti, A. Sottini, E. Quiros-Roldan, C. Rossi, A. Biondi, L. R. Bettini, M. D’Angio, P. Bonfanti, M. F. Tompkins, C. Alba, C. Dalgard, V. Sambri, G. Martinelli, J. D. Goldman, J. R. Heath, H. C. Su, L. D. Notarangelo, E. Paz-Artal, J. Martinez-Lopez, J. M. Carlson, H. S. Robins, Magnitude and dynamics of the T-cell response to SARS-CoV-2 Infection at both individual and population levels. medRxiv 2020.07.31.20165647 [Preprint] (2020); .</div><div ><div><a >Crossref</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >28</div><div ><div ><div >Wellcome Sanger Institute, “COVID-19 genomic surveillance” (2021); <a >https://covid19.sanger.ac.uk/lineages/raw</a>.</div><div ><div><a >Google Scholar</a></div></div></div></div></div><div ><div >29</div><div ><div ><div >F. Muecksch, Y. Weisblum, C. O. Barnes, F. Schmidt, D. Schaefer-Babajew, Z. Wang, J. C. C. Lorenzi, A. I. Flyak, A. T. DeLaitsch, K. E. Huey-Tubman, S. Hou, C. A. Schiffer, C. Gaebler, J. Da Silva, D. Poston, S. Finkin, A. Cho, M. Cipolla, T. Y. Oliveira, K. G. Millard, V. Ramos, A. Gazumyan, M. Rutkowska, M. Caskey, M. C. Nussenzweig, P. J. Bjorkman, T. Hatziioannou, P. D. Bieniasz, Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity <b>54</b>, 1853–1868.e7 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >30</div><div ><div ><div >Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H. H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. Da Silva, E. Bednarski, L. Aguado, J. Yee, M. Daga, M. Turroja, K. G. Millard, M. Jankovic, A. Gazumyan, Z. Zhao, C. M. Rice, P. D. Bieniasz, M. Caskey, T. Hatziioannou, M. C. Nussenzweig, Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature <b>595</b>, 426–431 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >31</div><div ><div ><div >C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, Y. Bram, G. Breton, T. Hägglöf, P. Mendoza, A. Hurley, M. Turroja, K. Gordon, K. G. Millard, V. Ramos, F. Schmidt, Y. Weisblum, D. Jha, M. Tankelevich, G. Martinez-Delgado, J. Yee, R. Patel, J. Dizon, C. Unson-O’Brien, I. Shimeliovich, D. F. Robbiani, Z. Zhao, A. Gazumyan, R. E. Schwartz, T. Hatziioannou, P. J. Bjorkman, S. Mehandru, P. D. Bieniasz, M. Caskey, M. C. Nussenzweig, Evolution of antibody immunity to SARS-CoV-2. Nature <b>591</b>, 639–644 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >32</div><div ><div ><div >N. Faulkner, K. W. Ng, M. Y. Wu, R. Harvey, M. Margaritis, S. Paraskevopoulou, C. Houlihan, S. Hussain, M. Greco, W. Bolland, S. Warchal, J. Heaney, H. Rickman, M. Spyer, D. Frampton, M. Byott, T. de Oliveira, A. Sigal, S. Kjaer, C. Swanton, S. Gandhi, R. Beale, S. J. Gamblin, J. W. McCauley, R. S. Daniels, M. Howell, D. Bauer, E. Nastouli, G. Kassiotis, Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife <b>10</b>, e69317 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >33</div><div ><div ><div >M. Bergwerk, T. Gonen, Y. Lustig, S. Amit, M. Lipsitch, C. Cohen, M. Mandelboim, E. G. Levin, C. Rubin, V. Indenbaum, I. Tal, M. Zavitan, N. Zuckerman, A. Bar-Chaim, Y. Kreiss, G. Regev-Yochay, Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. <b>385</b>, 1474–1484 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >34</div><div ><div ><div >T. Moyo-Gwete, M. Madzivhandila, Z. Makhado, F. Ayres, D. Mhlanga, B. Oosthuysen, B. E. Lambson, P. Kgagudi, H. Tegally, A. Iranzadeh, D. Doolabh, L. Tyers, L. R. Chinhoyi, M. Mennen, S. Skelem, G. Marais, C. K. Wibmer, J. N. Bhiman, V. Ueckermann, T. Rossouw, M. Boswell, T. de Oliveira, C. Williamson, W. A. Burgers, N. Ntusi, L. Morris, P. L. Moore, Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). N. Engl. J. Med. <b>384</b>, 2161–2163 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >35</div><div ><div ><div >M. McCallum, A. De Marco, F. A. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, L. E. Rosen, S. Bianchi, B. Guarino, C. S. Fregni, R. Abdelnabi, S. C. Foo, P. W. Rothlauf, L. M. Bloyet, F. Benigni, E. Cameroni, J. Neyts, A. Riva, G. Snell, A. Telenti, S. P. J. Whelan, H. W. Virgin, D. Corti, M. S. Pizzuto, D. Veesler, N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell <b>184</b>, 2332–2347.e16 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >36</div><div ><div ><div >Y. Goldberg, M. Mandel, Y. M. Bar-On, O. Bodenheimer, L. Freedman, E. J. Haas, R. Milo, S. Alroy-Preis, N. Ash, A. Huppert, Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. NEJMoa2114228 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >37</div><div ><div ><div >L. A. VanBlargan, L. J. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. K. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. M. Whitener, L. Droit, I. D. Aziati, T. L. Bricker, A. Joshi, P. Y. Shi, A. Creanga, A. Pegu, S. A. Handley, D. Wang, A. C. M. Boon, J. E. Crowe Jr., S. P. J. Whelan, D. H. Fremont, M. S. Diamond, A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity <b>54</b>, 2399–2416.e6 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >38</div><div ><div ><div >D. M. Altmann, C. J. Reynolds, R. J. Boyton, SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition. Cell Rep. Med. <b>2</b>, 100286 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >39</div><div ><div ><div >B. Reynisson, B. Alvarez, S. Paul, B. Peters, M. Nielsen, NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. <b>48</b> (W1), W449–W454 (2020).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >40</div><div ><div ><div >K. J. Quigley, C. J. Reynolds, A. Goudet, E. J. Raynsford, R. Sergeant, A. Quigley, S. Worgall, D. Bilton, R. Wilson, M. R. Loebinger, B. Maillere, D. M. Altmann, R. J. Boyton, Chronic infection by mucoid <i>Pseudomonas aeruginosa</i> associated with dysregulation in T-cell immunity to outer membrane porin F. Am. J. Respir. Crit. Care Med. <b>191</b>, 1250–1264 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >41</div><div ><div ><div >C. Reynolds, A. Goudet, K. Jenjaroen, M. Sumonwiriya, D. Rinchai, J. Musson, S. Overbeek, J. Makinde, K. Quigley, J. Manji, N. Spink, P. Yos, V. Wuthiekanun, G. Bancroft, J. Robinson, G. Lertmemongkolchai, S. Dunachie, B. Maillere, M. Holden, D. Altmann, R. Boyton, T cell immunity to the alkyl hydroperoxide reductase of <i>Burkholderia pseudomallei</i>: A correlate of disease outcome in acute melioidosis. J. Immunol. <b>194</b>, 4814–4824 (2015).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >42</div><div ><div ><div >K. Tao, P. L. Tzou, J. Nouhin, R. K. Gupta, T. de Oliveira, S. L. Kosakovsky Pond, D. Fera, R. W. Shafer, The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. <b>22</b>, 757–773 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div><div ><div >43</div><div ><div ><div >J. Zou, X. Xie, C. R. Fontes-Garfias, K. A. Swanson, I. Kanevsky, K. Tompkins, M. Cutler, D. Cooper, P. R. Dormitzer, P. Y. Shi, The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines <b>6</b>, 44 (2021).</div><div ><div><a >Crossref</a></div><div><a >PubMed</a></div><div><a >Google Scholar</a></div></div></div></div></div></section></div></section><div ><div ><header><h2>Information Authors</h2></header><section ><h3>Information</h3><section ><h4>Published In</h4><div > <div ><div >Science</div><div >First Release</div></div></div></section><section ><h4>Copyright</h4><div >Copyright © 2022, American Association for the Advancement of Science.</div></section><section ><h4>Submission history</h4><div><b >Received</b>: 25 August 2021</div><div><b >Accepted</b>: 25 November 2021</div></section><section ><h4>Permissions</h4><div>Request permissions for this article.</div><div>Request Permissions</div></section><section ><h4>Acknowledgments</h4><div ><b>ACKNOWLEDGMENTS:</b> The authors thank HCW participants for participating in the study and the research teams involved in recruitment, obtaining consent, and sampling the HCW participants. The COVIDsortium Healthcare Workers bioresource is approved by the ethical committee of UK National Research Ethics Service (20/SC/0149) and registered on ClinicalTrials.gov (NCT04318314). The study conforms to the principles of the Helsinki Declaration, and all subjects provided written informed consent. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV Isolate EVA catalog code 026V-03883 was obtained from European Virus Archive Global. (EVAg), Charité - Universitätsmedizin Berlin. The SARS-CoV-2 B.1.1.7 isolate was obtained from NIBSC, thanks to the contribution of PHE Porton Down and Dr Simon Funnell. The nCoV19 isolate/UK ex South African/2021 lineage B.1.351 EVA catalog code 04V-04071 was obtained from EVAg, PHE Porton Down. P.1 and B.1.617.2 isolates were purchased from EVAg. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. <b>Funding</b>: RJB and DMA are supported by MRC (MR/S019553/1, MR/R02622X/1, MR/V036939/1, MR/W020610/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC (2019SRC015), NIHR EME Fast Track (NIHR134607), NIHR Long Covid (COV-LT2-0027), Innovate Uk (SBRI 10008614) and Horizon 2020 Marie Skłodowska-Curie Innovative Training Network (ITN) European Training Network (No 860325). ÁM is supported by MRC (MR/W020610/1), NIHR EME Fast Track (NIHR134607), Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomew’s Hospital Trust. The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Kenneth C Griffin, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with University College London and Queen Mary University of London. MKM is supported by UKRI/NIHR UK-CIC, Wellcome Trust Investigator Award (214191/Z/18/Z) and CRUK Immunology grant (26603). JCM, CM and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223​). TT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. <b>Author contributions:</b> R.J.B conceptualised and designed the study reported. R.J.B and D.M.A designed and supervised the T cell and B cell experiments. Á.M. designed and supervised the nAb experiments. T.B. and A.Se supervised S1 IgG and N IgG/IgM studies. D.MS., KM.L., F.P., and D.K.B. performed and analyzed T cell experiments. C.J.R. developed, performed and analyzed T cell, and memory B cell experiments. J.M.G. and C.P developed, performed and analyzed nAb experiments. A.D.O. performed and A.Se analyzed RBD and N antibody assays. T.B., C.M., Á.M., T.T., J.C.M., and M.N conceptualised and established the COVIDsortium HCW cohort. R.J.B, T.T., J.C.M., and C.M designed the vaccine sub-study cohort. G.J., K.M., M.F., A.S., C.M., T.A.T., and J.C.M. recruited HCW and collected samples. B.K. and T.C-M. helped with confirmation of sequence of viral isolates. C.J.R., D.MS., KM.L., F.P., S.L., and D.K.B. and COVIDsortium Investigators processed HCW samples. C.J.R., J.M.G., C.P., Á.M., D.M.A., and R.J.B. analyzed the data. C.J.R., J.M.G., C.P., C.M., T.T., J.C.M., M.K.M., A.Se., T.B., M.N., Á.M., D.M.A., and R.J.B. interpreted the data. R.J.B. and D.M.A wrote the manuscript with input from all the authors. All the authors reviewed and edited the manuscript and figures. <b>Competing interests:</b> R.J.B. and D.M.A. are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. <b>Data and materials availability:</b> All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV, B.1.351, P.1 and B.1.617.2 isolates were obtained under material agreements with European Virus Archive Global (EVAg), France. The SARS-CoV-2 B.1.1.7 isolate was obtained under a material agreement with the National Institute for Biological Standards and Control (NIBSC), UK. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a >https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section></section><section ><h3>Authors</h3><section ><h4>Affiliations</h4><div ><div >Catherine J. Reynolds<sup >†</sup> <a >https://orcid.org/0000-0002-1371-653X</a></div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Joseph M. Gibbons<sup >†</sup> <a >https://orcid.org/0000-0002-7238-2381</a></div><div ><div ><div >Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</div></div><div ><a >View all articles by this author</a></div></div></div><div ><div >Corinna Pade<sup >†</sup> <a >https://orcid.org/0000-0003-0626-2346</a></div><div ><div ><div >Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Kai-Min Lin https://orcid.org/0000-0003-2109-1530</div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div></div><div ><a >View all articles by this author</a></div></div></div><div ><div >Diana Munoz Sandoval https://orcid.org/0000-0001-8350-3989</div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Franziska Pieper https://orcid.org/0000-0002-4857-0518</div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >David K. Butler https://orcid.org/0000-0003-1882-8159</div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Siyi Liu https://orcid.org/0000-0003-0206-9661</div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div></div><div ><a >View all articles by this author</a></div></div></div><div ><div >Ashley D. Otter https://orcid.org/0000-0002-8317-9194</div><div ><div ><div >UK Health Security Agency, Porton Down, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >George Joy https://orcid.org/0000-0003-1467-5490</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Katia Menacho https://orcid.org/0000-0001-5183-5655</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Marianna Fontana https://orcid.org/0000-0002-9233-9831</div><div ><div ><div >Royal Free London NHS Foundation Trust, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Angelique Smit https://orcid.org/0000-0002-2144-1249</div><div ><div ><div >Royal Free London NHS Foundation Trust, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Beatrix Kele https://orcid.org/0000-0003-1273-7299</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Teresa Cutino-Moguel https://orcid.org/0000-0002-1726-4278</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Mala K. Maini https://orcid.org/0000-0001-6384-1462</div><div ><div ><div >Division of Infection and Immunity, University College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Mahdad Noursadeghi https://orcid.org/0000-0002-4774-0853</div><div ><div ><div >Division of Infection and Immunity, University College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >COVIDsortium Immune Correlates Network‡</div></div><div ><div >Tim Brooks https://orcid.org/0000-0002-3783-1284</div><div ><div ><div >UK Health Security Agency, Porton Down, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Amanda Semper https://orcid.org/0000-0003-3656-1363</div><div ><div ><div >UK Health Security Agency, Porton Down, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Charlotte Manisty https://orcid.org/0000-0003-0245-7090</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div><div >Institute of Cardiovascular Science, University College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Thomas A. Treibel https://orcid.org/0000-0003-1560-7414</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div><div >Institute of Cardiovascular Science, University College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >James C. Moon<sup >‡</sup> https://orcid.org/0000-0001-8071-1491</div><div ><div ><div >St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div><div >Institute of Cardiovascular Science, University College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Áine McKnight<sup >§</sup> https://orcid.org/0000-0002-8113-817X</div><div ><div ><div >Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Daniel M. Altmann<sup >§</sup> https://orcid.org/0000-0002-2436-6192</div><div ><div ><div >Department of Immunology and Inflammation, Imperial College London, London, UK.</div></div><div >View all articles by this author</div></div></div><div ><div >Rosemary J. Boyton<sup >§,*</sup> <a >https://orcid.org/0000-0002-5608-0797</a> <a >[email protected]</a></div><div ><div ><div >Department of Infectious Disease, Imperial College London, London, UK.</div><div >Lung Division, Royal Brompton and Harefield Hospitals, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.</div></div><div >View all articles by this author</div></div></div></section><section ><h4>Funding Information</h4><div ><a >Medical Research Council</a>: MR/W020610/1</div><div ><a >Innovate UK</a>: SBRI 10008614</div><div ><a >University College London Hospitals NHS Foundation Trust</a>: </div><div ><a >UCLH Biomedical Research Centre</a>: MR/S019553/1</div><div >MRC: MR/R02622X/1</div><div >MRC: MR/V036939/1</div><div >MRC: MR/W020610/1</div><div >NIHR EME Fast Track: NIHR134607</div><div >Wellcome Trust UK: 207511/Z/17/Z</div><div >Wellcome Trust Senior Investigator Award: 214191/Z/18/Z</div><div >CRUK: 26603</div><div >British Heart Foundation Intermediate Research Fellowship: FS/19/35/34374</div><div >NIHR: COV-LT2-0027</div><div >Cystic Fibrosis Trust UK: 2019SRC015</div><div >NIHR EME Fast Track: NIHR134607</div><div >NIHR: COV-LT2-0027</div><div >UKRI: MR/W020610/1</div><div >NIHR: COV-LT2-0027</div><div ><a >NIHR Imperial Biomedical Research Centre</a>: NIHR Imperial Biomedical Research Centre (BRC):ITMAT,</div><div >UKRI: MR/S019553/1</div><div >Horizon 2020 Maria Sklodowska-Curie Innovative Training Network (ITN) European Training Network: 860325</div></section><section ><h4>Notes</h4><div ><div >†</div><div >These authors contributed equally to this work and are co-first authors.</div></div><div ><div >‡</div><div >The members of the COVIDsortium Immune Correlates Network and COVIDsortium Investigators are listed in the supplementary materials.</div></div><div ><div >§</div><div >These authors contributed equally to this work and are co-senior authors.</div></div><div >*Corresponding author. Email: <a >[email protected]</a></div></section></section></div><div ><header><h2>Metrics Citations</h2></header><section ><h3>Metrics</h3><section > <h5 > Article Usage </h5> </section><section > <h5 > Altmetrics </h5> </section></section><section ><h3>Citations</h3><section > <div > <h5 >Export citation</h5> <p>Select the format you want to export the citation of this publication.</p> </div> </section></section></div><div ><header><h2>View Options</h2></header><div ><h3>View options</h3><section ><h4>PDF format</h4><p>Download this article as a PDF file</p><a >Download PDF</a></section></div><div ><h3>Get Access</h3><section > <div ><h5>Log in to view the full text</h5> <p><a >AAAS Log in</a></p> <p>AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul > <li >Become a AAAS Member</li> <li ><a >Activate your Account</a></li> <li ><a >Purchase Access to Other Journals in the Science Family</a></li> <li><a >Account Help</a></li> </ul> <div > <div >Log in via OpenAthens. <div ><a >via OpenAthens</a></div> </div> <div >Log in via Shibboleth. <div ><a >via Shibboleth</a></div> </div> </div> </div> <div ><h5>More options</h5><p><a >Purchase digital access to this article</a></p><p >Download and print this article for your personal scholarly, research, and educational use.</p><p><a >Purchase this issue in print</a></p><p>Buy a single issue of Science for just $15 USD.</p></div> </section></div></div><div ><header><h2>Media</h2></header><section ><h3>Figures</h3></section><section ><h3>Multimedia</h3></section></div><div ><header><h2>Tables</h2></header></div><div ><header><h2>Share</h2></header><h3>Share</h3><div ><section ><h4>Share article link</h4><div ><a >Copy Link</a><div ><p >Copied!</p><p >Copying failed.</p></div></div></section><section ><h4>Share on social media</h4><div >facebook<a >twitter</a><a >linkedin</a><a >email</a></div></section></div></div></div></article><section ><div ><div ><div ><div ><h3 >Submit a Response to This Article</h3></div></div></div></div> <div > <div > <h2 >(0)eLetters</h2> </div> <p >eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> <a >Log In to Submit a Response</a> <p >No eLetters have been published for this article yet.</p> </div> </section> <div ><a >View Full Text</a><a >Download PDF</a></div> </div></div></div></div><div ><div ><div ><div ><section><div ><h4 > Current Issue </h4><div ><div > <div ><div><article ><div ><div ><h3 ><a >Cell-by-cell dissection of phloem development links a maturation gradient to cell specialization</a></h3><ul ><li >By<ul > <li >Pawel Roszak</li> <li >Jung-ok Heo</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >The energetics of uniquely human subsistence strategies</h3><ul ><li >By<ul > <li >Thomas S. Kraft</li> <li >Vivek V. Venkataraman</li> <li >et al.</li> </ul> </li></ul></div></div></article><article ><div ><div ><h3 >Early giant reveals faster evolution of large body size in ichthyosaurs than in cetaceans</h3><ul ><li >By<ul > <li >P. Martin Sander</li> <li >Eva Maria Griebeler</li> <li >et al.</li> </ul> </li></ul></div></div></article></div><div >Table of Contents</div></div> </div></div></div></section><section > <h4 >LATEST NEWS</h4> <div > <div ><div > <article > <div > <div > News<time >30 Dec 2021</time> </div> <div > Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article > <div > <div > ScienceInsider<time >29 Dec 2021</time> </div> <div > <a > Once a ‘crazy idea,’ patent-pooling nonprofit will help bring COVID-19 pills to world’s poor </a> </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > The natural world loses two of its biggest advocates </div> </div> </article> <article > <div > <div > ScienceInsider<time >28 Dec 2021</time> </div> <div > <a > What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article > <div > <div > ScienceInsider<time >25 Dec 2021</time> </div> <div > NASA’s Webb telescope takes flight—a Christmas gift to astronomers everywhere </div> </div> </article> <article > <div > <div > News<time >23 Dec 2021</time> </div> <div > <a > More than a virus: Science’s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, tag: body, level: 1" node_number="1"> <div class="valid" valid="valid" title="valid: True, node: 2, tag: div, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, tag: div, level: 3" node_number="3"> <div class="valid" valid="valid" title="valid: True, node: 4, tag: div, level: 4" node_number="4"> <div class="valid" valid="valid" title="valid: True, node: 5, tag: div, level: 5" node_number="5"> <div class="valid" valid="valid" title="valid: True, node: 6, tag: div, level: 6" node_number="6"> <div class="valid" valid="valid" title="valid: True, node: 7, tag: div, level: 7" node_number="7"> <div class="valid" valid="valid" title="valid: True, node: 8, tag: div, level: 8" node_number="8"> <div class="valid" valid="valid" title="valid: True, node: 9, tag: div, level: 9" node_number="9"> <div class="valid" valid="valid" title="valid: True, node: 10, tag: div, level: 10" node_number="10"> <div class="valid" valid="valid" title="valid: True, node: 11, tag: div, level: 11" node_number="11"> <span class="valid" valid="valid" title="valid: True, node: 12, tag: span, level: 12" node_number="12">Advertisement</span> </div> </div> </div> </div> </div> </div> </div> <header class="valid" valid="valid" title="valid: True, node: 13, tag: header, level: 5" node_number="13"> <div class="valid" valid="valid" title="valid: True, node: 14, tag: div, level: 6" node_number="14"><div class="valid" valid="valid" title="valid: True, node: 15, tag: div, level: 7" node_number="15"><div class="valid" valid="valid" title="valid: True, node: 16, tag: div, level: 8" node_number="16"><div class="valid" valid="valid" title="valid: True, node: 17, tag: div, level: 9" node_number="17"><div class="valid" valid="valid" title="valid: True, node: 18, tag: div, level: 10" node_number="18"><div class="valid" valid="valid" title="valid: True, node: 19, tag: div, level: 11" node_number="19"><div class="valid" valid="valid" title="valid: True, node: 20, tag: div, level: 12" node_number="20"><a class="valid" valid="valid" title="valid: True, node: 21, tag: a, level: 13" node_number="21"><div class="valid" valid="valid" title="valid: True, node: 22, tag: div, level: 14" node_number="22">science</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 23, tag: div, level: 11" node_number="23"><div class="valid" valid="valid" title="valid: True, node: 24, tag: div, level: 12" node_number="24"><a class="valid" valid="valid" title="valid: True, node: 25, tag: a, level: 13" node_number="25"><div class="valid" valid="valid" title="valid: True, node: 26, tag: div, level: 14" node_number="26">science advances</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 27, tag: div, level: 11" node_number="27"><div class="valid" valid="valid" title="valid: True, node: 28, tag: div, level: 12" node_number="28"><a class="valid" valid="valid" title="valid: True, node: 29, tag: a, level: 13" node_number="29"><div class="valid" valid="valid" title="valid: True, node: 30, tag: div, level: 14" node_number="30">science immunology</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 31, tag: div, level: 11" node_number="31"><div class="valid" valid="valid" title="valid: True, node: 32, tag: div, level: 12" node_number="32"><a class="valid" valid="valid" title="valid: True, node: 33, tag: a, level: 13" node_number="33"><div class="valid" valid="valid" title="valid: True, node: 34, tag: div, level: 14" node_number="34">science robotics</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 35, tag: div, level: 11" node_number="35"><div class="valid" valid="valid" title="valid: True, node: 36, tag: div, level: 12" node_number="36"><a class="valid" valid="valid" title="valid: True, node: 37, tag: a, level: 13" node_number="37"><div class="valid" valid="valid" title="valid: True, node: 38, tag: div, level: 14" node_number="38">science signaling</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 39, tag: div, level: 11" node_number="39"><div class="valid" valid="valid" title="valid: True, node: 40, tag: div, level: 12" node_number="40"><a class="valid" valid="valid" title="valid: True, node: 41, tag: a, level: 13" node_number="41"><div class="valid" valid="valid" title="valid: True, node: 42, tag: div, level: 14" node_number="42">science translational medicine</div></a></div></div><div class="valid" valid="valid" title="valid: True, node: 43, tag: div, level: 11" node_number="43"><div class="valid" valid="valid" title="valid: True, node: 44, tag: div, level: 12" node_number="44"><a class="valid" valid="valid" title="valid: True, node: 45, tag: a, level: 13" node_number="45"><div class="valid" valid="valid" title="valid: True, node: 46, tag: div, level: 14" node_number="46">science partner journals</div></a></div></div></div></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 47, tag: div, level: 6" node_number="47"> <div class="valid" valid="valid" title="valid: True, node: 48, tag: div, level: 7" node_number="48"> <div class="valid" valid="valid" title="valid: True, node: 49, tag: div, level: 8" node_number="49"> <div class="valid" valid="valid" title="valid: True, node: 50, tag: div, level: 9" node_number="50"> <div class="valid" valid="valid" title="valid: True, node: 51, tag: div, level: 10" node_number="51"><div class="valid" valid="valid" title="valid: True, node: 52, tag: div, level: 11" node_number="52"><div class="valid" valid="valid" title="valid: True, node: 53, tag: div, level: 12" node_number="53"><label class="valid" valid="valid" title="valid: True, node: 54, tag: label, level: 13" node_number="54">Searching:</label><div class="valid" valid="valid" title="valid: True, node: 55, tag: div, level: 13" node_number="55"><div class="valid" valid="valid" title="valid: True, node: 56, tag: div, level: 14" node_number="56"><div title="valid: False, node: 57, tag: div, level: 15" node_number="57">Anywhere<a title="valid: False, node: 58, tag: a, level: 16" node_number="58">Science</a><a title="valid: False, node: 59, tag: a, level: 16" node_number="59">Science Advances</a><a title="valid: False, node: 60, tag: a, level: 16" node_number="60">Science Immunology</a><a title="valid: False, node: 61, tag: a, level: 16" node_number="61">Science Robotics</a><a title="valid: False, node: 62, tag: a, level: 16" node_number="62">Science Signaling</a><a title="valid: False, node: 63, tag: a, level: 16" node_number="63">Science Translational Medicine</a></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 64, tag: div, level: 12" node_number="64"> <a class="valid" valid="valid" title="valid: True, node: 65, tag: a, level: 13" node_number="65"><u class="valid" valid="valid" title="valid: True, node: 66, tag: u, level: 14" node_number="66">Advanced Search</u></a> </div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 67, tag: div, level: 7" node_number="67"> <div class="valid" valid="valid" title="valid: True, node: 68, tag: div, level: 8" node_number="68"> <div class="valid" valid="valid" title="valid: True, node: 69, tag: div, level: 9" node_number="69"> <h6 class="valid" valid="valid" title="valid: True, node: 70, tag: h6, level: 10" node_number="70">Trending Terms:</h6> <ul class="valid" valid="valid" title="valid: True, node: 71, tag: ul, level: 10" node_number="71"> <li class="valid" valid="valid" title="valid: True, node: 72, tag: li, level: 11" node_number="72"> <a class="valid" valid="valid" title="valid: True, node: 73, tag: a, level: 12" node_number="73">covid-19</a> </li> <li class="valid" valid="valid" title="valid: True, node: 74, tag: li, level: 11" node_number="74"> <a class="valid" valid="valid" title="valid: True, node: 75, tag: a, level: 12" node_number="75">climate</a> </li> <li class="valid" valid="valid" title="valid: True, node: 76, tag: li, level: 11" node_number="76"> <a class="valid" valid="valid" title="valid: True, node: 77, tag: a, level: 12" node_number="77">science policy</a> </li> <li class="valid" valid="valid" title="valid: True, node: 78, tag: li, level: 11" node_number="78"> <a class="valid" valid="valid" title="valid: True, node: 79, tag: a, level: 12" node_number="79">genome editing</a> </li> <li class="valid" valid="valid" title="valid: True, node: 80, tag: li, level: 11" node_number="80"> <a class="valid" valid="valid" title="valid: True, node: 81, tag: a, level: 12" node_number="81">batteries</a> </li> </ul> </div> </div> </div> </div> </header><div class="valid" valid="valid" title="valid: True, node: 82, tag: div, level: 5" node_number="82"><div class="valid" valid="valid" title="valid: True, node: 83, tag: div, level: 6" node_number="83"><div class="valid" valid="valid" title="valid: True, node: 84, tag: div, level: 7" node_number="84"> <div class="valid" valid="valid" title="valid: True, node: 85, tag: div, level: 8" node_number="85"> <div class="valid" valid="valid" title="valid: True, node: 86, tag: div, level: 9" node_number="86"> <ul class="valid" valid="valid" title="valid: True, node: 87, tag: ul, level: 10" node_number="87"> <li class="valid" valid="valid" title="valid: True, node: 88, tag: li, level: 11" node_number="88"> <a class="valid" valid="valid" title="valid: True, node: 89, tag: a, level: 12" node_number="89">Current Issue</a> </li> <li class="valid" valid="valid" title="valid: True, node: 90, tag: li, level: 11" node_number="90"> <a class="valid" valid="valid" title="valid: True, node: 91, tag: a, level: 12" node_number="91">First release papers</a> </li> <li class="valid" valid="valid" title="valid: True, node: 92, tag: li, level: 11" node_number="92"> <a class="valid" valid="valid" title="valid: True, node: 93, tag: a, level: 12" node_number="93">Archive</a> </li> <li class="valid" valid="valid" title="valid: True, node: 94, tag: li, level: 11" node_number="94"> <div class="valid" valid="valid" title="valid: True, node: 95, tag: div, level: 12" node_number="95"> <a class="valid" valid="valid" title="valid: True, node: 96, tag: a, level: 13" node_number="96">About</a> <div class="valid" valid="valid" title="valid: True, node: 97, tag: div, level: 13" node_number="97"> <a class="valid" valid="valid" title="valid: True, node: 98, tag: a, level: 14" node_number="98">About Science</a> <a class="valid" valid="valid" title="valid: True, node: 99, tag: a, level: 14" node_number="99">Mission Scope</a> <a class="valid" valid="valid" title="valid: True, node: 100, tag: a, level: 14" node_number="100">Editors Advisory Boards</a> <a class="valid" valid="valid" title="valid: True, node: 101, tag: a, level: 14" node_number="101">Editorial Policies</a> <a class="valid" valid="valid" title="valid: True, node: 102, tag: a, level: 14" node_number="102">Information for Authors</a> <a class="valid" valid="valid" title="valid: True, node: 103, tag: a, level: 14" node_number="103">Information for Reviewers</a> <a class="valid" valid="valid" title="valid: True, node: 104, tag: a, level: 14" node_number="104">Journal Metrics</a> <a class="valid" valid="valid" title="valid: True, node: 105, tag: a, level: 14" node_number="105">Staff</a> <a class="valid" valid="valid" title="valid: True, node: 106, tag: a, level: 14" node_number="106">Contact Us</a> </div> </div> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 107, tag: div, level: 9" node_number="107"> <ul class="valid" valid="valid" title="valid: True, node: 108, tag: ul, level: 10" node_number="108"> <li class="valid" valid="valid" title="valid: True, node: 109, tag: li, level: 11" node_number="109"> <a class="valid" valid="valid" title="valid: True, node: 110, tag: a, level: 12" node_number="110">Submit manuscript</a> </li> <li class="valid" valid="valid" title="valid: True, node: 111, tag: li, level: 11" node_number="111"> <div class="valid" valid="valid" title="valid: True, node: 112, tag: div, level: 12" node_number="112"> <a class="valid" valid="valid" title="valid: True, node: 113, tag: a, level: 13" node_number="113">More</a> </div> </li> </ul> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 114, tag: a, level: 8" node_number="114">GET OUR E-ALERTS</a> </div></div></div> <main class="valid" valid="valid" title="valid: True, node: 115, tag: main, level: 5" node_number="115"> <div class="valid" valid="valid" title="valid: True, node: 116, tag: div, level: 6" node_number="116"><div class="valid" valid="valid" title="valid: True, node: 117, tag: div, level: 7" node_number="117"><div class="valid" valid="valid" title="valid: True, node: 118, tag: div, level: 8" node_number="118"><div class="valid" valid="valid" title="valid: True, node: 119, tag: div, level: 9" node_number="119"><div class="valid" valid="valid" title="valid: True, node: 120, tag: div, level: 10" node_number="120"> <div class="valid" valid="valid" title="valid: True, node: 121, tag: div, level: 11" node_number="121"><a class="valid" valid="valid" title="valid: True, node: 122, tag: a, level: 12" node_number="122">Home</a><a class="valid" valid="valid" title="valid: True, node: 123, tag: a, level: 12" node_number="123">Science</a><a class="valid" valid="valid" title="valid: True, node: 124, tag: a, level: 12" node_number="124">First Release</a>Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants</div><div class="valid" valid="valid" title="valid: True, node: 125, tag: div, level: 11" node_number="125">Back To First Release</div> </div> <article class="valid" valid="valid" title="valid: True, node: 126, tag: article, level: 10" node_number="126"><section class="valid" valid="valid" title="valid: True, node: 127, tag: section, level: 11" node_number="127"><header class="valid" valid="valid" title="valid: True, node: 128, tag: header, level: 12" node_number="128"><div class="valid" valid="valid" title="valid: True, node: 129, tag: div, level: 13" node_number="129"><div class="valid" valid="valid" title="valid: True, node: 130, tag: div, level: 14" node_number="130"><div title="valid: False, node: 131, tag: div, level: 15" node_number="131"><div title="valid: False, node: 132, tag: div, level: 16" node_number="132">OPEN ACCESS</div><div title="valid: False, node: 133, tag: div, level: 16" node_number="133">Research Article</div></div><div title="valid: False, node: 134, tag: div, level: 15" node_number="134"><div title="valid: False, node: 135, tag: div, level: 16" node_number="135"> <div title="valid: False, node: 136, tag: div, level: 17" node_number="136">Share on</div> </div></div></div><h1 class="valid" valid="valid" title="valid: True, node: 137, tag: h1, level: 14" node_number="137">Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants</h1><div class="valid" valid="valid" title="valid: True, node: 138, tag: div, level: 14" node_number="138">Catherine J. Reynolds https://orcid.org/0000-0002-1371-653X, Joseph M. Gibbons https://orcid.org/0000-0002-7238-2381, Corinna Pade https://orcid.org/0000-0003-0626-2346, Kai-Min Lin https://orcid.org/0000-0003-2109-1530, Diana Munoz Sandoval https://orcid.org/0000-0001-8350-3989, Franziska Pieper https://orcid.org/0000-0002-4857-0518, David K. Butler https://orcid.org/0000-0003-1882-8159, &#8230; Show All &#8230; , Siyi Liu https://orcid.org/0000-0003-0206-9661, Ashley D. Otter https://orcid.org/0000-0002-8317-9194, George Joy https://orcid.org/0000-0003-1467-5490, Katia Menacho https://orcid.org/0000-0001-5183-5655, Marianna Fontana https://orcid.org/0000-0002-9233-9831, Angelique Smit https://orcid.org/0000-0002-2144-1249, Beatrix Kele https://orcid.org/0000-0003-1273-7299, Teresa Cutino-Moguel https://orcid.org/0000-0002-1726-4278, Mala K. Maini https://orcid.org/0000-0001-6384-1462, Mahdad Noursadeghi https://orcid.org/0000-0002-4774-0853, COVIDsortium Immune Correlates Network&#8225;, Tim Brooks https://orcid.org/0000-0002-3783-1284, Amanda Semper https://orcid.org/0000-0003-3656-1363, Charlotte Manisty https://orcid.org/0000-0003-0245-7090, Thomas A. Treibel https://orcid.org/0000-0003-1560-7414, James C. Moon https://orcid.org/0000-0001-8071-1491, &#193;ine McKnight https://orcid.org/0000-0002-8113-817X, Daniel M. Altmann https://orcid.org/0000-0002-2436-6192, and Rosemary J. Boyton https://orcid.org/0000-0002-5608-0797 [email&#160;protected] Show Fewer</div><div class="valid" valid="valid" title="valid: True, node: 139, tag: div, level: 14" node_number="139">Science &#8226; 2 Dec 2021 &#8226; First Release &#8226; DOI: 10.1126/science.abm0811</div><div class="valid" valid="valid" title="valid: True, node: 140, tag: div, level: 14" node_number="140"><div title="valid: False, node: 141, tag: div, level: 15" node_number="141"> <div title="valid: False, node: 142, tag: div, level: 16" node_number="142"> <a title="valid: False, node: 143, tag: a, level: 17" node_number="143"><div title="valid: False, node: 144, tag: div, level: 18" node_number="144"><div title="valid: False, node: 145, tag: div, level: 19" node_number="145"><h6 title="valid: False, node: 146, tag: h6, level: 20" node_number="146">PREVIOUS ARTICLE</h6><div title="valid: False, node: 147, tag: div, level: 20" node_number="147">Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain</div></div></div>Previous</a><a title="valid: False, node: 148, tag: a, level: 17" node_number="148"><div title="valid: False, node: 149, tag: div, level: 18" node_number="149"><div title="valid: False, node: 150, tag: div, level: 19" node_number="150"><h6 title="valid: False, node: 151, tag: h6, level: 20" node_number="151">NEXT ARTICLE</h6><div title="valid: False, node: 152, tag: div, level: 20" node_number="152">Visualizing broken symmetry and topological defects in a quantum Hall ferromagnet</div></div></div>Next</a> </div> </div></div></div></header><div class="valid" valid="valid" title="valid: True, node: 153, tag: div, level: 12" node_number="153"><div class="valid" valid="valid" title="valid: True, node: 154, tag: div, level: 13" node_number="154"><section class="valid" valid="valid" title="valid: True, node: 155, tag: section, level: 14" node_number="155"><h2 title="valid: False, node: 156, tag: h2, level: 15" node_number="156">Abstract</h2><div title="valid: False, node: 157, tag: div, level: 15" node_number="157">The impact of initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOC) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection+two vaccine doses), S1 antibody, memory B cells and heterologous neutralization of B.1.351, P.1 and B.1.617.2 plateaued, while B.1.1.7 neutralization and spike T cell responses increased. Serology using Wuhan Hu-1 spike receptor binding domain poorly predicted neutralizing immunity against VOCs. Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over 5-months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.</div></section></div></div></section><section class="valid" valid="valid" title="valid: True, node: 158, tag: section, level: 11" node_number="158"><div class="valid" valid="valid" title="valid: True, node: 159, tag: div, level: 12" node_number="159"><div class="valid" valid="valid" title="valid: True, node: 160, tag: div, level: 13" node_number="160">After experiencing &gt;18 months of the COVID-19 pandemic, immunological analysis has shifted to issues of response durability, boosting, and mitigation against future variants of concern (VOC). In doing so we confront viral and population heterogeneities that affect immunity and future protection (<a class="valid" valid="valid" title="valid: True, node: 161, tag: a, level: 14" node_number="161"><i title="valid: False, node: 162, tag: i, level: 15" node_number="162">1</i></a>&#8211;<a class="valid" valid="valid" title="valid: True, node: 163, tag: a, level: 14" node_number="163"><i title="valid: False, node: 164, tag: i, level: 15" node_number="164">4</i></a>). Individuals are either immunologically na&#239;ve to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or have been infected with either the original Wuhan Hu-1 strain or one of the alpha to delta variants of concern (VOC; which we will refer to by full Pango lineage terms). Infection-na&#239;ve individuals, those infected by ancestral SARS-CoV-2 Wuhan Hu-1 or a VOC may have received different numbers of vaccine doses. Thus, there is a spectrum of individuals spanning the immunologically na&#239;ve to those who have experienced one, two, three exposures (and four with boosting) to homologous or heterologous spike sequences. The challenge is to understand whether different antigen exposure combinations are associated with the same quality, quantity and durability of immunity, and ability to cross-protect against other VOCs.</div><div class="valid" valid="valid" title="valid: True, node: 165, tag: div, level: 13" node_number="165">Using a cohort of UK healthcare workers (HCW) for which we have extensive, longitudinal, clinical, transcriptomic, and immunologic characterization (<a class="valid" valid="valid" title="valid: True, node: 166, tag: a, level: 14" node_number="166"><i title="valid: False, node: 167, tag: i, level: 15" node_number="167">5</i></a>&#8211;<a class="valid" valid="valid" title="valid: True, node: 168, tag: a, level: 14" node_number="168"><i title="valid: False, node: 169, tag: i, level: 15" node_number="169">10</i></a>)<i class="valid" valid="valid" title="valid: True, node: 170, tag: i, level: 14" node_number="170">,</i> we address these questions by immunological comparison of BNT162b2 (Pfizer-BioNTech vaccine) vaccinees, with or without infection. We and others have shown the boosting effect of prior infection by the Wuhan Hu-1 strain on the response to vaccination with homologous spike (<a class="valid" valid="valid" title="valid: True, node: 171, tag: a, level: 14" node_number="171"><i title="valid: False, node: 172, tag: i, level: 15" node_number="172">8</i></a>, <a class="valid" valid="valid" title="valid: True, node: 173, tag: a, level: 14" node_number="173"><i title="valid: False, node: 174, tag: i, level: 15" node_number="174">9</i></a>, <a class="valid" valid="valid" title="valid: True, node: 175, tag: a, level: 14" node_number="175"><i title="valid: False, node: 176, tag: i, level: 15" node_number="176">11</i></a>&#8211;<a class="valid" valid="valid" title="valid: True, node: 177, tag: a, level: 14" node_number="177"><i title="valid: False, node: 178, tag: i, level: 15" node_number="178">14</i></a>), and others are decoding changes in immune programming between first and second dose (<a class="valid" valid="valid" title="valid: True, node: 179, tag: a, level: 14" node_number="179"><i title="valid: False, node: 180, tag: i, level: 15" node_number="180">15</i></a>)<i class="valid" valid="valid" title="valid: True, node: 181, tag: i, level: 14" node_number="181">.</i> We compared the impact of prior infection with Wuhan Hu-1 or B.1.1.7. (alpha VOC) in the context of vaccination on T and memory B cell (MBC) responses, cross-neutralization against VOC, durability of immunity and susceptibility to B.1.617.2 (delta VOC) breakthrough infection. We considered the extent to which first encounter with spike sequence shapes subsequent response features to explore the possible effect of immune imprinting or &#8216;original antigenic sin&#8217; (<a class="valid" valid="valid" title="valid: True, node: 182, tag: a, level: 14" node_number="182"><i title="valid: False, node: 183, tag: i, level: 15" node_number="183">16</i></a>&#8211;<a class="valid" valid="valid" title="valid: True, node: 184, tag: a, level: 14" node_number="184"><i title="valid: False, node: 185, tag: i, level: 15" node_number="185">18</i></a>).</div><section class="valid" valid="valid" title="valid: True, node: 186, tag: section, level: 13" node_number="186"><h2 class="valid" valid="valid" title="valid: True, node: 187, tag: h2, level: 14" node_number="187">B and T cell immunity after three homologous antigen exposures</h2><div class="valid" valid="valid" title="valid: True, node: 188, tag: div, level: 14" node_number="188">We analyzed this longitudinal vaccine cohort (<i title="valid: False, node: 189, tag: i, level: 15" node_number="189">n</i> = 51) at 20d (interquartile range, IQR 7) after receiving a second BNT162b2 dose (fig. S1 and table S1). Twenty-five HCW were infected with SARS-CoV-2 approximately synchronous and coincident with peak transmission in London in March 2020 (6). At one year, nucleoprotein (N) antibody (Ab) responses had waned but were still positive (anti-N Ab expressed as a cut-off index of &#8805;1.0 were classified as positive), 16% having fallen to sub-threshold levels (<a title="valid: False, node: 190, tag: a, level: 15" node_number="190">Fig. 1A</a>). Two (2/25, 8%) HCW appeared to have been reinfected (increase in N) and two (2/26, 8%) newly infected (positive N having been previously negative) among the previously uninfected cohort (<a title="valid: False, node: 191, tag: a, level: 15" node_number="191">Fig. 1A</a>). T cell responses to N were sustained at 1 year in the majority of prior infected individuals (22/24, 92%) (fig. S2). All prior infected HCW with positive anti-S1 receptor binding domain (RBD) responses at 16-18 weeks had sustained responses at 28-30 weeks (22/24, 92%), which substantially enhanced following single dose vaccination (36-fold increase in Ab titer) (<a title="valid: False, node: 192, tag: a, level: 15" node_number="192">Fig. 1B</a>). This response plateaued (only increased a further 1.4-fold) following second dose vaccination (third antigen exposure). The prior infected HCW (2/24, 8%) with unrecordable anti-S1 RBD responses at 16-18 and 28-30 weeks showed a 155-fold increase anti-S1 response following second dose vaccination, demonstrating the benefit of a third antigen exposure in poor Ab responders (<a title="valid: False, node: 193, tag: a, level: 15" node_number="193"><i title="valid: False, node: 194, tag: i, level: 16" node_number="194">19</i></a>, <a title="valid: False, node: 195, tag: a, level: 15" node_number="195"><i title="valid: False, node: 196, tag: i, level: 16" node_number="196">20</i></a>)<i title="valid: False, node: 197, tag: i, level: 15" node_number="197">.</i> Infection-na&#239;ve HCW made incrementally increased Ab responses following first and second dose vaccination, achieving about half the Ab titer of their previously infected counterparts 20 days after second vaccine dose (<a title="valid: False, node: 198, tag: a, level: 15" node_number="198">Fig. 1B</a>).</div><div class="valid" valid="valid" title="valid: True, node: 199, tag: div, level: 14" node_number="199">T cell responses to spike mapped epitope peptide (MEP) pool (table S2) increased following second dose vaccination in prior infected individuals (i.e., third exposure to antigen) (<i title="valid: False, node: 200, tag: i, level: 15" node_number="200">P</i> = 0.0294; <a title="valid: False, node: 201, tag: a, level: 15" node_number="201">Fig. 1C</a>). T cell responses following two dose vaccination in infection-na&#239;ve HCW achieved similar levels to those seen at 16-18 weeks after natural SARS-CoV-2 infection. However, there were fewer non-responders (2/23, 9%) in double vaccinated infection-na&#239;ve individuals compared with (5/25, 20%) 16-18 weeks after natural infection.</div><div class="valid" valid="valid" title="valid: True, node: 202, tag: div, level: 14" node_number="202">Infection-na&#239;ve individuals showed incremental increases in neutralizing Ab (nAb) to authentic Wuhan Hu-1 virus and VOCs following first and second vaccination, the largest fold increase occurring after the second vaccine dose (Wuhan Hu-1,123-fold; B.1.1.7, 589-fold; B.1.351, 445-fold; P.1, 1765-fold; and B.1.617.2, 39-fold increase). There was a wider heterogeneity of nAb response to B.1.351, P.1 and B.1.617.2 VOCs compared to B.1.1.7 and Wuhan Hu-1 (<a title="valid: False, node: 203, tag: a, level: 15" node_number="203">Fig. 1D</a>). Individuals who had experienced SARS-CoV-2 infection prior to vaccination also showed the largest fold nAb increase on second antigen exposure (i.e., after first vaccine dose) (Wuhan Hu-1, 27-fold; B.1.1.7, 52-fold; B.1.351, 65-fold; P.1, 63-fold; and B.1.617.2, 20-fold increase) (<a title="valid: False, node: 204, tag: a, level: 15" node_number="204">Fig. 1E</a>). In contrast, nAb responses against Wuhan Hu-1 and VOCs B.1.351, P.1 and B.1.617.2 plateaued or decreased between the second and third antigen exposure. This was not the case for nAb responses against Wuhan Hu-1 and B.1.1.7, which increased 6-fold and 23-fold respectively between the second and third antigen exposure (<a title="valid: False, node: 205, tag: a, level: 15" node_number="205">Fig. 1E</a>). The potency of nAb response after third antigen exposure varied depending on the VOC being neutralized. Prior infected HCW who made a low nAb IC50 after the first vaccine dose caught up following the second vaccine dose (i.e., third antigen exposure). Heterologous neutralizing IC50s were lower than those against homologous Wuhan Hu-1 and at risk of falling below a threshold for protection as levels wane (<a title="valid: False, node: 206, tag: a, level: 15" node_number="206"><i title="valid: False, node: 207, tag: i, level: 16" node_number="207">21</i></a>, <a title="valid: False, node: 208, tag: a, level: 15" node_number="208"><i title="valid: False, node: 209, tag: i, level: 16" node_number="209">22</i></a>) (1F, S3).</div><div class="valid" valid="valid" title="valid: True, node: 210, tag: div, level: 14" node_number="210">There was a positive correlation between S1 RBD binding Ab and neutralization (IC50), with previously infected individuals showing higher nAb IC50 and S1 RBD binding (<a title="valid: False, node: 211, tag: a, level: 15" node_number="211">Fig. 1G</a>). Wuhan-Hu-1 sequence specific S1 RBD binding correlated less well with nAb IC50 against VOCs B.1.351, P.1 and B.1.617.2, especially for infection-na&#239;ve, double vaccinated HCW. To establish if this was due to different sequences in the VOC RBD, the relationship between VOC RBD binding titers and neutralization was explored. There was positive correlation between the Roche S1 RBD and VOC RBD specific binding (fig. S4). The weaker correlations between VOC nAb titers and VOC RBD binding indicate that antibodies targeting regions outside of RBD may contribute to neutralization and therefore the binding titer is not predictive of neutralization (<a title="valid: False, node: 212, tag: a, level: 15" node_number="212">Fig. 1H</a>). For example, a two-dose vaccinated HCW with an S1 RBD (Wuhan Hu-1) binding titer of 2950 U/ml, considered strongly positive, showed divergent neutralization of VOCs, with IC50s of: Wuhan Hu-1, 6,071, B.1.1.7, 1,037; B.1.351, 301; P.1, 560 and B.1.617.2 zero 20d after second dose vaccination that all fell to undetectable 18 weeks later. This individual was later infected by B.1.617.2. Thus, S1 serology data using the Wuhan Hu-1 S1 RBD and VOC sequence is an unreliable marker for neutralization potency against VOCs.</div><div class="valid" valid="valid" title="valid: True, node: 213, tag: div, level: 14" node_number="213">For infection-na&#239;ve subjects, frequency of S1 specific MBC 20d after first-dose vaccination was lower compared to 16-18 weeks after infection. On the other hand, MBCs were amplified in previously infected HCWs to a level similar to that seen following two doses of vaccine (<a title="valid: False, node: 214, tag: a, level: 15" node_number="214">Fig. 1I</a>). As expected from the S1 RBD binding Ab and nAb responses, MBC responses plateaued, with no further enhancement following a third antigen exposure (i.e., double vaccinated previously infected HCW) (<a title="valid: False, node: 215, tag: a, level: 15" node_number="215">Fig. 1, I and J</a>). For infection-na&#239;ve HCW, the MBC frequency for specificity to S1 containing the N501Y, E484K and K417N B.1.351 mutations was lower after one vaccine dose (<a title="valid: False, node: 216, tag: a, level: 15" node_number="216">Fig. 1K</a>, left panel). After two (two dose vaccination or single dose vaccination and prior infection) or three antigen exposures (two dose vaccination and prior infection), the MBC response is maintained whether stimulated by S1 or S1 containing mutations found in B.1.351 and B.1.617.2 (<a title="valid: False, node: 217, tag: a, level: 15" node_number="217">Fig. 1K</a>, middle and right panels). There was a high frequency of MBC able to recognize S1 and S1 containing VOC specific mutations, but not always correlated well with a VOC specific nAb response (fig. S5). Authentic P.1 (<i title="valid: False, node: 218, tag: i, level: 15" node_number="218">r</i> = 0.529, <i title="valid: False, node: 219, tag: i, level: 15" node_number="219">P</i> = 0.0138) and B.1.617.2 (<i title="valid: False, node: 220, tag: i, level: 15" node_number="220">r</i> = 0.548, <i title="valid: False, node: 221, tag: i, level: 15" node_number="221">P</i> = 0.001) nAb responses of double vaccinated HCW with and without prior Wuhan Hu-1 infection positively correlated with the MBC frequency against S1 containing the B.1.617.2 specific mutations (fig. S5C).</div><div class="valid" valid="valid" title="valid: True, node: 222, tag: div, level: 14" node_number="222">Next, we examined the T cell response against VOCs B.1.1.7, B.1.351, P.1, B.1.617.2 peptide pools and Wuhan Hu-1 matched pools and individual peptides with substituted epitopes covering N501Y and D1118H (table S2 and <a title="valid: False, node: 223, tag: a, level: 15" node_number="223">Fig. 2, A and B</a>). T cell responses in doubly vaccinated, infection-na&#239;ve individuals were variable. Previously infected doubly vaccinated individuals showed a significantly increased T cell response to B.1.1.7 (<i title="valid: False, node: 224, tag: i, level: 15" node_number="224">P</i> = 0.0153) and B.1.617.2 (<i title="valid: False, node: 225, tag: i, level: 15" node_number="225">P</i> = 0.0283) peptide pools and N501Y (<i title="valid: False, node: 226, tag: i, level: 15" node_number="226">P</i> = 0.0156) variant peptide compared to the respective Wuhan Hu-1 pools and peptide (<a title="valid: False, node: 227, tag: a, level: 15" node_number="227">Fig. 2B</a>). A cumulative increase in T cell response to the Wuhan Hu-1 spike MEP pool was observed as the number of antigen exposures increased (one to two exposures, <i title="valid: False, node: 228, tag: i, level: 15" node_number="228">P</i> = 0.0003; two to three exposures, <i title="valid: False, node: 229, tag: i, level: 15" node_number="229">P</i> = 0.0294; <a title="valid: False, node: 230, tag: a, level: 15" node_number="230">Fig. 2C</a>). There was a similarly increased T cell response to the B.1.1.7 variant peptide pool (one to two exposures, <i title="valid: False, node: 231, tag: i, level: 15" node_number="231">P</i> = 0.0008; two to three exposures, <i title="valid: False, node: 232, tag: i, level: 15" node_number="232">P</i> = 0.0004; <a title="valid: False, node: 233, tag: a, level: 15" node_number="233">Fig. 2E</a>) depending on number of antigen exposures, indicating a heteroclitic response to variant peptides (<a title="valid: False, node: 234, tag: a, level: 15" node_number="234"><i title="valid: False, node: 235, tag: i, level: 16" node_number="235">23</i></a>) (<a title="valid: False, node: 236, tag: a, level: 15" node_number="236">Fig. 2, D and E</a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 237, tag: section, level: 13" node_number="237"><h2 class="valid" valid="valid" title="valid: True, node: 238, tag: h2, level: 14" node_number="238">VOC mutation alters T cell effector program</h2><div class="valid" valid="valid" title="valid: True, node: 239, tag: div, level: 14" node_number="239">Immunization of transgenic mice expressing human HLADRB1*0401 were used to see if any of the variant peptides behave as an altered peptide ligand (APL), eliciting a differential T cell program (<a title="valid: False, node: 240, tag: a, level: 15" node_number="240"><i title="valid: False, node: 241, tag: i, level: 16" node_number="241">9</i></a>). <i title="valid: False, node: 242, tag: i, level: 15" node_number="242">In silico</i> analysis of P.1 variant peptides indicated that the majority are not predicted to bind to common HLAII alleles found in the UK population (table S3). The N501Y mutation is predicted to change from strong to weak binding to HLADRB1*0401. IFN&#947; T cell responses in mice primed with Wuhan-Hu-1 peptide pool were ablated for the 501Y variant peptide (found in the B.1.1.7, B.1.351 and P.1 VOCs (<a title="valid: False, node: 243, tag: a, level: 15" node_number="243">Fig. 2F</a>) when presented by HLA-DRB1*0401 (<i title="valid: False, node: 244, tag: i, level: 15" node_number="244">n</i> = 7, <i title="valid: False, node: 245, tag: i, level: 15" node_number="245">P</i> = 0.006). Altered CD4 recognition of the N501Y mutation merits further attention as it is a frequent replacement among reported sequences, comprising a convergent mutational signature shared by alpha, beta and gamma lineages (<a title="valid: False, node: 246, tag: a, level: 15" node_number="246"><i title="valid: False, node: 247, tag: i, level: 16" node_number="247">24</i></a>&#8211;<a title="valid: False, node: 248, tag: a, level: 15" node_number="248"><i title="valid: False, node: 249, tag: i, level: 16" node_number="249">26</i></a>)<i title="valid: False, node: 250, tag: i, level: 15" node_number="250">.</i> Thus far the lack of T cell responses to 501Y has been described in terms of absence of CD8 recognition (<a title="valid: False, node: 251, tag: a, level: 15" node_number="251"><i title="valid: False, node: 252, tag: i, level: 16" node_number="252">27</i></a>)<i title="valid: False, node: 253, tag: i, level: 15" node_number="253">.</i> Our transcriptomic analysis showed an absence of immune effector response to the variant peptide, although induction of the regulatory T cell (Treg) transcription factor, FOXP3, did occur, indicating that the variant peptide may exert an APL effect on T cell function, switching from effector to regulatory (<a title="valid: False, node: 254, tag: a, level: 15" node_number="254">Fig. 2G</a>). This was further confirmed by qPCR for IRF4 and by CD4 expression of FoxP3 protein, indicating that mutant epitopes may subvert T cell activation into a regulatory program (<a title="valid: False, node: 255, tag: a, level: 15" node_number="255">Fig. 2, G to I</a>).</div><div class="valid" valid="valid" title="valid: True, node: 256, tag: div, level: 14" node_number="256">Mice were primed with either B.1.617.2 or Wuhan Hu-1 matched specific peptide pools. In each case, T cells responded on challenge to the pool with which they were primed and not to the heterologous panel (<i title="valid: False, node: 257, tag: i, level: 15" node_number="257">P</i> = 0.0022; <a title="valid: False, node: 258, tag: a, level: 15" node_number="258">Fig. 2J</a>). That is, the T cell repertoire distinguishes VOC mutations, specifically recognizing the B.1.617.2 epitopes. <i title="valid: False, node: 259, tag: i, level: 15" node_number="259">In silico</i> analysis of the B.1.617.2 variant peptides indicated that the majority are predicted to bind one or more of the common HLAII alleles found in the UK population (table S4). The D950N mutation is predicted to change from HLADRB1*0401 binding from weak to strong. T cell responses after priming with B.1.617.2 peptide pool were present for the D950N variant peptide, but not after priming with the Wuhan Hu-1 pool (<i title="valid: False, node: 260, tag: i, level: 15" node_number="260">P</i> = 0.0022; <a title="valid: False, node: 261, tag: a, level: 15" node_number="261">Fig. 2J</a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 262, tag: section, level: 13" node_number="262"><h2 class="valid" valid="valid" title="valid: True, node: 263, tag: h2, level: 14" node_number="263">Heterologous B.1.1.7 infection shapes subsequent immunity</h2><div class="valid" valid="valid" title="valid: True, node: 264, tag: div, level: 14" node_number="264">We then looked at the impact of infection with B.1.1.7 during the second wave on immune responses in individuals given vaccine expressing Wuhan Hu-1 spike. For this part of the study, an additional 358 HCWs were followed up at 55-57 weeks after recruitment into the study (fig. S1). Of these, 63 had been infected with SARS-CoV-2 during the first Wuhan Hu-1 wave. Fifty-three of previously uninfected HCW (53/296, 18%) were identified by virtue of longitudinal N serology (from baseline to 16-18, 28-30, 42, 54, and 55-57 weeks) as having been newly infected during the B.1.1.7 s wave. Thirty-six (68%) were doubly vaccinated and eight (15%) unvaccinated at the time of follow up (fig. S1 and tables S5 and S6). Five previously infected HCW were reinfected (5/63, 8%) during the second wave. S1 IgG titers were measured at 55-57 weeks (fig. S6B). The median date of a positive SARS-CoV-2 PCR test was December 28<sup title="valid: False, node: 265, tag: sup, level: 15" node_number="265">th</sup>, 2020 (IQR, 22d). The B.1.1.7 VOC accounted for 94.7% of SARS-CoV-2 infections in central London in the two weeks leading up to January 2<sup title="valid: False, node: 266, tag: sup, level: 15" node_number="266">nd</sup>, 202 (<a title="valid: False, node: 267, tag: a, level: 15" node_number="267"><i title="valid: False, node: 268, tag: i, level: 16" node_number="268">28</i></a>); we thus made the starting assumption that for the majority of HCW infected during the second wave, the infecting strain was B.1.1.7. To support this, we compared the Wuhan Hu-1 and B.1.1.7 nAb IC50 results for unvaccinated (<i title="valid: False, node: 269, tag: i, level: 15" node_number="269">n</i> = 24 and 8), single dose (<i title="valid: False, node: 270, tag: i, level: 15" node_number="270">n</i> = 25 and 9), and two dose vaccinated (<i title="valid: False, node: 271, tag: i, level: 15" node_number="271">n</i> = 24 and 34), HCW infected during the first and second UK waves by Wuhan Hu-1 and B.1.1.7 respectively (fig. S7). In unvaccinated HCWs, those infected during the first wave (fig. S7A, LHS) made nAb IC50 responses against Wuhan Hu-1, but negligible or no nAb IC50 response against B.1.1.7 (<i title="valid: False, node: 272, tag: i, level: 15" node_number="272">P</i> &lt; 0.0001). In contrast, HCW infected as B.1.1.7 peaked (fig. S7A, RHS) made similar nAb IC50 against B.1.1.7 and Wuhan Hu-1 live virus. In Wuhan Hu-1 infected HCW, the Wuhan Hu-1 and B.1.1.7 nAb IC50 increased and remained significantly different after one (<i title="valid: False, node: 273, tag: i, level: 15" node_number="273">P</i> &lt; 0.0001) and two (<i title="valid: False, node: 274, tag: i, level: 15" node_number="274">P</i> &lt; 0.0001) dose vaccination, but the differential between them decreased (<a title="valid: False, node: 275, tag: a, level: 15" node_number="275">Fig. 3F</a> and fig. S7, B and C).</div><div class="valid" valid="valid" title="valid: True, node: 276, tag: div, level: 14" node_number="276">We set out to investigate the impact of heterologous antigen exposure with B.1.1.7. A confounder in assessing comparative post-vaccination immunity between first wave (Wuhan-Hu-1) infected and second wave (B.1.1.7) infected HCW is that they differ with respect to the infecting strain and in the time interval between infection and vaccination. We hypothesized that observed differences in immunity may relate to recall differences between heterologous spike sequences &#8211; immune imprinting (<a title="valid: False, node: 277, tag: a, level: 15" node_number="277"><i title="valid: False, node: 278, tag: i, level: 16" node_number="278">16</i></a>&#8211;<a title="valid: False, node: 279, tag: a, level: 15" node_number="279"><i title="valid: False, node: 280, tag: i, level: 16" node_number="280">18</i></a>), and/or to differences in affinity maturation of the Ab repertoire with time from initial infection. Somatic hypermutation and breadth of neutralizing response is known to improve with time from infection (<a title="valid: False, node: 281, tag: a, level: 15" node_number="281"><i title="valid: False, node: 282, tag: i, level: 16" node_number="282">29</i></a>&#8211;<a title="valid: False, node: 283, tag: a, level: 15" node_number="283"><i title="valid: False, node: 284, tag: i, level: 16" node_number="284">31</i></a>), but also, there may be intrinsic differences between the breadth and hierarchy of neutralizing responses primed by different variants (<a title="valid: False, node: 285, tag: a, level: 15" node_number="285"><i title="valid: False, node: 286, tag: i, level: 16" node_number="286">32</i></a>). We initially compared nAb profiles for neutralization of Wuhan Hu-1 and VOC alpha to delta at a similar number of weeks after PCR confirmed SARS-CoV-2 infection with Wuhan Hu-1 during the first wave and B.1.1.7 during the second wave (all HCW unvaccinated). This data supports the contention that there are qualitatively and quantitatively differential patterns, even matching for timepoint (fig. S9).</div><div class="valid" valid="valid" title="valid: True, node: 287, tag: div, level: 14" node_number="287">After a single vaccine dose, infection-na&#239;ve HCW made a similar S1 RBD response to that seen in infection with B.1.1.7. Those HCW that were infected by Wuhan Hu-1 12 months earlier made a 3.9-fold higher S1-RBD response than those infected more recently by the B.1.1.7 variant (<i title="valid: False, node: 288, tag: i, level: 15" node_number="288">P</i> = 0.004; <a title="valid: False, node: 289, tag: a, level: 15" node_number="289">Fig. 3A</a>). After two vaccine doses, HCW infected during March 2020 by Wuhan Hu-1 (<i title="valid: False, node: 290, tag: i, level: 15" node_number="290">n</i> = 70), having had three homologous antigen exposures, made a 1.5-fold higher S1-RBD response than those encountering three antigen exposures, with one of these being heterologous B.1.1.7 (<i title="valid: False, node: 291, tag: i, level: 15" node_number="291">n</i> = 36, <i title="valid: False, node: 292, tag: i, level: 15" node_number="292">P</i> = 0.0188; <a title="valid: False, node: 293, tag: a, level: 15" node_number="293">Fig. 3A</a>). The B.1.1.7 infected two dose vaccinated HCW made a similar S1-RBD response to two-dose infection-na&#239;ve vaccinees. Infection-na&#239;ve vacccinees made a 1.8-fold lower response compared to the Wuhan Hu-1 prior infected group (<i title="valid: False, node: 294, tag: i, level: 15" node_number="294">n</i> = 241, <i title="valid: False, node: 295, tag: i, level: 15" node_number="295">P</i> &lt; 0.0001; <a title="valid: False, node: 296, tag: a, level: 15" node_number="296">Fig. 3A</a>). The indication is that the phenomenon of enhanced vaccine responses by infection, which has been reproducibly described by us and others (<a title="valid: False, node: 297, tag: a, level: 15" node_number="297"><i title="valid: False, node: 298, tag: i, level: 16" node_number="298">8</i></a>, <a title="valid: False, node: 299, tag: a, level: 15" node_number="299"><i title="valid: False, node: 300, tag: i, level: 16" node_number="300">9</i></a>, <a title="valid: False, node: 301, tag: a, level: 15" node_number="301"><i title="valid: False, node: 302, tag: i, level: 16" node_number="302">11</i></a>&#8211;<a title="valid: False, node: 303, tag: a, level: 15" node_number="303"><i title="valid: False, node: 304, tag: i, level: 16" node_number="304">14</i></a>), is less effective if the infection involves heterologous spike from a VOC.</div><div class="valid" valid="valid" title="valid: True, node: 305, tag: div, level: 14" node_number="305">After two vaccine doses, individuals infected during the Wuhan Hu-1 wave made a higher T cell response to the B.1.1.7 peptide pool than those infected during the B.1.1.7 wave (<i title="valid: False, node: 306, tag: i, level: 15" node_number="306">P</i> = 0.0412), arguing for stronger T cell priming in those with three homologous exposures (<a title="valid: False, node: 307, tag: a, level: 15" node_number="307">Fig. 3, B to D</a>).</div><div class="valid" valid="valid" title="valid: True, node: 308, tag: div, level: 14" node_number="308">We next considered the effect of B.1.1.7 infection in single and double vaccination. In two dose vaccinated individuals, B.1.1.7 infection resulted in a different hierarchy of nAb IC50 responses against VOC compared to after Wuhan Hu-1 infection: Wuhan Hu-1&gt;B.1.1.7&gt;B.1.351&gt;P.1&gt;B.1.617.2. In the context of heterologous B.1.1.7 infection and two dose vaccination, the hierarchy changed to B.1.1.7&gt;Wuhan Hu-1&gt;B.1.617.2&gt;P.1&gt;B.1.351 (<a title="valid: False, node: 309, tag: a, level: 15" node_number="309">Fig. 3, E and F</a>). This indicates a process of selective discriminative heterologous imprinting following exposure to B.1.1.7 infection (<a title="valid: False, node: 310, tag: a, level: 15" node_number="310">Fig. 3, E and F</a>, and fig. S8). As predicted for immune imprinting by SARS-CoV-2 variants, first encounter imparts a differential subsequent pattern (<a title="valid: False, node: 311, tag: a, level: 15" node_number="311"><i title="valid: False, node: 312, tag: i, level: 16" node_number="312">16</i></a>&#8211;<a title="valid: False, node: 313, tag: a, level: 15" node_number="313"><i title="valid: False, node: 314, tag: i, level: 16" node_number="314">18</i></a>).</div><div class="valid" valid="valid" title="valid: True, node: 315, tag: div, level: 14" node_number="315">To better understand the relationship between differential nAb IC50 and S1 RBD binding we correlated the two. First we compared the impact of 2 homologous antigen exposures (either 2 dose vaccination [blue, infection-naive] or prior Wuhan Hu-1 infection followed by single-dose vaccination [red, Wuhan Hu-1]) to heterologous exposure through B.1.1.7 infection (single dose vaccination and B.1.1.7 infection [green, B.1.1.7]). Double dose vaccinated infection-na&#239;ve HCW (blue) achieved higher neutralization against authentic Wuhan Hu-1 live virus than those with heterologous infection by B.1.1.7 and single-dose vaccination (green) (<i title="valid: False, node: 316, tag: i, level: 15" node_number="316">P</i> = 0.0036; <a title="valid: False, node: 317, tag: a, level: 15" node_number="317">Fig. 3G</a> and fig. S10A). Individuals infected by B.1.1.7 and single-dose vaccinated (green) made higher nAb IC50 against B.1.1.7 compared to two dose infection-na&#239;ve HCW (<i title="valid: False, node: 318, tag: i, level: 15" node_number="318">P</i> &lt; 0.0001) (blue) and Wuhan Hu-1 prior infected single-dose vaccinated HCW (<i title="valid: False, node: 319, tag: i, level: 15" node_number="319">P</i> &lt; 0.0001) (red) (<a title="valid: False, node: 320, tag: a, level: 15" node_number="320">Fig. 3G</a> and fig. S10A). Furthermore, neutralization IC50 of B.1.351 live virus was less potent following heterologous B.1.1.7 infection and single dose vaccination (green) (<i title="valid: False, node: 321, tag: i, level: 15" node_number="321">P</i> = 0.0001; <a title="valid: False, node: 322, tag: a, level: 15" node_number="322">Fig. 3G</a> and fig. S10A). Following 3 antigen encounters, the impact of heterologous exposure becomes more pronounced. HCW with heterologous infection with B.1.1.7 (green) rather than Wuhan Hu-1 (red) had substantially lower neutralization against authentic Wuhan Hu-1 (<i title="valid: False, node: 323, tag: i, level: 15" node_number="323">P</i> &lt; 0.0001), B.1.351 (<i title="valid: False, node: 324, tag: i, level: 15" node_number="324">P</i> &lt; 0.0001) and P.1 (<i title="valid: False, node: 325, tag: i, level: 15" node_number="325">P</i> = 0.0616) live virus (fig. S10B). Furthermore, double vaccinated HCW with a history of heterologous infection by B.1.1.7 had lower nAb IC50 against B.1.351 than infection-na&#239;ve double vaccinated HCW (<i title="valid: False, node: 326, tag: i, level: 15" node_number="326">P</i> = 0.0007; fig. S10B). In contrast, double dose vaccinated HCW with a history of heterologous infection with B.1.1.7 (green) had higher nAb IC50 against B.1.617.2 than infection-na&#239;ve double vaccinated HCW (<i title="valid: False, node: 327, tag: i, level: 15" node_number="327">P</i> &lt; 0.0001; fig. S10B). Thus, neutralization potency achieved was dependent on number of antigen encounters and the presence or absence of heterologous exposure. Ab neutralization is a widely accepted correlate of protection (COP), estimated at a nAb IC50 of &gt;15, and S1 RBD binding an accessible and accepted marker of this (<a title="valid: False, node: 328, tag: a, level: 15" node_number="328"><i title="valid: False, node: 329, tag: i, level: 16" node_number="329">22</i></a>). Our data here show that S1 RBD and VOC S1 RBD titers are not a reliable COP for VOC, especially in the context of selective discriminative heterologous exposure during infection with B.1.1.7. In HCW with heterologous B.1.1.7 exposure, the nAb IC50 of B1.351 was significantly reduced (<i title="valid: False, node: 330, tag: i, level: 15" node_number="330">P</i> &lt; 0.0001) and B.1.617.2 significantly increased (<i title="valid: False, node: 331, tag: i, level: 15" node_number="331">P</i> = 0.0025) when compared to HCW with homologous Wuhan Hu-1 infection.</div></section><section class="valid" valid="valid" title="valid: True, node: 332, tag: section, level: 13" node_number="332"><h2 class="valid" valid="valid" title="valid: True, node: 333, tag: h2, level: 14" node_number="333">Differential longitudinal immunity after heterologous infection</h2><div class="valid" valid="valid" title="valid: True, node: 334, tag: div, level: 14" node_number="334">Next, we considered relative durability of immunity following 3 dose homologous (Wuhan Hu-1 infection plus vaccination) and heterologous (B.1.1.7 infection plus vaccination) antigen compared to two dose vaccinated infection-na&#239;ve individuals. S1 RBD Ab levels declined as the number of weeks post second dose increased in both infection-na&#239;ve (<i title="valid: False, node: 335, tag: i, level: 15" node_number="335">r</i> = 0.545; <i title="valid: False, node: 336, tag: i, level: 15" node_number="336">P</i> &lt; 0.0001) and prior infected (<i title="valid: False, node: 337, tag: i, level: 15" node_number="337">r</i> = 0.537; <i title="valid: False, node: 338, tag: i, level: 15" node_number="338">P</i> &lt; 0.0001) HCW (<a title="valid: False, node: 339, tag: a, level: 15" node_number="339">Fig. 4, A and B</a>, and tables S1 and S5 to S9). Following a third vaccine dose the S1 RBD binding increased in all three groups to a similar level (<a title="valid: False, node: 340, tag: a, level: 15" node_number="340">Fig. 4C</a>). B.1.1.7 infection (green circles) compared with Wuhan Hu-1 infection (red circles) was associated with lower nAb IC50 against Wuhan Hu-1 (<i title="valid: False, node: 341, tag: i, level: 15" node_number="341">P</i> &lt; 0.0001) and B.1.351 (<i title="valid: False, node: 342, tag: i, level: 15" node_number="342">P</i> &lt; 0.0001) VOC initially at (10d-8 weeks after vaccination) and P.1 (<i title="valid: False, node: 343, tag: i, level: 15" node_number="343">P</i> = 0.0020) 8 weeks later (12-22 weeks after vaccination), indicating differential nAb responses over time depend on the VOC (<a title="valid: False, node: 344, tag: a, level: 15" node_number="344">Fig. 4D</a>). Double vaccinated infection-na&#239;ve HCW were at a lower starting value for nAb IC50 against B.1.617.2 compared to B.1.1.7 (<i title="valid: False, node: 345, tag: i, level: 15" node_number="345">P</i> &lt; 0.0001) and Wuhan Hu-1 (<i title="valid: False, node: 346, tag: i, level: 15" node_number="346">P</i> = 0.0462) infected HCW (<a title="valid: False, node: 347, tag: a, level: 15" node_number="347">Fig. 3H</a> and fig. S10B). The nAb IC50 against authentic Wuhan Hu-1 and all four VOC (B.1.1.7, B.1.351, P.1, and B.1.617.2) fell differentially depending on the VOC being neutralized and SARS-CoV-2 infection history (<a title="valid: False, node: 348, tag: a, level: 15" node_number="348">Fig. 4E</a>).</div><div class="valid" valid="valid" title="valid: True, node: 349, tag: div, level: 14" node_number="349">In two dose vaccinated infection-na&#239;ve HCW, nAb IC50 against authentic Wuhan Hu-1 and all four of the VOCs fell significantly over 18 weeks (Wuhan Hu-1, 26-fold, <i title="valid: False, node: 350, tag: i, level: 15" node_number="350">P</i> &lt; 0.0001; B.1.1.7, 18-fold, <i title="valid: False, node: 351, tag: i, level: 15" node_number="351">P</i> &lt; 0.0001; B.1.351, 29-fold, <i title="valid: False, node: 352, tag: i, level: 15" node_number="352">P</i> &lt; 0.0001; P.1. 26-fold, <i title="valid: False, node: 353, tag: i, level: 15" node_number="353">P</i> &lt; 0.0001; B.1.617.2 233-fold, <i title="valid: False, node: 354, tag: i, level: 15" node_number="354">P</i> &lt; 0.0001). This was most marked for B.1.617.2 live virus neutralization where by 21 weeks after the second dose it was zero for 21/27 (78%) of HCW tested (median 0, IQR 0, <i title="valid: False, node: 355, tag: i, level: 15" node_number="355">n</i> = 27) (<a title="valid: False, node: 356, tag: a, level: 15" node_number="356">Fig. 4E</a>). For two dose vaccinated prior Wuhan Hu-1 infected HCW, there was a significantly and less pronounced fall in nAb IC50 against authentic Wuhan Hu-1 and three of the VOCs over 18 weeks (Wuhan Hu-1, 5-fold, <i title="valid: False, node: 357, tag: i, level: 15" node_number="357">P</i> = 0.0003; B.1.1.7, 7-fold, <i title="valid: False, node: 358, tag: i, level: 15" node_number="358">P</i> &lt; 0.0001; B.1.351, 4-fold, <i title="valid: False, node: 359, tag: i, level: 15" node_number="359">P</i> = 0.0042; P.1. 10-fold, <i title="valid: False, node: 360, tag: i, level: 15" node_number="360">P</i> = 0.0003). By contrast, in the presence of heterologous infection with B.1.1.7 and two dose vaccination, nAb IC50 fell significantly over 18 weeks for some variants (Wuhan Hu-1, 6-fold, <i title="valid: False, node: 361, tag: i, level: 15" node_number="361">P</i> = 0.0002; B.1.1.7 13-fold, <i title="valid: False, node: 362, tag: i, level: 15" node_number="362">P</i> &lt; 0.0001; P.1 7-fold, <i title="valid: False, node: 363, tag: i, level: 15" node_number="363">P</i> &lt; 0.0001; and B.1.617.2 41-fold, <i title="valid: False, node: 364, tag: i, level: 15" node_number="364">P</i> &lt; 0.0001) while nAb IC50 against B.1.351 did not (<i title="valid: False, node: 365, tag: i, level: 15" node_number="365">P</i> = 0.4304).</div><div class="valid" valid="valid" title="valid: True, node: 366, tag: div, level: 14" node_number="366">T cell responses against spike MEP pool 21 weeks after the second dose were higher in two dose vaccinated HCW that were infected with B.1.1.7 than two dose vaccinated infection-na&#239;ve HCW (<i title="valid: False, node: 367, tag: i, level: 15" node_number="367">P</i> = 0.0304; <a title="valid: False, node: 368, tag: a, level: 15" node_number="368">Fig. 4F</a>).</div><div class="valid" valid="valid" title="valid: True, node: 369, tag: div, level: 14" node_number="369">MBC frequencies against the Wuhan Hu-1 S1 and S1 containing the B.1.617.2 mutations were equivalent twenty-one weeks after second dose vaccination (<a title="valid: False, node: 370, tag: a, level: 15" node_number="370">Fig. 4G</a>). Two dose vaccinated B.1.1.7 infected HCW made higher frequency responses against S1 containing the B.1.617.2 mutations than two dose vaccinated infection-na&#239;ve HCW (<i title="valid: False, node: 371, tag: i, level: 15" node_number="371">P</i> = 0.0138; <a title="valid: False, node: 372, tag: a, level: 15" node_number="372">Fig. 4H</a>). MBC frequencies in two dose vaccinated infection-na&#239;ve HCW fell over 18 weeks (<i title="valid: False, node: 373, tag: i, level: 15" node_number="373">n</i> = 11, <i title="valid: False, node: 374, tag: i, level: 15" node_number="374">P</i> = 0.0098) while those from Wuhan Hu-1 prior infected HCW were sustained (<i title="valid: False, node: 375, tag: i, level: 15" node_number="375">n</i> = 4; <a title="valid: False, node: 376, tag: a, level: 15" node_number="376">Fig. 4I</a>).</div></section><section class="valid" valid="valid" title="valid: True, node: 377, tag: section, level: 13" node_number="377"><h2 class="valid" valid="valid" title="valid: True, node: 378, tag: h2, level: 14" node_number="378">Immune parameters associated with B.1.617.2 breakthrough infection</h2><div class="valid" valid="valid" title="valid: True, node: 379, tag: div, level: 14" node_number="379">At the time of the 71-72 and 83-84 week recruitments B.1.617.2 VOC infections accounted for 97.8% and 99.9% of UK SARS-CoV-2 infections respectively (<a title="valid: False, node: 380, tag: a, level: 15" node_number="380"><i title="valid: False, node: 381, tag: i, level: 16" node_number="381">26</i></a>)<i title="valid: False, node: 382, tag: i, level: 15" node_number="382">.</i> We identified 6/80 (8%) and 14/74 (19%) B.1.617.2 breakthrough infections in the double vaccinated HCW. Ten were previously infection-na&#239;ve, four had prior Wuhan Hu-1 infection and six were infected by B.1.1.7 (tables S8 and S10). PCR positive confirmed B.1.617.2 breakthrough infections occurred in the context of S1 RBD Ab levels ranging 1,110 to 29,308 U/ml (median = 9,010, IQR 13,650) 2-3 weeks after the second vaccine dose. We evaluated the S1 RBD, nAb, T cell and MBC data in these double vaccinated HCW before (purple circle) and after (lilac circle) their B.1.617.2 breakthrough infection (fig. S11, A to J). Analysis showed that both prior infected and infection-na&#239;ve HCW making S1 RBD Ab responses (20d post second dose) of over 1,100 U/ml had become infected and breakthrough infection was not specifically associated with being a low responder (fig. S11, A and B). Relatively potent nAb IC50 at 20d after second vaccine dose had fallen 12 weeks later. This fall was more pronounced in the infection-na&#239;ve double vaccinated HCW (fig. S11, D and E). For B.1.617.2 the nAb IC50 fell to zero in two dose vaccinated infection-na&#239;ve HCW (fig. S11, D and G). B.1.617.2 breakthrough infections have been linked to low nAb responses (<a title="valid: False, node: 383, tag: a, level: 15" node_number="383"><i title="valid: False, node: 384, tag: i, level: 16" node_number="384">33</i></a>). Current estimates for COP apply poorly in the case of B.1.617.2 (<a title="valid: False, node: 385, tag: a, level: 15" node_number="385"><i title="valid: False, node: 386, tag: i, level: 16" node_number="386">22</i></a>). In the cases reported here, breakthrough infections occurred in the face of good prior S1 RBD Ab titers, nAb IC50s and MBC frequency 20d after second vaccine dose, but responses fell in the subsequent 18 weeks especially in the infection na&#239;ve two dose vaccinated. Initial immune responses poorly predicted protection against B.1.617.2 breakthrough infection (fig. S11, A to J).</div></section><section class="valid" valid="valid" title="valid: True, node: 387, tag: section, level: 13" node_number="387"><h2 class="valid" valid="valid" title="valid: True, node: 388, tag: h2, level: 14" node_number="388">Discussion</h2><div class="valid" valid="valid" title="valid: True, node: 389, tag: div, level: 14" node_number="389">The new challenge in a world facing diverse VOC is to understand both cross-neutralization of these by first-generation spike vaccines, but also, how protective immunity is differentially shaped in those who have had infection by the different VOC (<a title="valid: False, node: 390, tag: a, level: 15" node_number="390"><i title="valid: False, node: 391, tag: i, level: 16" node_number="391">34</i></a>). These real-life issues of immune imprinting have implications for optimal design of second-generation variant spike vaccine boosters in parts of the world experiencing different VOCs, or in assessing heterogeneity in the quantity, quality, and durability of immune protection in those who have experienced different combinations of infecting and vaccinating sequences. Infection by B.1.1.7 had different features to Wuhan Hu-1 in terms of protection against VOC, evident in the response to infection and in the differential impact of vaccine-boosting previously described (<a title="valid: False, node: 392, tag: a, level: 15" node_number="392"><i title="valid: False, node: 393, tag: i, level: 16" node_number="393">8</i></a>, <a title="valid: False, node: 394, tag: a, level: 15" node_number="394"><i title="valid: False, node: 395, tag: i, level: 16" node_number="395">9</i></a>, <a title="valid: False, node: 396, tag: a, level: 15" node_number="396"><i title="valid: False, node: 397, tag: i, level: 16" node_number="397">11</i></a>&#8211;<a title="valid: False, node: 398, tag: a, level: 15" node_number="398"><i title="valid: False, node: 399, tag: i, level: 16" node_number="399">14</i></a>). Differential skewing of the immune repertoire may occur if the prime/boost is through B.1.1.7, since epitope modification at DY144 and N501Y changes the nAb repertoire (<a title="valid: False, node: 400, tag: a, level: 15" node_number="400"><i title="valid: False, node: 401, tag: i, level: 16" node_number="401">4</i></a>, <a title="valid: False, node: 402, tag: a, level: 15" node_number="402"><i title="valid: False, node: 403, tag: i, level: 16" node_number="403">35</i></a>). We found a differential hierarchy of cross-neutralization to VOC after natural infection, one or two vaccine doses, depending on the infecting strain. That different immune priming by B.1.1.7 is likely a consequence of heterologous virus per se and not of a shorter timespan for affinity maturation is supported by data from Israel, confirming that susceptibility grows with time and with declining Ab levels (<a title="valid: False, node: 404, tag: a, level: 15" node_number="404"><i title="valid: False, node: 405, tag: i, level: 16" node_number="405">36</i></a>). Vaccine programs currently use prototypic Wuhan Hu-1 sequence against a background of infection by different VOC predominating in different parts of the world. Decoding the differential breadth of VOC neutralizing response ensuing from diverse priming combinations will affect which variant spike sequences may best serve in second generation vaccines. This appears a more complex choice than simply opting for the most concerning variant at any given time. Since heterologous combinations can confer a diminished response against other variants, there may be a case for sticking with the Wuhan Hu-1 sequence in booster vaccinations in the first instance in the face of unknown future VOCs, or for improved efforts to define vaccines based on optimization of common, conserved, neutralizing epitopes (<a title="valid: False, node: 406, tag: a, level: 15" node_number="406"><i title="valid: False, node: 407, tag: i, level: 16" node_number="407">37</i></a>). In any case, the inference from this cohort is that populations infected during waves of different variants carry distinct immune memory, with implications for differential protection against future VOCs.</div></section><section class="valid" valid="valid" title="valid: True, node: 408, tag: section, level: 13" node_number="408"><h2 class="valid" valid="valid" title="valid: True, node: 409, tag: h2, level: 14" node_number="409">Methods summary</h2><div class="valid" valid="valid" title="valid: True, node: 410, tag: div, level: 14" node_number="410">Detailed materials and methods are reported in the supplementary materials. Recruitment of 731 HCW into the COVIDsortium cohort followed longitudinally with weekly self-reported symptom diaries, SARS-CoV-2 PCR, N and S1 RBD serology for 16-weeks from the start of the first UK wave has been described (<a title="valid: False, node: 411, tag: a, level: 15" node_number="411"><i title="valid: False, node: 412, tag: i, level: 16" node_number="412">5</i></a>&#8211;<a title="valid: False, node: 413, tag: a, level: 15" node_number="413"><i title="valid: False, node: 414, tag: i, level: 16" node_number="414">10</i></a>). This enabled a cross-sectional case controlled sub-study of 136 HCW recruited 16-18 weeks after the March 2020 UK lockdown that reported discordant neutralizing antibody and T cell responses in SARS-CoV-2 natural infection during the 1<sup title="valid: False, node: 415, tag: sup, level: 15" node_number="415">st</sup> wave (Wuhan Hu-1) (<a title="valid: False, node: 416, tag: a, level: 15" node_number="416"><i title="valid: False, node: 417, tag: i, level: 16" node_number="417">6</i></a>). A cross-sectional, case-controlled vaccine sub-study cohort of 51 HCW at 22d after first BNT162b2 dose described vaccine immunity in HCW with (<i title="valid: False, node: 418, tag: i, level: 15" node_number="418">n</i> = 25) and without (<i title="valid: False, node: 419, tag: i, level: 15" node_number="419">n</i> = 26) prior SARS-CoV-2 infection during the Wuhan Hu-1 wave (<a title="valid: False, node: 420, tag: a, level: 15" node_number="420"><i title="valid: False, node: 421, tag: i, level: 16" node_number="421">8</i></a>, <a title="valid: False, node: 422, tag: a, level: 15" node_number="422"><i title="valid: False, node: 423, tag: i, level: 16" node_number="423">9</i></a>). The current sub-study includes longitudinal follow-up of this previously published vaccine sub-study cohort (<i title="valid: False, node: 424, tag: i, level: 15" node_number="424">n</i> = 51) at 20d (IQR, 7) after second BNT162b2 dose plus an additional 358 HCW, 53 of whom were infected with B.1.1.7 during the second UK wave. At 71-72 weeks, 80 2-dose vaccinated HCW were re-recruited 18-21 weeks after their second dose for longitudinal follow up of SARS-CoV-2 infection-na&#239;ve (<i title="valid: False, node: 425, tag: i, level: 15" node_number="425">n</i> = 27) or prior-infected HCW infected during the Wuhan Hu-1 UK wave (<i title="valid: False, node: 426, tag: i, level: 15" node_number="426">n</i> = 31) or the second B.1.1.7 UK wave (<i title="valid: False, node: 427, tag: i, level: 15" node_number="427">n</i> = 22). At 83-84 weeks, 74 previously 2-dose vaccinated HCW were re-recruited 30-33 weeks after their second dose that were infection na&#239;ve (<i title="valid: False, node: 428, tag: i, level: 15" node_number="428">n</i> = 30) or infected during the Wuhan Hu-1 (<i title="valid: False, node: 429, tag: i, level: 15" node_number="429">n</i> = 18) or B.1.1.7 wave (<i title="valid: False, node: 430, tag: i, level: 15" node_number="430">n</i> = 19). Sixty-seven (91%) were within a median of 18d (IQR, 12) after their third BNT162b2 dose. HCW with breakthrough infection by B.1.617.2 were identified by PCR and N serology. Peripheral blood mononuclear cells (PBMC) and serum samples were prepared and cryopreserved as previously described (<a title="valid: False, node: 431, tag: a, level: 15" node_number="431"><i title="valid: False, node: 432, tag: i, level: 16" node_number="432">6</i></a>, <a title="valid: False, node: 433, tag: a, level: 15" node_number="433"><i title="valid: False, node: 434, tag: i, level: 16" node_number="434">9</i></a>). Anti-nucleocapsid (COI &#8805; 1.0, positive) and anti-spike antibody (&#8805;0.8 U/ml, positive) detection Ab testing was conducted at UK Health Security Agency (UKHSA) using the Roche cobas<sup title="valid: False, node: 435, tag: sup, level: 15" node_number="435">&#174;</sup>e801 analyser. Recombinant proteins were used in ELISAs looking at the VOC S1 RBD responses: SARS-CoV-2 Spike Glycoprotein (S1) RBD, SARS-CoV-2 (N501Y Mutant), (501Y.V2: K417N, E484K, N501Y), (B.1.1.28: K417T, E484K, N501Y) and (B.1.617.2: L452R, T478K) Spike Glycoprotein (S1) RBDs derived from Wuhan Hu-1, B.1.1.7, B.1.351, P.1 and B.1.617.2 VOC respectively. T cell experiments peptide panels included spike mapped epitope pool (MEP) comprised of a pool of eighteen 12-20mer peptide epitopes (<a title="valid: False, node: 436, tag: a, level: 15" node_number="436"><i title="valid: False, node: 437, tag: i, level: 16" node_number="437">6</i></a>, <a title="valid: False, node: 438, tag: a, level: 15" node_number="438"><i title="valid: False, node: 439, tag: i, level: 16" node_number="439">9</i></a>) and VOC pools contained peptides from the B.1.1.7, B.1.351, P.1 and B.1.617.2 sequences and their respective Wuhan Hu-1 sequence (table S2). IFN&#947;-T cell ELISpots and MBC ELISpots were performed as previously described (<a title="valid: False, node: 440, tag: a, level: 15" node_number="440"><i title="valid: False, node: 441, tag: i, level: 16" node_number="441">6</i></a>, <a title="valid: False, node: 442, tag: a, level: 15" node_number="442"><i title="valid: False, node: 443, tag: i, level: 16" node_number="443">9</i></a>). MBC ELISpot plates were coated with PBS, purified anti-human IgG MT91/145, SARS-CoV-2 S1 spike, E484K, K417N, N501Y spike or T19R, G142D, del 156-157, R158G, L452R, T478K, D614G, P681R spike. <i title="valid: False, node: 444, tag: i, level: 15" node_number="444">In silico</i> predictions of HLA-DRB1/peptide-binding utilized NetMHCIIpan-4.0 (<a title="valid: False, node: 445, tag: a, level: 15" node_number="445"><i title="valid: False, node: 446, tag: i, level: 16" node_number="446">9</i></a>, <a title="valid: False, node: 447, tag: a, level: 15" node_number="447"><i title="valid: False, node: 448, tag: i, level: 16" node_number="448">38</i></a>, <a title="valid: False, node: 449, tag: a, level: 15" node_number="449"><i title="valid: False, node: 450, tag: i, level: 16" node_number="450">39</i></a>). Studies using HLAII transgenics (DRB1*0401) were performed as previously described (<a title="valid: False, node: 451, tag: a, level: 15" node_number="451"><i title="valid: False, node: 452, tag: i, level: 16" node_number="452">9</i></a>, <a title="valid: False, node: 453, tag: a, level: 15" node_number="453"><i title="valid: False, node: 454, tag: i, level: 16" node_number="454">40</i></a>, <a title="valid: False, node: 455, tag: a, level: 15" node_number="455"><i title="valid: False, node: 456, tag: i, level: 16" node_number="456">41</i></a>). For transcriptomic and flow cytometry analysis, mouse lymph node cells were cultured with no peptide, wild-type or variant N501Y peptides, then, at 24h, cells were harvested and lysed for RNA extraction or stained for flow cytometry. SARS-CoV-2 microneutralization assays were carried out as described previously using VeroE6 cells (<a title="valid: False, node: 457, tag: a, level: 15" node_number="457"><i title="valid: False, node: 458, tag: i, level: 16" node_number="458">6</i></a>, <a title="valid: False, node: 459, tag: a, level: 15" node_number="459"><i title="valid: False, node: 460, tag: i, level: 16" node_number="460">9</i></a>). Participant sera were incubated with 3x10<sup title="valid: False, node: 461, tag: sup, level: 15" node_number="461">4</sup> FFU SARS-CoV-2 (Wuhan Hu-1, B.1.1.7, B.1.351, P.1, or B.1617.2 isolates of SARS-CoV-2 live virus).</div></section><section class="valid" valid="valid" title="valid: True, node: 462, tag: section, level: 13" node_number="462"><h2 class="valid" valid="valid" title="valid: True, node: 463, tag: h2, level: 14" node_number="463">Acknowledgments</h2><div class="valid" valid="valid" title="valid: True, node: 464, tag: div, level: 14" node_number="464"><b title="valid: False, node: 465, tag: b, level: 15" node_number="465">ACKNOWLEDGMENTS:</b> The authors thank HCW participants for participating in the study and the research teams involved in recruitment, obtaining consent, and sampling the HCW participants. The COVIDsortium Healthcare Workers bioresource is approved by the ethical committee of UK National Research Ethics Service (20/SC/0149) and registered on ClinicalTrials.gov (NCT04318314). The study conforms to the principles of the Helsinki Declaration, and all subjects provided written informed consent. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV Isolate EVA catalog code 026V-03883 was obtained from European Virus Archive Global. (EVAg), Charit&#233; - Universit&#228;tsmedizin Berlin. The SARS-CoV-2 B.1.1.7 isolate was obtained from NIBSC, thanks to the contribution of PHE Porton Down and Dr Simon Funnell. The nCoV19 isolate/UK ex South African/2021 lineage B.1.351 EVA catalog code 04V-04071 was obtained from EVAg, PHE Porton Down. P.1 and B.1.617.2 isolates were purchased from EVAg. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 466, tag: a, level: 15" node_number="466">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. <b title="valid: False, node: 467, tag: b, level: 15" node_number="467">Funding</b>: RJB and DMA are supported by MRC (MR/S019553/1, MR/R02622X/1, MR/V036939/1, MR/W020610/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC (2019SRC015), NIHR EME Fast Track (NIHR134607), NIHR Long Covid (COV-LT2-0027), Innovate Uk (SBRI 10008614) and Horizon 2020 Marie Sk&#322;odowska-Curie Innovative Training Network (ITN) European Training Network (No 860325). &#193;M is supported by MRC (MR/W020610/1), NIHR EME Fast Track (NIHR134607), Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomew&#8217;s Hospital Trust. The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Kenneth C Griffin, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with University College London and Queen Mary University of London. MKM is supported by UKRI/NIHR UK-CIC, Wellcome Trust Investigator Award (214191/Z/18/Z) and CRUK Immunology grant (26603). JCM, CM and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223&#8203;). TT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. <b title="valid: False, node: 468, tag: b, level: 15" node_number="468">Author contributions:</b> R.J.B conceptualised and designed the study reported. R.J.B and D.M.A designed and supervised the T cell and B cell experiments. &#193;.M. designed and supervised the nAb experiments. T.B. and A.Se supervised S1 IgG and N IgG/IgM studies. D.MS., KM.L., F.P., and D.K.B. performed and analyzed T cell experiments. C.J.R. developed, performed and analyzed T cell, and memory B cell experiments. J.M.G. and C.P developed, performed and analyzed nAb experiments. A.D.O. performed and A.Se analyzed RBD and N antibody assays. T.B., C.M., &#193;.M., T.T., J.C.M., and M.N conceptualised and established the COVIDsortium HCW cohort. R.J.B, T.T., J.C.M., and C.M designed the vaccine sub-study cohort. G.J., K.M., M.F., A.S., C.M., T.A.T., and J.C.M. recruited HCW and collected samples. B.K. and T.C-M. helped with confirmation of sequence of viral isolates. C.J.R., D.MS., KM.L., F.P., S.L., and D.K.B. and COVIDsortium Investigators processed HCW samples. C.J.R., J.M.G., C.P., &#193;.M., D.M.A., and R.J.B. analyzed the data. C.J.R., J.M.G., C.P., C.M., T.T., J.C.M., M.K.M., A.Se., T.B., M.N., &#193;.M., D.M.A., and R.J.B. interpreted the data. R.J.B. and D.M.A wrote the manuscript with input from all the authors. All the authors reviewed and edited the manuscript and figures. <b title="valid: False, node: 469, tag: b, level: 15" node_number="469">Competing interests:</b> R.J.B. and D.M.A. are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. <b title="valid: False, node: 470, tag: b, level: 15" node_number="470">Data and materials availability:</b> All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV, B.1.351, P.1 and B.1.617.2 isolates were obtained under material agreements with European Virus Archive Global (EVAg), France. The SARS-CoV-2 B.1.1.7 isolate was obtained under a material agreement with the National Institute for Biological Standards and Control (NIBSC), UK. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 471, tag: a, level: 15" node_number="471">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section> </div></section><section class="valid" valid="valid" title="valid: True, node: 472, tag: section, level: 11" node_number="472"><div class="valid" valid="valid" title="valid: True, node: 473, tag: div, level: 12" node_number="473"><section class="valid" valid="valid" title="valid: True, node: 474, tag: section, level: 13" node_number="474"><h2 class="valid" valid="valid" title="valid: True, node: 475, tag: h2, level: 14" node_number="475">Supplementary Material</h2><section class="valid" valid="valid" title="valid: True, node: 476, tag: section, level: 14" node_number="476"><h3 title="valid: False, node: 477, tag: h3, level: 15" node_number="477">Summary</h3><div title="valid: False, node: 478, tag: div, level: 15" node_number="478"><a title="valid: False, node: 479, tag: a, level: 16" node_number="479">science.org/doi/10.1126/science.abm0811</a></div><div title="valid: False, node: 480, tag: div, level: 15" node_number="480">Materials and Methods</div><div title="valid: False, node: 481, tag: div, level: 15" node_number="481">Figs. S1 to S11</div><div title="valid: False, node: 482, tag: div, level: 15" node_number="482">Tables S1 to S13</div><div title="valid: False, node: 483, tag: div, level: 15" node_number="483">References (<a title="valid: False, node: 484, tag: a, level: 16" node_number="484"><i title="valid: False, node: 485, tag: i, level: 17" node_number="485">42</i></a>, <a title="valid: False, node: 486, tag: a, level: 16" node_number="486"><i title="valid: False, node: 487, tag: i, level: 17" node_number="487">43</i></a>)</div><div title="valid: False, node: 488, tag: div, level: 15" node_number="488">Data Table S14</div><div title="valid: False, node: 489, tag: div, level: 15" node_number="489">MDAR Reproducibility Checklist</div></section><section class="valid" valid="valid" title="valid: True, node: 490, tag: section, level: 14" node_number="490"><h3 title="valid: False, node: 491, tag: h3, level: 15" node_number="491">Resources</h3><div title="valid: False, node: 492, tag: div, level: 15" node_number="492"><div title="valid: False, node: 493, tag: div, level: 16" node_number="493"><div title="valid: False, node: 494, tag: div, level: 17" node_number="494">File (science.abm0811_mdar_reproducibility_checklist.pdf)</div><div title="valid: False, node: 495, tag: div, level: 17" node_number="495">Download</div></div><div title="valid: False, node: 496, tag: div, level: 16" node_number="496"><div title="valid: False, node: 497, tag: div, level: 17" node_number="497">File (science.abm0811_sm.pdf)</div><div title="valid: False, node: 498, tag: div, level: 17" node_number="498">Download</div></div><div title="valid: False, node: 499, tag: div, level: 16" node_number="499"><div title="valid: False, node: 500, tag: div, level: 17" node_number="500">File (science.abm0811_table_s14.xlsx)</div><div title="valid: False, node: 501, tag: div, level: 17" node_number="501">Download</div></div></div></section></section><section class="valid" valid="valid" title="valid: True, node: 502, tag: section, level: 13" node_number="502"><h2 class="valid" valid="valid" title="valid: True, node: 503, tag: h2, level: 14" node_number="503">References and Notes</h2><div class="valid" valid="valid" title="valid: True, node: 504, tag: div, level: 14" node_number="504"><div title="valid: False, node: 505, tag: div, level: 15" node_number="505">1</div><div title="valid: False, node: 506, tag: div, level: 15" node_number="506"><div title="valid: False, node: 507, tag: div, level: 16" node_number="507"><div title="valid: False, node: 508, tag: div, level: 17" node_number="508">D. A. Collier, I. A. T. M. Ferreira, P. Kotagiri, R. P. Datir, E. Y. Lim, E. Touizer, B. Meng, A. Abdullahi, CITIID-NIHR BioResource COVID-19 Collaboration, A. Elmer, N. Kingston, B. Graves, E. Le Gresley, D. Caputo, L. Bergamaschi, K. G. C. Smith, J. R. Bradley, L. Ceron-Gutierrez, P. Cortes-Acevedo, G. Barcenas-Morales, M. A. Linterman, L. E. McCoy, C. Davis, E. Thomson, P. A. Lyons, E. McKinney, R. Doffinger, M. Wills, R. K. Gupta, Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature <b title="valid: False, node: 509, tag: b, level: 18" node_number="509">596</b>, 417&#8211;422 (2021).</div><div title="valid: False, node: 510, tag: div, level: 17" node_number="510"><div title="valid: False, node: 511, tag: div, level: 18" node_number="511">Crossref</div><div title="valid: False, node: 512, tag: div, level: 18" node_number="512"><a title="valid: False, node: 513, tag: a, level: 19" node_number="513">PubMed</a></div><div title="valid: False, node: 514, tag: div, level: 18" node_number="514"><a title="valid: False, node: 515, tag: a, level: 19" node_number="515">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 516, tag: div, level: 14" node_number="516"><div title="valid: False, node: 517, tag: div, level: 15" node_number="517">2</div><div title="valid: False, node: 518, tag: div, level: 15" node_number="518"><div title="valid: False, node: 519, tag: div, level: 16" node_number="519"><div title="valid: False, node: 520, tag: div, level: 17" node_number="520">E. C. Wall, M. Wu, R. Harvey, G. Kelly, S. Warchal, C. Sawyer, R. Daniels, P. Hobson, E. Hatipoglu, Y. Ngai, S. Hussain, J. Nicod, R. Goldstone, K. Ambrose, S. Hindmarsh, R. Beale, A. Riddell, S. Gamblin, M. Howell, G. Kassiotis, V. Libri, B. Williams, C. Swanton, S. Gandhi, D. L. Bauer, Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet <b title="valid: False, node: 521, tag: b, level: 18" node_number="521">397</b>, 2331&#8211;2333 (2021).</div><div title="valid: False, node: 522, tag: div, level: 17" node_number="522"><div title="valid: False, node: 523, tag: div, level: 18" node_number="523"><a title="valid: False, node: 524, tag: a, level: 19" node_number="524">Crossref</a></div><div title="valid: False, node: 525, tag: div, level: 18" node_number="525"><a title="valid: False, node: 526, tag: a, level: 19" node_number="526">PubMed</a></div><div title="valid: False, node: 527, tag: div, level: 18" node_number="527"><a title="valid: False, node: 528, tag: a, level: 19" node_number="528">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 529, tag: div, level: 14" node_number="529"><div title="valid: False, node: 530, tag: div, level: 15" node_number="530">3</div><div title="valid: False, node: 531, tag: div, level: 15" node_number="531"><div title="valid: False, node: 532, tag: div, level: 16" node_number="532"><div title="valid: False, node: 533, tag: div, level: 17" node_number="533">D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, N. Kassis-Chikhani, D. Edriss, L. Belec, A. Seve, L. Courtellemont, H. P&#233;r&#233;, L. Hocqueloux, S. Fafi-Kremer, T. Prazuck, H. Mouquet, T. Bruel, E. Simon-Lori&#232;re, F. A. Rey, O. Schwartz, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature <b title="valid: False, node: 534, tag: b, level: 18" node_number="534">596</b>, 276&#8211;280 (2021).</div><div title="valid: False, node: 535, tag: div, level: 17" node_number="535"><div title="valid: False, node: 536, tag: div, level: 18" node_number="536"><a title="valid: False, node: 537, tag: a, level: 19" node_number="537">Crossref</a></div><div title="valid: False, node: 538, tag: div, level: 18" node_number="538"><a title="valid: False, node: 539, tag: a, level: 19" node_number="539">PubMed</a></div><div title="valid: False, node: 540, tag: div, level: 18" node_number="540"><a title="valid: False, node: 541, tag: a, level: 19" node_number="541">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 542, tag: div, level: 14" node_number="542"><div title="valid: False, node: 543, tag: div, level: 15" node_number="543">4</div><div title="valid: False, node: 544, tag: div, level: 15" node_number="544"><div title="valid: False, node: 545, tag: div, level: 16" node_number="545"><div title="valid: False, node: 546, tag: div, level: 17" node_number="546">W. T. Harvey, A. M. Carabelli, B. Jackson, R. K. Gupta, E. C. Thomson, E. M. Harrison, C. Ludden, R. Reeve, A. Rambaut, S. J. Peacock, D. L. Robertson; COVID-19 Genomics UK (COG-UK) Consortium, SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. <b title="valid: False, node: 547, tag: b, level: 18" node_number="547">19</b>, 409&#8211;424 (2021).</div><div title="valid: False, node: 548, tag: div, level: 17" node_number="548"><div title="valid: False, node: 549, tag: div, level: 18" node_number="549"><a title="valid: False, node: 550, tag: a, level: 19" node_number="550">Crossref</a></div><div title="valid: False, node: 551, tag: div, level: 18" node_number="551"><a title="valid: False, node: 552, tag: a, level: 19" node_number="552">PubMed</a></div><div title="valid: False, node: 553, tag: div, level: 18" node_number="553"><a title="valid: False, node: 554, tag: a, level: 19" node_number="554">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 555, tag: div, level: 14" node_number="555"><div title="valid: False, node: 556, tag: div, level: 15" node_number="556">5</div><div title="valid: False, node: 557, tag: div, level: 15" node_number="557"><div title="valid: False, node: 558, tag: div, level: 16" node_number="558"><div title="valid: False, node: 559, tag: div, level: 17" node_number="559">T. A. Treibel, C. Manisty, M. Burton, &#193;. McKnight, J. Lambourne, J. B. Augusto, X. Couto-Parada, T. Cutino-Moguel, M. Noursadeghi, J. C. Moon, COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet <b title="valid: False, node: 560, tag: b, level: 18" node_number="560">395</b>, 1608&#8211;1610 (2020).</div><div title="valid: False, node: 561, tag: div, level: 17" node_number="561"><div title="valid: False, node: 562, tag: div, level: 18" node_number="562"><a title="valid: False, node: 563, tag: a, level: 19" node_number="563">Crossref</a></div><div title="valid: False, node: 564, tag: div, level: 18" node_number="564"><a title="valid: False, node: 565, tag: a, level: 19" node_number="565">PubMed</a></div><div title="valid: False, node: 566, tag: div, level: 18" node_number="566"><a title="valid: False, node: 567, tag: a, level: 19" node_number="567">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 568, tag: div, level: 14" node_number="568"><div title="valid: False, node: 569, tag: div, level: 15" node_number="569">6</div><div title="valid: False, node: 570, tag: div, level: 15" node_number="570"><div title="valid: False, node: 571, tag: div, level: 16" node_number="571"><div title="valid: False, node: 572, tag: div, level: 17" node_number="572">C. J. Reynolds, L. Swadling, J. M. Gibbons, C. Pade, M. P. Jensen, M. O. Diniz, N. M. Schmidt, D. K. Butler, O. E. Amin, S. N. L. Bailey, S. M. Murray, F. P. Pieper, S. Taylor, J. Jones, M. Jones, W. J. Lee, J. Rosenheim, A. Chandran, G. Joy, C. Di Genova, N. Temperton, J. Lambourne, T. Cutino-Moguel, M. Andiapen, M. Fontana, A. Smit, A. Semper, B. O&#8217;Brien, B. Chain, T. Brooks, C. Manisty, T. Treibel, J. C. Moon, M. Noursadeghi, D. M. Altmann, M. K. Maini, &#193;. McKnight, R. J. Boyton; COVIDsortium investigators; COVIDsortium immune correlates network, Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. <b title="valid: False, node: 573, tag: b, level: 18" node_number="573">5</b>, eabf3698 (2020).</div><div title="valid: False, node: 574, tag: div, level: 17" node_number="574"><div title="valid: False, node: 575, tag: div, level: 18" node_number="575"><a title="valid: False, node: 576, tag: a, level: 19" node_number="576">Crossref</a></div><div title="valid: False, node: 577, tag: div, level: 18" node_number="577"><a title="valid: False, node: 578, tag: a, level: 19" node_number="578">PubMed</a></div><div title="valid: False, node: 579, tag: div, level: 18" node_number="579"><a title="valid: False, node: 580, tag: a, level: 19" node_number="580">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 581, tag: div, level: 14" node_number="581"><div title="valid: False, node: 582, tag: div, level: 15" node_number="582">7</div><div title="valid: False, node: 583, tag: div, level: 15" node_number="583"><div title="valid: False, node: 584, tag: div, level: 16" node_number="584"><div title="valid: False, node: 585, tag: div, level: 17" node_number="585">C. Manisty, T. A. Treibel, M. Jensen, A. Semper, G. Joy, R. K. Gupta, T. Cutino-Moguel, M. Andiapen, J. Jones, S. Taylor, A. Otter, C. Pade, J. Gibbons, J. Lee, J. Bacon, S. Thomas, C. Moon, M. Jones, D. Williams, J. Lambourne, M. Fontana, D. M. Altmann, R. Boyton, M. Maini, A. McKnight, B. Chain, M. Noursadeghi, J. C. Moon, Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS&#8209;CoV-2 infection. EBioMedicine <b title="valid: False, node: 586, tag: b, level: 18" node_number="586">65</b>, 103259 (2021).</div><div title="valid: False, node: 587, tag: div, level: 17" node_number="587"><div title="valid: False, node: 588, tag: div, level: 18" node_number="588"><a title="valid: False, node: 589, tag: a, level: 19" node_number="589">Crossref</a></div><div title="valid: False, node: 590, tag: div, level: 18" node_number="590"><a title="valid: False, node: 591, tag: a, level: 19" node_number="591">PubMed</a></div><div title="valid: False, node: 592, tag: div, level: 18" node_number="592"><a title="valid: False, node: 593, tag: a, level: 19" node_number="593">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 594, tag: div, level: 14" node_number="594"><div title="valid: False, node: 595, tag: div, level: 15" node_number="595">8</div><div title="valid: False, node: 596, tag: div, level: 15" node_number="596"><div title="valid: False, node: 597, tag: div, level: 16" node_number="597"><div title="valid: False, node: 598, tag: div, level: 17" node_number="598">C. Manisty, A. D. Otter, T. A. Treibel, &#193;. McKnight, D. M. Altmann, T. Brooks, M. Noursadeghi, R. J. Boyton, A. Semper, J. C. Moon, Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet <b title="valid: False, node: 599, tag: b, level: 18" node_number="599">397</b>, 1057&#8211;1058 (2021).</div><div title="valid: False, node: 600, tag: div, level: 17" node_number="600"><div title="valid: False, node: 601, tag: div, level: 18" node_number="601"><a title="valid: False, node: 602, tag: a, level: 19" node_number="602">Crossref</a></div><div title="valid: False, node: 603, tag: div, level: 18" node_number="603"><a title="valid: False, node: 604, tag: a, level: 19" node_number="604">PubMed</a></div><div title="valid: False, node: 605, tag: div, level: 18" node_number="605"><a title="valid: False, node: 606, tag: a, level: 19" node_number="606">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 607, tag: div, level: 14" node_number="607"><div title="valid: False, node: 608, tag: div, level: 15" node_number="608">9</div><div title="valid: False, node: 609, tag: div, level: 15" node_number="609"><div title="valid: False, node: 610, tag: div, level: 16" node_number="610"><div title="valid: False, node: 611, tag: div, level: 17" node_number="611">C. J. Reynolds, C. Pade, J. M. Gibbons, D. K. Butler, A. D. Otter, K. Menacho, M. Fontana, A. Smit, J. E. Sackville-West, T. Cutino-Moguel, M. K. Maini, B. Chain, M. Noursadeghi, ; UK COVIDsortium Immune Correlates Network, T. Brooks, A. Semper, C. Manisty, T. A. Treibel, J. C. Moon, UK COVIDsortium Investigators, A. M. Valdes, &#193;. McKnight, D. M. Altmann, R. Boyton, Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science <b title="valid: False, node: 612, tag: b, level: 18" node_number="612">372</b>, eabh1282 (2021).</div><div title="valid: False, node: 613, tag: div, level: 17" node_number="613"><div title="valid: False, node: 614, tag: div, level: 18" node_number="614"><a title="valid: False, node: 615, tag: a, level: 19" node_number="615">Crossref</a></div><div title="valid: False, node: 616, tag: div, level: 18" node_number="616"><a title="valid: False, node: 617, tag: a, level: 19" node_number="617">PubMed</a></div><div title="valid: False, node: 618, tag: div, level: 18" node_number="618"><a title="valid: False, node: 619, tag: a, level: 19" node_number="619">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 620, tag: div, level: 14" node_number="620"><div title="valid: False, node: 621, tag: div, level: 15" node_number="621">10</div><div title="valid: False, node: 622, tag: div, level: 15" node_number="622"><div title="valid: False, node: 623, tag: div, level: 16" node_number="623"><div title="valid: False, node: 624, tag: div, level: 17" node_number="624">R. K. Gupta, J. Rosenheim, L. C. Bell, A. Chandran, J. A. Guerra-Assuncao, G. Pollara, M. Whelan, J. Artico, G. Joy, H. Kurdi, D. M. Altmann, R. J. Boyton, M. K. Maini, A. McKnight, J. Lambourne, T. Cutino-Moguel, C. Manisty, T. A. Treibel, J. C. Moon, B. M. Chain, M. Noursadeghi, COVIDsortium Investigators, Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: A nested, case-control diagnostic accuracy study. Lancet Microbe <b title="valid: False, node: 625, tag: b, level: 18" node_number="625">2</b>, e508&#8211;e517 (2021).</div><div title="valid: False, node: 626, tag: div, level: 17" node_number="626"><div title="valid: False, node: 627, tag: div, level: 18" node_number="627"><a title="valid: False, node: 628, tag: a, level: 19" node_number="628">Crossref</a></div><div title="valid: False, node: 629, tag: div, level: 18" node_number="629"><a title="valid: False, node: 630, tag: a, level: 19" node_number="630">PubMed</a></div><div title="valid: False, node: 631, tag: div, level: 18" node_number="631"><a title="valid: False, node: 632, tag: a, level: 19" node_number="632">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 633, tag: div, level: 14" node_number="633"><div title="valid: False, node: 634, tag: div, level: 15" node_number="634">11</div><div title="valid: False, node: 635, tag: div, level: 15" node_number="635"><div title="valid: False, node: 636, tag: div, level: 16" node_number="636"><div title="valid: False, node: 637, tag: div, level: 17" node_number="637">F. Krammer, K. Srivastava, H. Alshammary, A. A. Amoako, M. H. Awawda, K. F. Beach, M. C. Berm&#250;dez-Gonz&#225;lez, D. A. Bielak, J. M. Carre&#241;o, R. L. Chernet, L. Q. Eaker, E. D. Ferreri, D. L. Floda, C. R. Gleason, J. Z. Hamburger, K. Jiang, G. Kleiner, D. Jurczyszak, J. C. Matthews, W. A. Mendez, I. Nabeel, L. C. F. Mulder, A. J. Raskin, K. T. Russo, A. T. Salimbangon, M. Saksena, A. S. Shin, G. Singh, L. A. Sominsky, D. Stadlbauer, A. Wajnberg, V. Simon, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. <b title="valid: False, node: 638, tag: b, level: 18" node_number="638">384</b>, 1372&#8211;1374 (2021).</div><div title="valid: False, node: 639, tag: div, level: 17" node_number="639"><div title="valid: False, node: 640, tag: div, level: 18" node_number="640"><a title="valid: False, node: 641, tag: a, level: 19" node_number="641">Crossref</a></div><div title="valid: False, node: 642, tag: div, level: 18" node_number="642"><a title="valid: False, node: 643, tag: a, level: 19" node_number="643">PubMed</a></div><div title="valid: False, node: 644, tag: div, level: 18" node_number="644"><a title="valid: False, node: 645, tag: a, level: 19" node_number="645">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 646, tag: div, level: 14" node_number="646"><div title="valid: False, node: 647, tag: div, level: 15" node_number="647">12</div><div title="valid: False, node: 648, tag: div, level: 15" node_number="648"><div title="valid: False, node: 649, tag: div, level: 16" node_number="649"><div title="valid: False, node: 650, tag: div, level: 17" node_number="650">L. Stamatatos, J. Czartoski, Y. H. Wan, L. J. Homad, V. Rubin, H. Glantz, M. Neradilek, E. Seydoux, M. F. Jennewein, A. J. MacCamy, J. Feng, G. Mize, S. C. De Rosa, A. Finzi, M. P. Lemos, K. W. Cohen, Z. Moodie, M. J. McElrath, A. T. McGuire, mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science <b title="valid: False, node: 651, tag: b, level: 18" node_number="651">372</b>, eabg9175 (2021).</div><div title="valid: False, node: 652, tag: div, level: 17" node_number="652"><div title="valid: False, node: 653, tag: div, level: 18" node_number="653"><a title="valid: False, node: 654, tag: a, level: 19" node_number="654">Crossref</a></div><div title="valid: False, node: 655, tag: div, level: 18" node_number="655"><a title="valid: False, node: 656, tag: a, level: 19" node_number="656">PubMed</a></div><div title="valid: False, node: 657, tag: div, level: 18" node_number="657"><a title="valid: False, node: 658, tag: a, level: 19" node_number="658">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 659, tag: div, level: 14" node_number="659"><div title="valid: False, node: 660, tag: div, level: 15" node_number="660">13</div><div title="valid: False, node: 661, tag: div, level: 15" node_number="661"><div title="valid: False, node: 662, tag: div, level: 16" node_number="662"><div title="valid: False, node: 663, tag: div, level: 17" node_number="663">R. R. Goel, S. A. Apostolidis, M. M. Painter, D. Mathew, A. Pattekar, O. Kuthuru, S. Gouma, P. Hicks, W. Meng, A. M. Rosenfeld, S. Dysinger, K. A. Lundgreen, L. Kuri-Cervantes, S. Adamski, A. Hicks, S. Korte, D. A. Oldridge, A. E. Baxter, J. R. Giles, M. E. Weirick, C. M. McAllister, J. Dougherty, S. Long, K. D&#8217;Andrea, J. T. Hamilton, M. R. Betts, E. T. Luning Prak, P. Bates, S. E. Hensley, A. R. Greenplate, E. J. Wherry, Distinct antibody and memory B cell responses in SARS-CoV-2 na&#239;ve and recovered individuals after mRNA vaccination. Sci. Immunol. <b title="valid: False, node: 664, tag: b, level: 18" node_number="664">6</b>, eabi6950 (2021).</div><div title="valid: False, node: 665, tag: div, level: 17" node_number="665"><div title="valid: False, node: 666, tag: div, level: 18" node_number="666"><a title="valid: False, node: 667, tag: a, level: 19" node_number="667">Crossref</a></div><div title="valid: False, node: 668, tag: div, level: 18" node_number="668"><a title="valid: False, node: 669, tag: a, level: 19" node_number="669">PubMed</a></div><div title="valid: False, node: 670, tag: div, level: 18" node_number="670"><a title="valid: False, node: 671, tag: a, level: 19" node_number="671">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 672, tag: div, level: 14" node_number="672"><div title="valid: False, node: 673, tag: div, level: 15" node_number="673">14</div><div title="valid: False, node: 674, tag: div, level: 15" node_number="674"><div title="valid: False, node: 675, tag: div, level: 16" node_number="675"><div title="valid: False, node: 676, tag: div, level: 17" node_number="676">J. E. Ebinger, J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J. C. Prostko, E. C. Frias, J. L. Stewart, J. E. Van Eyk, J. G. Braun, S. Cheng, K. Sobhani, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat. Med. <b title="valid: False, node: 677, tag: b, level: 18" node_number="677">27</b>, 981&#8211;984 (2021).</div><div title="valid: False, node: 678, tag: div, level: 17" node_number="678"><div title="valid: False, node: 679, tag: div, level: 18" node_number="679"><a title="valid: False, node: 680, tag: a, level: 19" node_number="680">Crossref</a></div><div title="valid: False, node: 681, tag: div, level: 18" node_number="681"><a title="valid: False, node: 682, tag: a, level: 19" node_number="682">PubMed</a></div><div title="valid: False, node: 683, tag: div, level: 18" node_number="683"><a title="valid: False, node: 684, tag: a, level: 19" node_number="684">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 685, tag: div, level: 14" node_number="685"><div title="valid: False, node: 686, tag: div, level: 15" node_number="686">15</div><div title="valid: False, node: 687, tag: div, level: 15" node_number="687"><div title="valid: False, node: 688, tag: div, level: 16" node_number="688"><div title="valid: False, node: 689, tag: div, level: 17" node_number="689">P. S. Arunachalam, M. K. D. Scott, T. Hagan, C. Li, Y. Feng, F. Wimmers, L. Grigoryan, M. Trisal, V. V. Edara, L. Lai, S. E. Chang, A. Feng, S. Dhingra, M. Shah, A. S. Lee, S. Chinthrajah, S. B. Sindher, V. Mallajosyula, F. Gao, N. Sigal, S. Kowli, S. Gupta, K. Pellegrini, G. Tharp, S. Maysel-Auslender, S. Hamilton, H. Aoued, K. Hrusovsky, M. Roskey, S. E. Bosinger, H. T. Maecker, S. D. Boyd, M. M. Davis, P. J. Utz, M. S. Suthar, P. Khatri, K. C. Nadeau, B. Pulendran, Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature <b title="valid: False, node: 690, tag: b, level: 18" node_number="690">596</b>, 410&#8211;416 (2021).</div><div title="valid: False, node: 691, tag: div, level: 17" node_number="691"><div title="valid: False, node: 692, tag: div, level: 18" node_number="692"><a title="valid: False, node: 693, tag: a, level: 19" node_number="693">Crossref</a></div><div title="valid: False, node: 694, tag: div, level: 18" node_number="694"><a title="valid: False, node: 695, tag: a, level: 19" node_number="695">PubMed</a></div><div title="valid: False, node: 696, tag: div, level: 18" node_number="696"><a title="valid: False, node: 697, tag: a, level: 19" node_number="697">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 698, tag: div, level: 14" node_number="698"><div title="valid: False, node: 699, tag: div, level: 15" node_number="699">16</div><div title="valid: False, node: 700, tag: div, level: 15" node_number="700"><div title="valid: False, node: 701, tag: div, level: 16" node_number="701"><div title="valid: False, node: 702, tag: div, level: 17" node_number="702">A. Zhang, H. D. Stacey, C. E. Mullarkey, M. S. Miller, Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J. Immunol. <b title="valid: False, node: 703, tag: b, level: 18" node_number="703">202</b>, 335&#8211;340 (2019).</div><div title="valid: False, node: 704, tag: div, level: 17" node_number="704"><div title="valid: False, node: 705, tag: div, level: 18" node_number="705"><a title="valid: False, node: 706, tag: a, level: 19" node_number="706">Crossref</a></div><div title="valid: False, node: 707, tag: div, level: 18" node_number="707"><a title="valid: False, node: 708, tag: a, level: 19" node_number="708">PubMed</a></div><div title="valid: False, node: 709, tag: div, level: 18" node_number="709"><a title="valid: False, node: 710, tag: a, level: 19" node_number="710">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 711, tag: div, level: 14" node_number="711"><div title="valid: False, node: 712, tag: div, level: 15" node_number="712">17</div><div title="valid: False, node: 713, tag: div, level: 15" node_number="713"><div title="valid: False, node: 714, tag: div, level: 16" node_number="714"><div title="valid: False, node: 715, tag: div, level: 17" node_number="715">T. Aydillo, A. Rombauts, D. Stadlbauer, S. Aslam, G. Abelenda-Alonso, A. Escalera, F. Amanat, K. Jiang, F. Krammer, J. Carratala, A. Garc&#237;a-Sastre, Immunological imprinting of the antibody response in COVID-19 patients. Nat. Commun. <b title="valid: False, node: 716, tag: b, level: 18" node_number="716">12</b>, 3781 (2021).</div><div title="valid: False, node: 717, tag: div, level: 17" node_number="717"><div title="valid: False, node: 718, tag: div, level: 18" node_number="718"><a title="valid: False, node: 719, tag: a, level: 19" node_number="719">Crossref</a></div><div title="valid: False, node: 720, tag: div, level: 18" node_number="720"><a title="valid: False, node: 721, tag: a, level: 19" node_number="721">PubMed</a></div><div title="valid: False, node: 722, tag: div, level: 18" node_number="722"><a title="valid: False, node: 723, tag: a, level: 19" node_number="723">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 724, tag: div, level: 14" node_number="724"><div title="valid: False, node: 725, tag: div, level: 15" node_number="725">18</div><div title="valid: False, node: 726, tag: div, level: 15" node_number="726"><div title="valid: False, node: 727, tag: div, level: 16" node_number="727"><div title="valid: False, node: 728, tag: div, level: 17" node_number="728">A. K. Wheatley, A. Fox, H. X. Tan, J. A. Juno, M. P. Davenport, K. Subbarao, S. J. Kent, Immune imprinting and SARS-CoV-2 vaccine design. Trends Immunol. <b title="valid: False, node: 729, tag: b, level: 18" node_number="729">42</b>, 956&#8211;959 (2021).</div><div title="valid: False, node: 730, tag: div, level: 17" node_number="730"><div title="valid: False, node: 731, tag: div, level: 18" node_number="731"><a title="valid: False, node: 732, tag: a, level: 19" node_number="732">Crossref</a></div><div title="valid: False, node: 733, tag: div, level: 18" node_number="733"><a title="valid: False, node: 734, tag: a, level: 19" node_number="734">PubMed</a></div><div title="valid: False, node: 735, tag: div, level: 18" node_number="735"><a title="valid: False, node: 736, tag: a, level: 19" node_number="736">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 737, tag: div, level: 14" node_number="737"><div title="valid: False, node: 738, tag: div, level: 15" node_number="738">19</div><div title="valid: False, node: 739, tag: div, level: 15" node_number="739"><div title="valid: False, node: 740, tag: div, level: 16" node_number="740"><div title="valid: False, node: 741, tag: div, level: 17" node_number="741">N. Kamar, F. Abravanel, O. Marion, C. Couat, J. Izopet, A. Del Bello, Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. <b title="valid: False, node: 742, tag: b, level: 18" node_number="742">385</b>, 661&#8211;662 (2021).</div><div title="valid: False, node: 743, tag: div, level: 17" node_number="743"><div title="valid: False, node: 744, tag: div, level: 18" node_number="744"><a title="valid: False, node: 745, tag: a, level: 19" node_number="745">Crossref</a></div><div title="valid: False, node: 746, tag: div, level: 18" node_number="746"><a title="valid: False, node: 747, tag: a, level: 19" node_number="747">PubMed</a></div><div title="valid: False, node: 748, tag: div, level: 18" node_number="748"><a title="valid: False, node: 749, tag: a, level: 19" node_number="749">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 750, tag: div, level: 14" node_number="750"><div title="valid: False, node: 751, tag: div, level: 15" node_number="751">20</div><div title="valid: False, node: 752, tag: div, level: 15" node_number="752"><div title="valid: False, node: 753, tag: div, level: 16" node_number="753"><div title="valid: False, node: 754, tag: div, level: 17" node_number="754">A. Del Bello, F. Abravanel, O. Marion, C. Couat, L. Esposito, L. Lavayssi&#232;re, J. Izopet, N. Kamar, Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am. J. Transplant. ajt.16775 (2021).</div><div title="valid: False, node: 755, tag: div, level: 17" node_number="755"><div title="valid: False, node: 756, tag: div, level: 18" node_number="756"><a title="valid: False, node: 757, tag: a, level: 19" node_number="757">Crossref</a></div><div title="valid: False, node: 758, tag: div, level: 18" node_number="758"><a title="valid: False, node: 759, tag: a, level: 19" node_number="759">PubMed</a></div><div title="valid: False, node: 760, tag: div, level: 18" node_number="760"><a title="valid: False, node: 761, tag: a, level: 19" node_number="761">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 762, tag: div, level: 14" node_number="762"><div title="valid: False, node: 763, tag: div, level: 15" node_number="763">21</div><div title="valid: False, node: 764, tag: div, level: 15" node_number="764"><div title="valid: False, node: 765, tag: div, level: 16" node_number="765"><div title="valid: False, node: 766, tag: div, level: 17" node_number="766">D. M. Altmann, R. J. Boyton, R. Beale, Immunity to SARS-CoV-2 variants of concern. Science <b title="valid: False, node: 767, tag: b, level: 18" node_number="767">371</b>, 1103&#8211;1104 (2021).</div><div title="valid: False, node: 768, tag: div, level: 17" node_number="768"><div title="valid: False, node: 769, tag: div, level: 18" node_number="769"><a title="valid: False, node: 770, tag: a, level: 19" node_number="770">Crossref</a></div><div title="valid: False, node: 771, tag: div, level: 18" node_number="771"><a title="valid: False, node: 772, tag: a, level: 19" node_number="772">PubMed</a></div><div title="valid: False, node: 773, tag: div, level: 18" node_number="773"><a title="valid: False, node: 774, tag: a, level: 19" node_number="774">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 775, tag: div, level: 14" node_number="775"><div title="valid: False, node: 776, tag: div, level: 15" node_number="776">22</div><div title="valid: False, node: 777, tag: div, level: 15" node_number="777"><div title="valid: False, node: 778, tag: div, level: 16" node_number="778"><div title="valid: False, node: 779, tag: div, level: 17" node_number="779">D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Subbarao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. <b title="valid: False, node: 780, tag: b, level: 18" node_number="780">27</b>, 1205&#8211;1211 (2021).</div><div title="valid: False, node: 781, tag: div, level: 17" node_number="781"><div title="valid: False, node: 782, tag: div, level: 18" node_number="782"><a title="valid: False, node: 783, tag: a, level: 19" node_number="783">Crossref</a></div><div title="valid: False, node: 784, tag: div, level: 18" node_number="784"><a title="valid: False, node: 785, tag: a, level: 19" node_number="785">PubMed</a></div><div title="valid: False, node: 786, tag: div, level: 18" node_number="786"><a title="valid: False, node: 787, tag: a, level: 19" node_number="787">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 788, tag: div, level: 14" node_number="788"><div title="valid: False, node: 789, tag: div, level: 15" node_number="789">23</div><div title="valid: False, node: 790, tag: div, level: 15" node_number="790"><div title="valid: False, node: 791, tag: div, level: 16" node_number="791"><div title="valid: False, node: 792, tag: div, level: 17" node_number="792">A. M. Solinger, M. E. Ultee, E. Margoliash, R. H. Schwartz, T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibility complex-linked immune response genes. J. Exp. Med. <b title="valid: False, node: 793, tag: b, level: 18" node_number="793">150</b>, 830&#8211;848 (1979).</div><div title="valid: False, node: 794, tag: div, level: 17" node_number="794"><div title="valid: False, node: 795, tag: div, level: 18" node_number="795"><a title="valid: False, node: 796, tag: a, level: 19" node_number="796">Crossref</a></div><div title="valid: False, node: 797, tag: div, level: 18" node_number="797"><a title="valid: False, node: 798, tag: a, level: 19" node_number="798">PubMed</a></div><div title="valid: False, node: 799, tag: div, level: 18" node_number="799"><a title="valid: False, node: 800, tag: a, level: 19" node_number="800">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 801, tag: div, level: 14" node_number="801"><div title="valid: False, node: 802, tag: div, level: 15" node_number="802">24</div><div title="valid: False, node: 803, tag: div, level: 15" node_number="803"><div title="valid: False, node: 804, tag: div, level: 16" node_number="804"><div title="valid: False, node: 805, tag: div, level: 17" node_number="805">D. P. Martin, S. Weaver, H. Tegally, J. E. San, S. D. Shank, E. Wilkinson, A. G. Lucaci, J. Giandhari, S. Naidoo, Y. Pillay, L. Singh, R. J. Lessells, R. K. Gupta, J. O. Wertheim, A. Nekturenko, B. Murrell, G. W. Harkins, P. Lemey, O. A. MacLean, D. L. Robertson, T. de Oliveira, S. L. Kosakovsky Pond; NGS-SA; COVID-19 Genomics UK (COG-UK), The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. Cell <b title="valid: False, node: 806, tag: b, level: 18" node_number="806">184</b>, 5189&#8211;5200.e7 (2021).</div><div title="valid: False, node: 807, tag: div, level: 17" node_number="807"><div title="valid: False, node: 808, tag: div, level: 18" node_number="808"><a title="valid: False, node: 809, tag: a, level: 19" node_number="809">Crossref</a></div><div title="valid: False, node: 810, tag: div, level: 18" node_number="810"><a title="valid: False, node: 811, tag: a, level: 19" node_number="811">PubMed</a></div><div title="valid: False, node: 812, tag: div, level: 18" node_number="812"><a title="valid: False, node: 813, tag: a, level: 19" node_number="813">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 814, tag: div, level: 14" node_number="814"><div title="valid: False, node: 815, tag: div, level: 15" node_number="815">25</div><div title="valid: False, node: 816, tag: div, level: 15" node_number="816"><div title="valid: False, node: 817, tag: div, level: 16" node_number="817"><div title="valid: False, node: 818, tag: div, level: 17" node_number="818">L. Lu, A. W. Chu, R. R. Zhang, W. M. Chan, J. D. Ip, H. W. Tsoi, L. L. Chen, J. P. Cai, D. C. Lung, A. R. Tam, Y. S. Yau, M. Y. Kwan, W. K. To, O. T. Tsang, L. L. Lee, H. Yi, T. C. Ip, R. W. Poon, G. K. Siu, B. W. Mok, V. C. Cheng, K. H. Chan, K. Y. Yuen, I. F. Hung, K. K. To, The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine <b title="valid: False, node: 819, tag: b, level: 18" node_number="819">71</b>, 103544 (2021).</div><div title="valid: False, node: 820, tag: div, level: 17" node_number="820"><div title="valid: False, node: 821, tag: div, level: 18" node_number="821"><a title="valid: False, node: 822, tag: a, level: 19" node_number="822">Crossref</a></div><div title="valid: False, node: 823, tag: div, level: 18" node_number="823"><a title="valid: False, node: 824, tag: a, level: 19" node_number="824">PubMed</a></div><div title="valid: False, node: 825, tag: div, level: 18" node_number="825"><a title="valid: False, node: 826, tag: a, level: 19" node_number="826">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 827, tag: div, level: 14" node_number="827"><div title="valid: False, node: 828, tag: div, level: 15" node_number="828">26</div><div title="valid: False, node: 829, tag: div, level: 15" node_number="829"><div title="valid: False, node: 830, tag: div, level: 16" node_number="830"><div title="valid: False, node: 831, tag: div, level: 17" node_number="831">GISAID, &#8220;Tracking of variants&#8221; (2021); <a title="valid: False, node: 832, tag: a, level: 18" node_number="832">https://www.gisaid.org/hcov19-variants/</a></div><div title="valid: False, node: 833, tag: div, level: 17" node_number="833"><div title="valid: False, node: 834, tag: div, level: 18" node_number="834"><a title="valid: False, node: 835, tag: a, level: 19" node_number="835">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 836, tag: div, level: 14" node_number="836"><div title="valid: False, node: 837, tag: div, level: 15" node_number="837">27</div><div title="valid: False, node: 838, tag: div, level: 15" node_number="838"><div title="valid: False, node: 839, tag: div, level: 16" node_number="839"><div title="valid: False, node: 840, tag: div, level: 17" node_number="840">T. M. Snyder, R. M. Gittelman, M. Klinger, D. H. May, E. J. Osborne, R. Taniguchi, H. J. Zahid, I. M. Kaplan, J. N. Dines, M. T. Noakes, R. Pandya, X. Chen, S. Elasady, E. Svejnoha, P. Ebert, M. W. Pesesky, P. De Almeida, H. O&#8217;Donnell, Q. DeGottardi, G. Keitany, J. Lu, A. Vong, R. Elyanow, P. Fields, J. Greissl, L. Baldo, S. Semprini, C. Cerchione, F. Nicolini, M. Mazza, O. M. Delmonte, K. Dobbs, R. Laguna-Goya, G. Carre&#241;o-Tarragona, S. Barrio, L. Imberti, A. Sottini, E. Quiros-Roldan, C. Rossi, A. Biondi, L. R. Bettini, M. D&#8217;Angio, P. Bonfanti, M. F. Tompkins, C. Alba, C. Dalgard, V. Sambri, G. Martinelli, J. D. Goldman, J. R. Heath, H. C. Su, L. D. Notarangelo, E. Paz-Artal, J. Martinez-Lopez, J. M. Carlson, H. S. Robins, Magnitude and dynamics of the T-cell response to SARS-CoV-2 Infection at both individual and population levels. medRxiv 2020.07.31.20165647 [Preprint] (2020); .</div><div title="valid: False, node: 841, tag: div, level: 17" node_number="841"><div title="valid: False, node: 842, tag: div, level: 18" node_number="842"><a title="valid: False, node: 843, tag: a, level: 19" node_number="843">Crossref</a></div><div title="valid: False, node: 844, tag: div, level: 18" node_number="844"><a title="valid: False, node: 845, tag: a, level: 19" node_number="845">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 846, tag: div, level: 14" node_number="846"><div title="valid: False, node: 847, tag: div, level: 15" node_number="847">28</div><div title="valid: False, node: 848, tag: div, level: 15" node_number="848"><div title="valid: False, node: 849, tag: div, level: 16" node_number="849"><div title="valid: False, node: 850, tag: div, level: 17" node_number="850">Wellcome Sanger Institute, &#8220;COVID-19 genomic surveillance&#8221; (2021); <a title="valid: False, node: 851, tag: a, level: 18" node_number="851">https://covid19.sanger.ac.uk/lineages/raw</a>.</div><div title="valid: False, node: 852, tag: div, level: 17" node_number="852"><div title="valid: False, node: 853, tag: div, level: 18" node_number="853"><a title="valid: False, node: 854, tag: a, level: 19" node_number="854">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 855, tag: div, level: 14" node_number="855"><div title="valid: False, node: 856, tag: div, level: 15" node_number="856">29</div><div title="valid: False, node: 857, tag: div, level: 15" node_number="857"><div title="valid: False, node: 858, tag: div, level: 16" node_number="858"><div title="valid: False, node: 859, tag: div, level: 17" node_number="859">F. Muecksch, Y. Weisblum, C. O. Barnes, F. Schmidt, D. Schaefer-Babajew, Z. Wang, J. C. C. Lorenzi, A. I. Flyak, A. T. DeLaitsch, K. E. Huey-Tubman, S. Hou, C. A. Schiffer, C. Gaebler, J. Da Silva, D. Poston, S. Finkin, A. Cho, M. Cipolla, T. Y. Oliveira, K. G. Millard, V. Ramos, A. Gazumyan, M. Rutkowska, M. Caskey, M. C. Nussenzweig, P. J. Bjorkman, T. Hatziioannou, P. D. Bieniasz, Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity <b title="valid: False, node: 860, tag: b, level: 18" node_number="860">54</b>, 1853&#8211;1868.e7 (2021).</div><div title="valid: False, node: 861, tag: div, level: 17" node_number="861"><div title="valid: False, node: 862, tag: div, level: 18" node_number="862"><a title="valid: False, node: 863, tag: a, level: 19" node_number="863">Crossref</a></div><div title="valid: False, node: 864, tag: div, level: 18" node_number="864"><a title="valid: False, node: 865, tag: a, level: 19" node_number="865">PubMed</a></div><div title="valid: False, node: 866, tag: div, level: 18" node_number="866"><a title="valid: False, node: 867, tag: a, level: 19" node_number="867">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 868, tag: div, level: 14" node_number="868"><div title="valid: False, node: 869, tag: div, level: 15" node_number="869">30</div><div title="valid: False, node: 870, tag: div, level: 15" node_number="870"><div title="valid: False, node: 871, tag: div, level: 16" node_number="871"><div title="valid: False, node: 872, tag: div, level: 17" node_number="872">Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H. H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. Da Silva, E. Bednarski, L. Aguado, J. Yee, M. Daga, M. Turroja, K. G. Millard, M. Jankovic, A. Gazumyan, Z. Zhao, C. M. Rice, P. D. Bieniasz, M. Caskey, T. Hatziioannou, M. C. Nussenzweig, Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature <b title="valid: False, node: 873, tag: b, level: 18" node_number="873">595</b>, 426&#8211;431 (2021).</div><div title="valid: False, node: 874, tag: div, level: 17" node_number="874"><div title="valid: False, node: 875, tag: div, level: 18" node_number="875"><a title="valid: False, node: 876, tag: a, level: 19" node_number="876">Crossref</a></div><div title="valid: False, node: 877, tag: div, level: 18" node_number="877"><a title="valid: False, node: 878, tag: a, level: 19" node_number="878">PubMed</a></div><div title="valid: False, node: 879, tag: div, level: 18" node_number="879"><a title="valid: False, node: 880, tag: a, level: 19" node_number="880">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 881, tag: div, level: 14" node_number="881"><div title="valid: False, node: 882, tag: div, level: 15" node_number="882">31</div><div title="valid: False, node: 883, tag: div, level: 15" node_number="883"><div title="valid: False, node: 884, tag: div, level: 16" node_number="884"><div title="valid: False, node: 885, tag: div, level: 17" node_number="885">C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, Y. Bram, G. Breton, T. H&#228;ggl&#246;f, P. Mendoza, A. Hurley, M. Turroja, K. Gordon, K. G. Millard, V. Ramos, F. Schmidt, Y. Weisblum, D. Jha, M. Tankelevich, G. Martinez-Delgado, J. Yee, R. Patel, J. Dizon, C. Unson-O&#8217;Brien, I. Shimeliovich, D. F. Robbiani, Z. Zhao, A. Gazumyan, R. E. Schwartz, T. Hatziioannou, P. J. Bjorkman, S. Mehandru, P. D. Bieniasz, M. Caskey, M. C. Nussenzweig, Evolution of antibody immunity to SARS-CoV-2. Nature <b title="valid: False, node: 886, tag: b, level: 18" node_number="886">591</b>, 639&#8211;644 (2021).</div><div title="valid: False, node: 887, tag: div, level: 17" node_number="887"><div title="valid: False, node: 888, tag: div, level: 18" node_number="888"><a title="valid: False, node: 889, tag: a, level: 19" node_number="889">Crossref</a></div><div title="valid: False, node: 890, tag: div, level: 18" node_number="890"><a title="valid: False, node: 891, tag: a, level: 19" node_number="891">PubMed</a></div><div title="valid: False, node: 892, tag: div, level: 18" node_number="892"><a title="valid: False, node: 893, tag: a, level: 19" node_number="893">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 894, tag: div, level: 14" node_number="894"><div title="valid: False, node: 895, tag: div, level: 15" node_number="895">32</div><div title="valid: False, node: 896, tag: div, level: 15" node_number="896"><div title="valid: False, node: 897, tag: div, level: 16" node_number="897"><div title="valid: False, node: 898, tag: div, level: 17" node_number="898">N. Faulkner, K. W. Ng, M. Y. Wu, R. Harvey, M. Margaritis, S. Paraskevopoulou, C. Houlihan, S. Hussain, M. Greco, W. Bolland, S. Warchal, J. Heaney, H. Rickman, M. Spyer, D. Frampton, M. Byott, T. de Oliveira, A. Sigal, S. Kjaer, C. Swanton, S. Gandhi, R. Beale, S. J. Gamblin, J. W. McCauley, R. S. Daniels, M. Howell, D. Bauer, E. Nastouli, G. Kassiotis, Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife <b title="valid: False, node: 899, tag: b, level: 18" node_number="899">10</b>, e69317 (2021).</div><div title="valid: False, node: 900, tag: div, level: 17" node_number="900"><div title="valid: False, node: 901, tag: div, level: 18" node_number="901"><a title="valid: False, node: 902, tag: a, level: 19" node_number="902">Crossref</a></div><div title="valid: False, node: 903, tag: div, level: 18" node_number="903"><a title="valid: False, node: 904, tag: a, level: 19" node_number="904">PubMed</a></div><div title="valid: False, node: 905, tag: div, level: 18" node_number="905"><a title="valid: False, node: 906, tag: a, level: 19" node_number="906">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 907, tag: div, level: 14" node_number="907"><div title="valid: False, node: 908, tag: div, level: 15" node_number="908">33</div><div title="valid: False, node: 909, tag: div, level: 15" node_number="909"><div title="valid: False, node: 910, tag: div, level: 16" node_number="910"><div title="valid: False, node: 911, tag: div, level: 17" node_number="911">M. Bergwerk, T. Gonen, Y. Lustig, S. Amit, M. Lipsitch, C. Cohen, M. Mandelboim, E. G. Levin, C. Rubin, V. Indenbaum, I. Tal, M. Zavitan, N. Zuckerman, A. Bar-Chaim, Y. Kreiss, G. Regev-Yochay, Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. <b title="valid: False, node: 912, tag: b, level: 18" node_number="912">385</b>, 1474&#8211;1484 (2021).</div><div title="valid: False, node: 913, tag: div, level: 17" node_number="913"><div title="valid: False, node: 914, tag: div, level: 18" node_number="914"><a title="valid: False, node: 915, tag: a, level: 19" node_number="915">Crossref</a></div><div title="valid: False, node: 916, tag: div, level: 18" node_number="916"><a title="valid: False, node: 917, tag: a, level: 19" node_number="917">PubMed</a></div><div title="valid: False, node: 918, tag: div, level: 18" node_number="918"><a title="valid: False, node: 919, tag: a, level: 19" node_number="919">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 920, tag: div, level: 14" node_number="920"><div title="valid: False, node: 921, tag: div, level: 15" node_number="921">34</div><div title="valid: False, node: 922, tag: div, level: 15" node_number="922"><div title="valid: False, node: 923, tag: div, level: 16" node_number="923"><div title="valid: False, node: 924, tag: div, level: 17" node_number="924">T. Moyo-Gwete, M. Madzivhandila, Z. Makhado, F. Ayres, D. Mhlanga, B. Oosthuysen, B. E. Lambson, P. Kgagudi, H. Tegally, A. Iranzadeh, D. Doolabh, L. Tyers, L. R. Chinhoyi, M. Mennen, S. Skelem, G. Marais, C. K. Wibmer, J. N. Bhiman, V. Ueckermann, T. Rossouw, M. Boswell, T. de Oliveira, C. Williamson, W. A. Burgers, N. Ntusi, L. Morris, P. L. Moore, Cross-reactive neutralizing antibody responses elicited by SARS-CoV-2 501Y.V2 (B.1.351). N. Engl. J. Med. <b title="valid: False, node: 925, tag: b, level: 18" node_number="925">384</b>, 2161&#8211;2163 (2021).</div><div title="valid: False, node: 926, tag: div, level: 17" node_number="926"><div title="valid: False, node: 927, tag: div, level: 18" node_number="927"><a title="valid: False, node: 928, tag: a, level: 19" node_number="928">Crossref</a></div><div title="valid: False, node: 929, tag: div, level: 18" node_number="929"><a title="valid: False, node: 930, tag: a, level: 19" node_number="930">PubMed</a></div><div title="valid: False, node: 931, tag: div, level: 18" node_number="931"><a title="valid: False, node: 932, tag: a, level: 19" node_number="932">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 933, tag: div, level: 14" node_number="933"><div title="valid: False, node: 934, tag: div, level: 15" node_number="934">35</div><div title="valid: False, node: 935, tag: div, level: 15" node_number="935"><div title="valid: False, node: 936, tag: div, level: 16" node_number="936"><div title="valid: False, node: 937, tag: div, level: 17" node_number="937">M. McCallum, A. De Marco, F. A. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, L. E. Rosen, S. Bianchi, B. Guarino, C. S. Fregni, R. Abdelnabi, S. C. Foo, P. W. Rothlauf, L. M. Bloyet, F. Benigni, E. Cameroni, J. Neyts, A. Riva, G. Snell, A. Telenti, S. P. J. Whelan, H. W. Virgin, D. Corti, M. S. Pizzuto, D. Veesler, N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell <b title="valid: False, node: 938, tag: b, level: 18" node_number="938">184</b>, 2332&#8211;2347.e16 (2021).</div><div title="valid: False, node: 939, tag: div, level: 17" node_number="939"><div title="valid: False, node: 940, tag: div, level: 18" node_number="940"><a title="valid: False, node: 941, tag: a, level: 19" node_number="941">Crossref</a></div><div title="valid: False, node: 942, tag: div, level: 18" node_number="942"><a title="valid: False, node: 943, tag: a, level: 19" node_number="943">PubMed</a></div><div title="valid: False, node: 944, tag: div, level: 18" node_number="944"><a title="valid: False, node: 945, tag: a, level: 19" node_number="945">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 946, tag: div, level: 14" node_number="946"><div title="valid: False, node: 947, tag: div, level: 15" node_number="947">36</div><div title="valid: False, node: 948, tag: div, level: 15" node_number="948"><div title="valid: False, node: 949, tag: div, level: 16" node_number="949"><div title="valid: False, node: 950, tag: div, level: 17" node_number="950">Y. Goldberg, M. Mandel, Y. M. Bar-On, O. Bodenheimer, L. Freedman, E. J. Haas, R. Milo, S. Alroy-Preis, N. Ash, A. Huppert, Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. NEJMoa2114228 (2021).</div><div title="valid: False, node: 951, tag: div, level: 17" node_number="951"><div title="valid: False, node: 952, tag: div, level: 18" node_number="952"><a title="valid: False, node: 953, tag: a, level: 19" node_number="953">Crossref</a></div><div title="valid: False, node: 954, tag: div, level: 18" node_number="954"><a title="valid: False, node: 955, tag: a, level: 19" node_number="955">PubMed</a></div><div title="valid: False, node: 956, tag: div, level: 18" node_number="956"><a title="valid: False, node: 957, tag: a, level: 19" node_number="957">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 958, tag: div, level: 14" node_number="958"><div title="valid: False, node: 959, tag: div, level: 15" node_number="959">37</div><div title="valid: False, node: 960, tag: div, level: 15" node_number="960"><div title="valid: False, node: 961, tag: div, level: 16" node_number="961"><div title="valid: False, node: 962, tag: div, level: 17" node_number="962">L. A. VanBlargan, L. J. Adams, Z. Liu, R. E. Chen, P. Gilchuk, S. Raju, B. K. Smith, H. Zhao, J. B. Case, E. S. Winkler, B. M. Whitener, L. Droit, I. D. Aziati, T. L. Bricker, A. Joshi, P. Y. Shi, A. Creanga, A. Pegu, S. A. Handley, D. Wang, A. C. M. Boon, J. E. Crowe Jr., S. P. J. Whelan, D. H. Fremont, M. S. Diamond, A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity <b title="valid: False, node: 963, tag: b, level: 18" node_number="963">54</b>, 2399&#8211;2416.e6 (2021).</div><div title="valid: False, node: 964, tag: div, level: 17" node_number="964"><div title="valid: False, node: 965, tag: div, level: 18" node_number="965"><a title="valid: False, node: 966, tag: a, level: 19" node_number="966">Crossref</a></div><div title="valid: False, node: 967, tag: div, level: 18" node_number="967"><a title="valid: False, node: 968, tag: a, level: 19" node_number="968">PubMed</a></div><div title="valid: False, node: 969, tag: div, level: 18" node_number="969"><a title="valid: False, node: 970, tag: a, level: 19" node_number="970">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 971, tag: div, level: 14" node_number="971"><div title="valid: False, node: 972, tag: div, level: 15" node_number="972">38</div><div title="valid: False, node: 973, tag: div, level: 15" node_number="973"><div title="valid: False, node: 974, tag: div, level: 16" node_number="974"><div title="valid: False, node: 975, tag: div, level: 17" node_number="975">D. M. Altmann, C. J. Reynolds, R. J. Boyton, SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T&#160;cell recognition. Cell Rep. Med. <b title="valid: False, node: 976, tag: b, level: 18" node_number="976">2</b>, 100286 (2021).</div><div title="valid: False, node: 977, tag: div, level: 17" node_number="977"><div title="valid: False, node: 978, tag: div, level: 18" node_number="978"><a title="valid: False, node: 979, tag: a, level: 19" node_number="979">Crossref</a></div><div title="valid: False, node: 980, tag: div, level: 18" node_number="980"><a title="valid: False, node: 981, tag: a, level: 19" node_number="981">PubMed</a></div><div title="valid: False, node: 982, tag: div, level: 18" node_number="982"><a title="valid: False, node: 983, tag: a, level: 19" node_number="983">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 984, tag: div, level: 14" node_number="984"><div title="valid: False, node: 985, tag: div, level: 15" node_number="985">39</div><div title="valid: False, node: 986, tag: div, level: 15" node_number="986"><div title="valid: False, node: 987, tag: div, level: 16" node_number="987"><div title="valid: False, node: 988, tag: div, level: 17" node_number="988">B. Reynisson, B. Alvarez, S. Paul, B. Peters, M. Nielsen, NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. <b title="valid: False, node: 989, tag: b, level: 18" node_number="989">48</b> (W1), W449&#8211;W454 (2020).</div><div title="valid: False, node: 990, tag: div, level: 17" node_number="990"><div title="valid: False, node: 991, tag: div, level: 18" node_number="991"><a title="valid: False, node: 992, tag: a, level: 19" node_number="992">Crossref</a></div><div title="valid: False, node: 993, tag: div, level: 18" node_number="993"><a title="valid: False, node: 994, tag: a, level: 19" node_number="994">PubMed</a></div><div title="valid: False, node: 995, tag: div, level: 18" node_number="995"><a title="valid: False, node: 996, tag: a, level: 19" node_number="996">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 997, tag: div, level: 14" node_number="997"><div title="valid: False, node: 998, tag: div, level: 15" node_number="998">40</div><div title="valid: False, node: 999, tag: div, level: 15" node_number="999"><div title="valid: False, node: 1000, tag: div, level: 16" node_number="1000"><div title="valid: False, node: 1001, tag: div, level: 17" node_number="1001">K. J. Quigley, C. J. Reynolds, A. Goudet, E. J. Raynsford, R. Sergeant, A. Quigley, S. Worgall, D. Bilton, R. Wilson, M. R. Loebinger, B. Maillere, D. M. Altmann, R. J. Boyton, Chronic infection by mucoid <i title="valid: False, node: 1002, tag: i, level: 18" node_number="1002">Pseudomonas aeruginosa</i> associated with dysregulation in T-cell immunity to outer membrane porin F. Am. J. Respir. Crit. Care Med. <b title="valid: False, node: 1003, tag: b, level: 18" node_number="1003">191</b>, 1250&#8211;1264 (2015).</div><div title="valid: False, node: 1004, tag: div, level: 17" node_number="1004"><div title="valid: False, node: 1005, tag: div, level: 18" node_number="1005"><a title="valid: False, node: 1006, tag: a, level: 19" node_number="1006">Crossref</a></div><div title="valid: False, node: 1007, tag: div, level: 18" node_number="1007"><a title="valid: False, node: 1008, tag: a, level: 19" node_number="1008">PubMed</a></div><div title="valid: False, node: 1009, tag: div, level: 18" node_number="1009"><a title="valid: False, node: 1010, tag: a, level: 19" node_number="1010">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1011, tag: div, level: 14" node_number="1011"><div title="valid: False, node: 1012, tag: div, level: 15" node_number="1012">41</div><div title="valid: False, node: 1013, tag: div, level: 15" node_number="1013"><div title="valid: False, node: 1014, tag: div, level: 16" node_number="1014"><div title="valid: False, node: 1015, tag: div, level: 17" node_number="1015">C. Reynolds, A. Goudet, K. Jenjaroen, M. Sumonwiriya, D. Rinchai, J. Musson, S. Overbeek, J. Makinde, K. Quigley, J. Manji, N. Spink, P. Yos, V. Wuthiekanun, G. Bancroft, J. Robinson, G. Lertmemongkolchai, S. Dunachie, B. Maillere, M. Holden, D. Altmann, R. Boyton, T cell immunity to the alkyl hydroperoxide reductase of <i title="valid: False, node: 1016, tag: i, level: 18" node_number="1016">Burkholderia pseudomallei</i>: A correlate of disease outcome in acute melioidosis. J. Immunol. <b title="valid: False, node: 1017, tag: b, level: 18" node_number="1017">194</b>, 4814&#8211;4824 (2015).</div><div title="valid: False, node: 1018, tag: div, level: 17" node_number="1018"><div title="valid: False, node: 1019, tag: div, level: 18" node_number="1019"><a title="valid: False, node: 1020, tag: a, level: 19" node_number="1020">Crossref</a></div><div title="valid: False, node: 1021, tag: div, level: 18" node_number="1021"><a title="valid: False, node: 1022, tag: a, level: 19" node_number="1022">PubMed</a></div><div title="valid: False, node: 1023, tag: div, level: 18" node_number="1023"><a title="valid: False, node: 1024, tag: a, level: 19" node_number="1024">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1025, tag: div, level: 14" node_number="1025"><div title="valid: False, node: 1026, tag: div, level: 15" node_number="1026">42</div><div title="valid: False, node: 1027, tag: div, level: 15" node_number="1027"><div title="valid: False, node: 1028, tag: div, level: 16" node_number="1028"><div title="valid: False, node: 1029, tag: div, level: 17" node_number="1029">K. Tao, P. L. Tzou, J. Nouhin, R. K. Gupta, T. de Oliveira, S. L. Kosakovsky Pond, D. Fera, R. W. Shafer, The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. <b title="valid: False, node: 1030, tag: b, level: 18" node_number="1030">22</b>, 757&#8211;773 (2021).</div><div title="valid: False, node: 1031, tag: div, level: 17" node_number="1031"><div title="valid: False, node: 1032, tag: div, level: 18" node_number="1032"><a title="valid: False, node: 1033, tag: a, level: 19" node_number="1033">Crossref</a></div><div title="valid: False, node: 1034, tag: div, level: 18" node_number="1034"><a title="valid: False, node: 1035, tag: a, level: 19" node_number="1035">PubMed</a></div><div title="valid: False, node: 1036, tag: div, level: 18" node_number="1036"><a title="valid: False, node: 1037, tag: a, level: 19" node_number="1037">Google Scholar</a></div></div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1038, tag: div, level: 14" node_number="1038"><div title="valid: False, node: 1039, tag: div, level: 15" node_number="1039">43</div><div title="valid: False, node: 1040, tag: div, level: 15" node_number="1040"><div title="valid: False, node: 1041, tag: div, level: 16" node_number="1041"><div title="valid: False, node: 1042, tag: div, level: 17" node_number="1042">J. Zou, X. Xie, C. R. Fontes-Garfias, K. A. Swanson, I. Kanevsky, K. Tompkins, M. Cutler, D. Cooper, P. R. Dormitzer, P. Y. Shi, The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines <b title="valid: False, node: 1043, tag: b, level: 18" node_number="1043">6</b>, 44 (2021).</div><div title="valid: False, node: 1044, tag: div, level: 17" node_number="1044"><div title="valid: False, node: 1045, tag: div, level: 18" node_number="1045"><a title="valid: False, node: 1046, tag: a, level: 19" node_number="1046">Crossref</a></div><div title="valid: False, node: 1047, tag: div, level: 18" node_number="1047"><a title="valid: False, node: 1048, tag: a, level: 19" node_number="1048">PubMed</a></div><div title="valid: False, node: 1049, tag: div, level: 18" node_number="1049"><a title="valid: False, node: 1050, tag: a, level: 19" node_number="1050">Google Scholar</a></div></div></div></div></div></section></div></section><div class="valid" valid="valid" title="valid: True, node: 1051, tag: div, level: 11" node_number="1051"><div class="valid" valid="valid" title="valid: True, node: 1052, tag: div, level: 12" node_number="1052"><header class="valid" valid="valid" title="valid: True, node: 1053, tag: header, level: 13" node_number="1053"><h2 class="valid" valid="valid" title="valid: True, node: 1054, tag: h2, level: 14" node_number="1054">Information Authors</h2></header><section class="valid" valid="valid" title="valid: True, node: 1055, tag: section, level: 13" node_number="1055"><h3 class="valid" valid="valid" title="valid: True, node: 1056, tag: h3, level: 14" node_number="1056">Information</h3><section class="valid" valid="valid" title="valid: True, node: 1057, tag: section, level: 14" node_number="1057"><h4 title="valid: False, node: 1058, tag: h4, level: 15" node_number="1058">Published In</h4><div title="valid: False, node: 1059, tag: div, level: 15" node_number="1059"> <div title="valid: False, node: 1060, tag: div, level: 16" node_number="1060"><div title="valid: False, node: 1061, tag: div, level: 17" node_number="1061">Science</div><div title="valid: False, node: 1062, tag: div, level: 17" node_number="1062">First Release</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1063, tag: section, level: 14" node_number="1063"><h4 title="valid: False, node: 1064, tag: h4, level: 15" node_number="1064">Copyright</h4><div title="valid: False, node: 1065, tag: div, level: 15" node_number="1065">Copyright &#169; 2022, American Association for the Advancement of Science.</div></section><section class="valid" valid="valid" title="valid: True, node: 1066, tag: section, level: 14" node_number="1066"><h4 title="valid: False, node: 1067, tag: h4, level: 15" node_number="1067">Submission history</h4><div title="valid: False, node: 1068, tag: div, level: 15" node_number="1068"><b title="valid: False, node: 1069, tag: b, level: 16" node_number="1069">Received</b>: 25 August 2021</div><div title="valid: False, node: 1070, tag: div, level: 15" node_number="1070"><b title="valid: False, node: 1071, tag: b, level: 16" node_number="1071">Accepted</b>: 25 November 2021</div></section><section class="valid" valid="valid" title="valid: True, node: 1072, tag: section, level: 14" node_number="1072"><h4 title="valid: False, node: 1073, tag: h4, level: 15" node_number="1073">Permissions</h4><div title="valid: False, node: 1074, tag: div, level: 15" node_number="1074">Request permissions for this article.</div><div title="valid: False, node: 1075, tag: div, level: 15" node_number="1075">Request Permissions</div></section><section class="valid" valid="valid" title="valid: True, node: 1076, tag: section, level: 14" node_number="1076"><h4 title="valid: False, node: 1077, tag: h4, level: 15" node_number="1077">Acknowledgments</h4><div title="valid: False, node: 1078, tag: div, level: 15" node_number="1078"><b title="valid: False, node: 1079, tag: b, level: 16" node_number="1079">ACKNOWLEDGMENTS:</b> The authors thank HCW participants for participating in the study and the research teams involved in recruitment, obtaining consent, and sampling the HCW participants. The COVIDsortium Healthcare Workers bioresource is approved by the ethical committee of UK National Research Ethics Service (20/SC/0149) and registered on ClinicalTrials.gov (NCT04318314). The study conforms to the principles of the Helsinki Declaration, and all subjects provided written informed consent. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV Isolate EVA catalog code 026V-03883 was obtained from European Virus Archive Global. (EVAg), Charit&#233; - Universit&#228;tsmedizin Berlin. The SARS-CoV-2 B.1.1.7 isolate was obtained from NIBSC, thanks to the contribution of PHE Porton Down and Dr Simon Funnell. The nCoV19 isolate/UK ex South African/2021 lineage B.1.351 EVA catalog code 04V-04071 was obtained from EVAg, PHE Porton Down. P.1 and B.1.617.2 isolates were purchased from EVAg. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 1080, tag: a, level: 16" node_number="1080">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material. <b title="valid: False, node: 1081, tag: b, level: 16" node_number="1081">Funding</b>: RJB and DMA are supported by MRC (MR/S019553/1, MR/R02622X/1, MR/V036939/1, MR/W020610/1), NIHR Imperial Biomedical Research Centre (BRC):ITMAT, Cystic Fibrosis Trust SRC (2019SRC015), NIHR EME Fast Track (NIHR134607), NIHR Long Covid (COV-LT2-0027), Innovate Uk (SBRI 10008614) and Horizon 2020 Marie Sk&#322;odowska-Curie Innovative Training Network (ITN) European Training Network (No 860325). &#193;M is supported by MRC (MR/W020610/1), NIHR EME Fast Track (NIHR134607), Rosetrees Trust, The John Black Charitable Foundation, and Medical College of St Bartholomew&#8217;s Hospital Trust. The COVIDsortium is supported by funding donated by individuals, charitable Trusts, and corporations including Goldman Sachs, Kenneth C Griffin, The Guy Foundation, GW Pharmaceuticals, Kusuma Trust, and Jagclif Charitable Trust, and enabled by Barts Charity with support from UCLH Charity. Wider support is acknowledged on the COVIDsortium website. Institutional support from Barts Health NHS Trust and Royal Free NHS Foundation Trust facilitated study processes, in partnership with University College London and Queen Mary University of London. MKM is supported by UKRI/NIHR UK-CIC, Wellcome Trust Investigator Award (214191/Z/18/Z) and CRUK Immunology grant (26603). JCM, CM and TAT are directly and indirectly supported by the University College London Hospitals (UCLH) and Barts NIHR Biomedical Research Centres and through the British Heart Foundation (BHF) Accelerator Award (AA/18/6/34223&#8203;). TT is funded by a BHF Intermediate Research Fellowship (FS/19/35/34374). MN is supported by the Wellcome Trust (207511/Z/17/Z) and by NIHR Biomedical Research Funding to UCL and UCLH. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. <b title="valid: False, node: 1082, tag: b, level: 16" node_number="1082">Author contributions:</b> R.J.B conceptualised and designed the study reported. R.J.B and D.M.A designed and supervised the T cell and B cell experiments. &#193;.M. designed and supervised the nAb experiments. T.B. and A.Se supervised S1 IgG and N IgG/IgM studies. D.MS., KM.L., F.P., and D.K.B. performed and analyzed T cell experiments. C.J.R. developed, performed and analyzed T cell, and memory B cell experiments. J.M.G. and C.P developed, performed and analyzed nAb experiments. A.D.O. performed and A.Se analyzed RBD and N antibody assays. T.B., C.M., &#193;.M., T.T., J.C.M., and M.N conceptualised and established the COVIDsortium HCW cohort. R.J.B, T.T., J.C.M., and C.M designed the vaccine sub-study cohort. G.J., K.M., M.F., A.S., C.M., T.A.T., and J.C.M. recruited HCW and collected samples. B.K. and T.C-M. helped with confirmation of sequence of viral isolates. C.J.R., D.MS., KM.L., F.P., S.L., and D.K.B. and COVIDsortium Investigators processed HCW samples. C.J.R., J.M.G., C.P., &#193;.M., D.M.A., and R.J.B. analyzed the data. C.J.R., J.M.G., C.P., C.M., T.T., J.C.M., M.K.M., A.Se., T.B., M.N., &#193;.M., D.M.A., and R.J.B. interpreted the data. R.J.B. and D.M.A wrote the manuscript with input from all the authors. All the authors reviewed and edited the manuscript and figures. <b title="valid: False, node: 1083, tag: b, level: 16" node_number="1083">Competing interests:</b> R.J.B. and D.M.A. are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. <b title="valid: False, node: 1084, tag: b, level: 16" node_number="1084">Data and materials availability:</b> All data needed to evaluate the conclusions in the paper are present in the paper or the supplementary materials. The SARS-CoV-2 Wuhan Hu-1 Human 2019-nCoV, B.1.351, P.1 and B.1.617.2 isolates were obtained under material agreements with European Virus Archive Global (EVAg), France. The SARS-CoV-2 B.1.1.7 isolate was obtained under a material agreement with the National Institute for Biological Standards and Control (NIBSC), UK. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <a title="valid: False, node: 1085, tag: a, level: 16" node_number="1085">https://creativecommons.org/licenses/by/4.0/</a>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.</div></section></section><section class="valid" valid="valid" title="valid: True, node: 1086, tag: section, level: 13" node_number="1086"><h3 class="valid" valid="valid" title="valid: True, node: 1087, tag: h3, level: 14" node_number="1087">Authors</h3><section class="valid" valid="valid" title="valid: True, node: 1088, tag: section, level: 14" node_number="1088"><h4 title="valid: False, node: 1089, tag: h4, level: 15" node_number="1089">Affiliations</h4><div title="valid: False, node: 1090, tag: div, level: 15" node_number="1090"><div title="valid: False, node: 1091, tag: div, level: 16" node_number="1091">Catherine J. Reynolds<sup title="valid: False, node: 1092, tag: sup, level: 17" node_number="1092">&#8224;</sup> <a title="valid: False, node: 1093, tag: a, level: 17" node_number="1093">https://orcid.org/0000-0002-1371-653X</a></div><div title="valid: False, node: 1094, tag: div, level: 16" node_number="1094"><div title="valid: False, node: 1095, tag: div, level: 17" node_number="1095"><div title="valid: False, node: 1096, tag: div, level: 18" node_number="1096">Department of Infectious Disease, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1097, tag: div, level: 17" node_number="1097">View all articles by this author</div></div></div><div title="valid: False, node: 1098, tag: div, level: 15" node_number="1098"><div title="valid: False, node: 1099, tag: div, level: 16" node_number="1099">Joseph M. Gibbons<sup title="valid: False, node: 1100, tag: sup, level: 17" node_number="1100">&#8224;</sup> <a title="valid: False, node: 1101, tag: a, level: 17" node_number="1101">https://orcid.org/0000-0002-7238-2381</a></div><div title="valid: False, node: 1102, tag: div, level: 16" node_number="1102"><div title="valid: False, node: 1103, tag: div, level: 17" node_number="1103"><div title="valid: False, node: 1104, tag: div, level: 18" node_number="1104">Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</div></div><div title="valid: False, node: 1105, tag: div, level: 17" node_number="1105"><a title="valid: False, node: 1106, tag: a, level: 18" node_number="1106">View all articles by this author</a></div></div></div><div title="valid: False, node: 1107, tag: div, level: 15" node_number="1107"><div title="valid: False, node: 1108, tag: div, level: 16" node_number="1108">Corinna Pade<sup title="valid: False, node: 1109, tag: sup, level: 17" node_number="1109">&#8224;</sup> <a title="valid: False, node: 1110, tag: a, level: 17" node_number="1110">https://orcid.org/0000-0003-0626-2346</a></div><div title="valid: False, node: 1111, tag: div, level: 16" node_number="1111"><div title="valid: False, node: 1112, tag: div, level: 17" node_number="1112"><div title="valid: False, node: 1113, tag: div, level: 18" node_number="1113">Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</div></div><div title="valid: False, node: 1114, tag: div, level: 17" node_number="1114">View all articles by this author</div></div></div><div title="valid: False, node: 1115, tag: div, level: 15" node_number="1115"><div title="valid: False, node: 1116, tag: div, level: 16" node_number="1116">Kai-Min Lin https://orcid.org/0000-0003-2109-1530</div><div title="valid: False, node: 1117, tag: div, level: 16" node_number="1117"><div title="valid: False, node: 1118, tag: div, level: 17" node_number="1118"><div title="valid: False, node: 1119, tag: div, level: 18" node_number="1119">Department of Infectious Disease, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1120, tag: div, level: 17" node_number="1120"><a title="valid: False, node: 1121, tag: a, level: 18" node_number="1121">View all articles by this author</a></div></div></div><div title="valid: False, node: 1122, tag: div, level: 15" node_number="1122"><div title="valid: False, node: 1123, tag: div, level: 16" node_number="1123">Diana Munoz Sandoval https://orcid.org/0000-0001-8350-3989</div><div title="valid: False, node: 1124, tag: div, level: 16" node_number="1124"><div title="valid: False, node: 1125, tag: div, level: 17" node_number="1125"><div title="valid: False, node: 1126, tag: div, level: 18" node_number="1126">Department of Infectious Disease, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1127, tag: div, level: 17" node_number="1127">View all articles by this author</div></div></div><div title="valid: False, node: 1128, tag: div, level: 15" node_number="1128"><div title="valid: False, node: 1129, tag: div, level: 16" node_number="1129">Franziska Pieper https://orcid.org/0000-0002-4857-0518</div><div title="valid: False, node: 1130, tag: div, level: 16" node_number="1130"><div title="valid: False, node: 1131, tag: div, level: 17" node_number="1131"><div title="valid: False, node: 1132, tag: div, level: 18" node_number="1132">Department of Infectious Disease, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1133, tag: div, level: 17" node_number="1133">View all articles by this author</div></div></div><div title="valid: False, node: 1134, tag: div, level: 15" node_number="1134"><div title="valid: False, node: 1135, tag: div, level: 16" node_number="1135">David K. Butler https://orcid.org/0000-0003-1882-8159</div><div title="valid: False, node: 1136, tag: div, level: 16" node_number="1136"><div title="valid: False, node: 1137, tag: div, level: 17" node_number="1137"><div title="valid: False, node: 1138, tag: div, level: 18" node_number="1138">Department of Infectious Disease, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1139, tag: div, level: 17" node_number="1139">View all articles by this author</div></div></div><div title="valid: False, node: 1140, tag: div, level: 15" node_number="1140"><div title="valid: False, node: 1141, tag: div, level: 16" node_number="1141">Siyi Liu https://orcid.org/0000-0003-0206-9661</div><div title="valid: False, node: 1142, tag: div, level: 16" node_number="1142"><div title="valid: False, node: 1143, tag: div, level: 17" node_number="1143"><div title="valid: False, node: 1144, tag: div, level: 18" node_number="1144">Department of Infectious Disease, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1145, tag: div, level: 17" node_number="1145"><a title="valid: False, node: 1146, tag: a, level: 18" node_number="1146">View all articles by this author</a></div></div></div><div title="valid: False, node: 1147, tag: div, level: 15" node_number="1147"><div title="valid: False, node: 1148, tag: div, level: 16" node_number="1148">Ashley D. Otter https://orcid.org/0000-0002-8317-9194</div><div title="valid: False, node: 1149, tag: div, level: 16" node_number="1149"><div title="valid: False, node: 1150, tag: div, level: 17" node_number="1150"><div title="valid: False, node: 1151, tag: div, level: 18" node_number="1151">UK Health Security Agency, Porton Down, UK.</div></div><div title="valid: False, node: 1152, tag: div, level: 17" node_number="1152">View all articles by this author</div></div></div><div title="valid: False, node: 1153, tag: div, level: 15" node_number="1153"><div title="valid: False, node: 1154, tag: div, level: 16" node_number="1154">George Joy https://orcid.org/0000-0003-1467-5490</div><div title="valid: False, node: 1155, tag: div, level: 16" node_number="1155"><div title="valid: False, node: 1156, tag: div, level: 17" node_number="1156"><div title="valid: False, node: 1157, tag: div, level: 18" node_number="1157">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div title="valid: False, node: 1158, tag: div, level: 17" node_number="1158">View all articles by this author</div></div></div><div title="valid: False, node: 1159, tag: div, level: 15" node_number="1159"><div title="valid: False, node: 1160, tag: div, level: 16" node_number="1160">Katia Menacho https://orcid.org/0000-0001-5183-5655</div><div title="valid: False, node: 1161, tag: div, level: 16" node_number="1161"><div title="valid: False, node: 1162, tag: div, level: 17" node_number="1162"><div title="valid: False, node: 1163, tag: div, level: 18" node_number="1163">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div title="valid: False, node: 1164, tag: div, level: 17" node_number="1164">View all articles by this author</div></div></div><div title="valid: False, node: 1165, tag: div, level: 15" node_number="1165"><div title="valid: False, node: 1166, tag: div, level: 16" node_number="1166">Marianna Fontana https://orcid.org/0000-0002-9233-9831</div><div title="valid: False, node: 1167, tag: div, level: 16" node_number="1167"><div title="valid: False, node: 1168, tag: div, level: 17" node_number="1168"><div title="valid: False, node: 1169, tag: div, level: 18" node_number="1169">Royal Free London NHS Foundation Trust, London, UK.</div></div><div title="valid: False, node: 1170, tag: div, level: 17" node_number="1170">View all articles by this author</div></div></div><div title="valid: False, node: 1171, tag: div, level: 15" node_number="1171"><div title="valid: False, node: 1172, tag: div, level: 16" node_number="1172">Angelique Smit https://orcid.org/0000-0002-2144-1249</div><div title="valid: False, node: 1173, tag: div, level: 16" node_number="1173"><div title="valid: False, node: 1174, tag: div, level: 17" node_number="1174"><div title="valid: False, node: 1175, tag: div, level: 18" node_number="1175">Royal Free London NHS Foundation Trust, London, UK.</div></div><div title="valid: False, node: 1176, tag: div, level: 17" node_number="1176">View all articles by this author</div></div></div><div title="valid: False, node: 1177, tag: div, level: 15" node_number="1177"><div title="valid: False, node: 1178, tag: div, level: 16" node_number="1178">Beatrix Kele https://orcid.org/0000-0003-1273-7299</div><div title="valid: False, node: 1179, tag: div, level: 16" node_number="1179"><div title="valid: False, node: 1180, tag: div, level: 17" node_number="1180"><div title="valid: False, node: 1181, tag: div, level: 18" node_number="1181">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div title="valid: False, node: 1182, tag: div, level: 17" node_number="1182">View all articles by this author</div></div></div><div title="valid: False, node: 1183, tag: div, level: 15" node_number="1183"><div title="valid: False, node: 1184, tag: div, level: 16" node_number="1184">Teresa Cutino-Moguel https://orcid.org/0000-0002-1726-4278</div><div title="valid: False, node: 1185, tag: div, level: 16" node_number="1185"><div title="valid: False, node: 1186, tag: div, level: 17" node_number="1186"><div title="valid: False, node: 1187, tag: div, level: 18" node_number="1187">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div></div><div title="valid: False, node: 1188, tag: div, level: 17" node_number="1188">View all articles by this author</div></div></div><div title="valid: False, node: 1189, tag: div, level: 15" node_number="1189"><div title="valid: False, node: 1190, tag: div, level: 16" node_number="1190">Mala K. Maini https://orcid.org/0000-0001-6384-1462</div><div title="valid: False, node: 1191, tag: div, level: 16" node_number="1191"><div title="valid: False, node: 1192, tag: div, level: 17" node_number="1192"><div title="valid: False, node: 1193, tag: div, level: 18" node_number="1193">Division of Infection and Immunity, University College London, London, UK.</div></div><div title="valid: False, node: 1194, tag: div, level: 17" node_number="1194">View all articles by this author</div></div></div><div title="valid: False, node: 1195, tag: div, level: 15" node_number="1195"><div title="valid: False, node: 1196, tag: div, level: 16" node_number="1196">Mahdad Noursadeghi https://orcid.org/0000-0002-4774-0853</div><div title="valid: False, node: 1197, tag: div, level: 16" node_number="1197"><div title="valid: False, node: 1198, tag: div, level: 17" node_number="1198"><div title="valid: False, node: 1199, tag: div, level: 18" node_number="1199">Division of Infection and Immunity, University College London, London, UK.</div></div><div title="valid: False, node: 1200, tag: div, level: 17" node_number="1200">View all articles by this author</div></div></div><div title="valid: False, node: 1201, tag: div, level: 15" node_number="1201"><div title="valid: False, node: 1202, tag: div, level: 16" node_number="1202">COVIDsortium Immune Correlates Network&#8225;</div></div><div title="valid: False, node: 1203, tag: div, level: 15" node_number="1203"><div title="valid: False, node: 1204, tag: div, level: 16" node_number="1204">Tim Brooks https://orcid.org/0000-0002-3783-1284</div><div title="valid: False, node: 1205, tag: div, level: 16" node_number="1205"><div title="valid: False, node: 1206, tag: div, level: 17" node_number="1206"><div title="valid: False, node: 1207, tag: div, level: 18" node_number="1207">UK Health Security Agency, Porton Down, UK.</div></div><div title="valid: False, node: 1208, tag: div, level: 17" node_number="1208">View all articles by this author</div></div></div><div title="valid: False, node: 1209, tag: div, level: 15" node_number="1209"><div title="valid: False, node: 1210, tag: div, level: 16" node_number="1210">Amanda Semper https://orcid.org/0000-0003-3656-1363</div><div title="valid: False, node: 1211, tag: div, level: 16" node_number="1211"><div title="valid: False, node: 1212, tag: div, level: 17" node_number="1212"><div title="valid: False, node: 1213, tag: div, level: 18" node_number="1213">UK Health Security Agency, Porton Down, UK.</div></div><div title="valid: False, node: 1214, tag: div, level: 17" node_number="1214">View all articles by this author</div></div></div><div title="valid: False, node: 1215, tag: div, level: 15" node_number="1215"><div title="valid: False, node: 1216, tag: div, level: 16" node_number="1216">Charlotte Manisty https://orcid.org/0000-0003-0245-7090</div><div title="valid: False, node: 1217, tag: div, level: 16" node_number="1217"><div title="valid: False, node: 1218, tag: div, level: 17" node_number="1218"><div title="valid: False, node: 1219, tag: div, level: 18" node_number="1219">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div><div title="valid: False, node: 1220, tag: div, level: 18" node_number="1220">Institute of Cardiovascular Science, University College London, London, UK.</div></div><div title="valid: False, node: 1221, tag: div, level: 17" node_number="1221">View all articles by this author</div></div></div><div title="valid: False, node: 1222, tag: div, level: 15" node_number="1222"><div title="valid: False, node: 1223, tag: div, level: 16" node_number="1223">Thomas A. Treibel https://orcid.org/0000-0003-1560-7414</div><div title="valid: False, node: 1224, tag: div, level: 16" node_number="1224"><div title="valid: False, node: 1225, tag: div, level: 17" node_number="1225"><div title="valid: False, node: 1226, tag: div, level: 18" node_number="1226">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div><div title="valid: False, node: 1227, tag: div, level: 18" node_number="1227">Institute of Cardiovascular Science, University College London, London, UK.</div></div><div title="valid: False, node: 1228, tag: div, level: 17" node_number="1228">View all articles by this author</div></div></div><div title="valid: False, node: 1229, tag: div, level: 15" node_number="1229"><div title="valid: False, node: 1230, tag: div, level: 16" node_number="1230">James C. Moon<sup title="valid: False, node: 1231, tag: sup, level: 17" node_number="1231">&#8225;</sup> https://orcid.org/0000-0001-8071-1491</div><div title="valid: False, node: 1232, tag: div, level: 16" node_number="1232"><div title="valid: False, node: 1233, tag: div, level: 17" node_number="1233"><div title="valid: False, node: 1234, tag: div, level: 18" node_number="1234">St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.</div><div title="valid: False, node: 1235, tag: div, level: 18" node_number="1235">Institute of Cardiovascular Science, University College London, London, UK.</div></div><div title="valid: False, node: 1236, tag: div, level: 17" node_number="1236">View all articles by this author</div></div></div><div title="valid: False, node: 1237, tag: div, level: 15" node_number="1237"><div title="valid: False, node: 1238, tag: div, level: 16" node_number="1238">&#193;ine McKnight<sup title="valid: False, node: 1239, tag: sup, level: 17" node_number="1239">&#167;</sup> https://orcid.org/0000-0002-8113-817X</div><div title="valid: False, node: 1240, tag: div, level: 16" node_number="1240"><div title="valid: False, node: 1241, tag: div, level: 17" node_number="1241"><div title="valid: False, node: 1242, tag: div, level: 18" node_number="1242">Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</div></div><div title="valid: False, node: 1243, tag: div, level: 17" node_number="1243">View all articles by this author</div></div></div><div title="valid: False, node: 1244, tag: div, level: 15" node_number="1244"><div title="valid: False, node: 1245, tag: div, level: 16" node_number="1245">Daniel M. Altmann<sup title="valid: False, node: 1246, tag: sup, level: 17" node_number="1246">&#167;</sup> https://orcid.org/0000-0002-2436-6192</div><div title="valid: False, node: 1247, tag: div, level: 16" node_number="1247"><div title="valid: False, node: 1248, tag: div, level: 17" node_number="1248"><div title="valid: False, node: 1249, tag: div, level: 18" node_number="1249">Department of Immunology and Inflammation, Imperial College London, London, UK.</div></div><div title="valid: False, node: 1250, tag: div, level: 17" node_number="1250">View all articles by this author</div></div></div><div title="valid: False, node: 1251, tag: div, level: 15" node_number="1251"><div title="valid: False, node: 1252, tag: div, level: 16" node_number="1252">Rosemary J. Boyton<sup title="valid: False, node: 1253, tag: sup, level: 17" node_number="1253">&#167;,*</sup> <a title="valid: False, node: 1254, tag: a, level: 17" node_number="1254">https://orcid.org/0000-0002-5608-0797</a> <a title="valid: False, node: 1255, tag: a, level: 17" node_number="1255">[email&#160;protected]</a></div><div title="valid: False, node: 1256, tag: div, level: 16" node_number="1256"><div title="valid: False, node: 1257, tag: div, level: 17" node_number="1257"><div title="valid: False, node: 1258, tag: div, level: 18" node_number="1258">Department of Infectious Disease, Imperial College London, London, UK.</div><div title="valid: False, node: 1259, tag: div, level: 18" node_number="1259">Lung Division, Royal Brompton and Harefield Hospitals, Guy&#8217;s and St. Thomas&#8217; NHS Foundation Trust, London, UK.</div></div><div title="valid: False, node: 1260, tag: div, level: 17" node_number="1260">View all articles by this author</div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1261, tag: section, level: 14" node_number="1261"><h4 title="valid: False, node: 1262, tag: h4, level: 15" node_number="1262">Funding Information</h4><div title="valid: False, node: 1263, tag: div, level: 15" node_number="1263"><a title="valid: False, node: 1264, tag: a, level: 16" node_number="1264">Medical Research Council</a>: MR/W020610/1</div><div title="valid: False, node: 1265, tag: div, level: 15" node_number="1265"><a title="valid: False, node: 1266, tag: a, level: 16" node_number="1266">Innovate UK</a>: SBRI 10008614</div><div title="valid: False, node: 1267, tag: div, level: 15" node_number="1267"><a title="valid: False, node: 1268, tag: a, level: 16" node_number="1268">University College London Hospitals NHS Foundation Trust</a>: </div><div title="valid: False, node: 1269, tag: div, level: 15" node_number="1269"><a title="valid: False, node: 1270, tag: a, level: 16" node_number="1270">UCLH Biomedical Research Centre</a>: MR/S019553/1</div><div title="valid: False, node: 1271, tag: div, level: 15" node_number="1271">MRC: MR/R02622X/1</div><div title="valid: False, node: 1272, tag: div, level: 15" node_number="1272">MRC: MR/V036939/1</div><div title="valid: False, node: 1273, tag: div, level: 15" node_number="1273">MRC: MR/W020610/1</div><div title="valid: False, node: 1274, tag: div, level: 15" node_number="1274">NIHR EME Fast Track: NIHR134607</div><div title="valid: False, node: 1275, tag: div, level: 15" node_number="1275">Wellcome Trust UK: 207511/Z/17/Z</div><div title="valid: False, node: 1276, tag: div, level: 15" node_number="1276">Wellcome Trust Senior Investigator Award: 214191/Z/18/Z</div><div title="valid: False, node: 1277, tag: div, level: 15" node_number="1277">CRUK: 26603</div><div title="valid: False, node: 1278, tag: div, level: 15" node_number="1278">British Heart Foundation Intermediate Research Fellowship: FS/19/35/34374</div><div title="valid: False, node: 1279, tag: div, level: 15" node_number="1279">NIHR: COV-LT2-0027</div><div title="valid: False, node: 1280, tag: div, level: 15" node_number="1280">Cystic Fibrosis Trust UK: 2019SRC015</div><div title="valid: False, node: 1281, tag: div, level: 15" node_number="1281">NIHR EME Fast Track: NIHR134607</div><div title="valid: False, node: 1282, tag: div, level: 15" node_number="1282">NIHR: COV-LT2-0027</div><div title="valid: False, node: 1283, tag: div, level: 15" node_number="1283">UKRI: MR/W020610/1</div><div title="valid: False, node: 1284, tag: div, level: 15" node_number="1284">NIHR: COV-LT2-0027</div><div title="valid: False, node: 1285, tag: div, level: 15" node_number="1285"><a title="valid: False, node: 1286, tag: a, level: 16" node_number="1286">NIHR Imperial Biomedical Research Centre</a>: NIHR Imperial Biomedical Research Centre (BRC):ITMAT,</div><div title="valid: False, node: 1287, tag: div, level: 15" node_number="1287">UKRI: MR/S019553/1</div><div title="valid: False, node: 1288, tag: div, level: 15" node_number="1288">Horizon 2020 Maria Sklodowska-Curie Innovative Training Network (ITN) European Training Network: 860325</div></section><section class="valid" valid="valid" title="valid: True, node: 1289, tag: section, level: 14" node_number="1289"><h4 title="valid: False, node: 1290, tag: h4, level: 15" node_number="1290">Notes</h4><div title="valid: False, node: 1291, tag: div, level: 15" node_number="1291"><div title="valid: False, node: 1292, tag: div, level: 16" node_number="1292">&#8224;</div><div title="valid: False, node: 1293, tag: div, level: 16" node_number="1293">These authors contributed equally to this work and are co-first authors.</div></div><div title="valid: False, node: 1294, tag: div, level: 15" node_number="1294"><div title="valid: False, node: 1295, tag: div, level: 16" node_number="1295">&#8225;</div><div title="valid: False, node: 1296, tag: div, level: 16" node_number="1296">The members of the COVIDsortium Immune Correlates Network and COVIDsortium Investigators are listed in the supplementary materials.</div></div><div title="valid: False, node: 1297, tag: div, level: 15" node_number="1297"><div title="valid: False, node: 1298, tag: div, level: 16" node_number="1298">&#167;</div><div title="valid: False, node: 1299, tag: div, level: 16" node_number="1299">These authors contributed equally to this work and are co-senior authors.</div></div><div title="valid: False, node: 1300, tag: div, level: 15" node_number="1300">*Corresponding author. Email: <a title="valid: False, node: 1301, tag: a, level: 16" node_number="1301">[email&#160;protected]</a></div></section></section></div><div class="valid" valid="valid" title="valid: True, node: 1302, tag: div, level: 12" node_number="1302"><header class="valid" valid="valid" title="valid: True, node: 1303, tag: header, level: 13" node_number="1303"><h2 class="valid" valid="valid" title="valid: True, node: 1304, tag: h2, level: 14" node_number="1304">Metrics Citations</h2></header><section class="valid" valid="valid" title="valid: True, node: 1305, tag: section, level: 13" node_number="1305"><h3 class="valid" valid="valid" title="valid: True, node: 1306, tag: h3, level: 14" node_number="1306">Metrics</h3><section class="valid" valid="valid" title="valid: True, node: 1307, tag: section, level: 14" node_number="1307"> <h5 title="valid: False, node: 1308, tag: h5, level: 15" node_number="1308"> Article Usage </h5> </section><section class="valid" valid="valid" title="valid: True, node: 1309, tag: section, level: 14" node_number="1309"> <h5 title="valid: False, node: 1310, tag: h5, level: 15" node_number="1310"> Altmetrics </h5> </section></section><section class="valid" valid="valid" title="valid: True, node: 1311, tag: section, level: 13" node_number="1311"><h3 class="valid" valid="valid" title="valid: True, node: 1312, tag: h3, level: 14" node_number="1312">Citations</h3><section class="valid" valid="valid" title="valid: True, node: 1313, tag: section, level: 14" node_number="1313"> <div title="valid: False, node: 1314, tag: div, level: 15" node_number="1314"> <h5 title="valid: False, node: 1315, tag: h5, level: 16" node_number="1315">Export citation</h5> <p title="valid: False, node: 1316, tag: p, level: 16" node_number="1316">Select the format you want to export the citation of this publication.</p> </div> </section></section></div><div class="valid" valid="valid" title="valid: True, node: 1317, tag: div, level: 12" node_number="1317"><header class="valid" valid="valid" title="valid: True, node: 1318, tag: header, level: 13" node_number="1318"><h2 class="valid" valid="valid" title="valid: True, node: 1319, tag: h2, level: 14" node_number="1319">View Options</h2></header><div class="valid" valid="valid" title="valid: True, node: 1320, tag: div, level: 13" node_number="1320"><h3 class="valid" valid="valid" title="valid: True, node: 1321, tag: h3, level: 14" node_number="1321">View options</h3><section class="valid" valid="valid" title="valid: True, node: 1322, tag: section, level: 14" node_number="1322"><h4 title="valid: False, node: 1323, tag: h4, level: 15" node_number="1323">PDF format</h4><p title="valid: False, node: 1324, tag: p, level: 15" node_number="1324">Download this article as a PDF file</p><a title="valid: False, node: 1325, tag: a, level: 15" node_number="1325">Download PDF</a></section></div><div class="valid" valid="valid" title="valid: True, node: 1326, tag: div, level: 13" node_number="1326"><h3 class="valid" valid="valid" title="valid: True, node: 1327, tag: h3, level: 14" node_number="1327">Get Access</h3><section class="valid" valid="valid" title="valid: True, node: 1328, tag: section, level: 14" node_number="1328"> <div title="valid: False, node: 1329, tag: div, level: 15" node_number="1329"><h5 title="valid: False, node: 1330, tag: h5, level: 16" node_number="1330">Log in to view the full text</h5> <p title="valid: False, node: 1331, tag: p, level: 16" node_number="1331"><a title="valid: False, node: 1332, tag: a, level: 17" node_number="1332">AAAS Log in</a></p> <p title="valid: False, node: 1333, tag: p, level: 16" node_number="1333">AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.</p> <ul title="valid: False, node: 1334, tag: ul, level: 16" node_number="1334"> <li title="valid: False, node: 1335, tag: li, level: 17" node_number="1335">Become a AAAS Member</li> <li title="valid: False, node: 1336, tag: li, level: 17" node_number="1336"><a title="valid: False, node: 1337, tag: a, level: 18" node_number="1337">Activate your Account</a></li> <li title="valid: False, node: 1338, tag: li, level: 17" node_number="1338"><a title="valid: False, node: 1339, tag: a, level: 18" node_number="1339">Purchase Access to Other Journals in the Science Family</a></li> <li title="valid: False, node: 1340, tag: li, level: 17" node_number="1340"><a title="valid: False, node: 1341, tag: a, level: 18" node_number="1341">Account Help</a></li> </ul> <div title="valid: False, node: 1342, tag: div, level: 16" node_number="1342"> <div title="valid: False, node: 1343, tag: div, level: 17" node_number="1343">Log in via OpenAthens. <div title="valid: False, node: 1344, tag: div, level: 18" node_number="1344"><a title="valid: False, node: 1345, tag: a, level: 19" node_number="1345">via OpenAthens</a></div> </div> <div title="valid: False, node: 1346, tag: div, level: 17" node_number="1346">Log in via Shibboleth. <div title="valid: False, node: 1347, tag: div, level: 18" node_number="1347"><a title="valid: False, node: 1348, tag: a, level: 19" node_number="1348">via Shibboleth</a></div> </div> </div> </div> <div title="valid: False, node: 1349, tag: div, level: 15" node_number="1349"><h5 title="valid: False, node: 1350, tag: h5, level: 16" node_number="1350">More options</h5><p title="valid: False, node: 1351, tag: p, level: 16" node_number="1351"><a title="valid: False, node: 1352, tag: a, level: 17" node_number="1352">Purchase digital access to this article</a></p><p title="valid: False, node: 1353, tag: p, level: 16" node_number="1353">Download and print this article for your personal scholarly, research, and educational use.</p><p title="valid: False, node: 1354, tag: p, level: 16" node_number="1354"><a title="valid: False, node: 1355, tag: a, level: 17" node_number="1355">Purchase this issue in print</a></p><p title="valid: False, node: 1356, tag: p, level: 16" node_number="1356">Buy a single issue of Science for just $15 USD.</p></div> </section></div></div><div class="valid" valid="valid" title="valid: True, node: 1357, tag: div, level: 12" node_number="1357"><header class="valid" valid="valid" title="valid: True, node: 1358, tag: header, level: 13" node_number="1358"><h2 class="valid" valid="valid" title="valid: True, node: 1359, tag: h2, level: 14" node_number="1359">Media</h2></header><section class="valid" valid="valid" title="valid: True, node: 1360, tag: section, level: 13" node_number="1360"><h3 class="valid" valid="valid" title="valid: True, node: 1361, tag: h3, level: 14" node_number="1361">Figures</h3></section><section class="valid" valid="valid" title="valid: True, node: 1362, tag: section, level: 13" node_number="1362"><h3 class="valid" valid="valid" title="valid: True, node: 1363, tag: h3, level: 14" node_number="1363">Multimedia</h3></section></div><div class="valid" valid="valid" title="valid: True, node: 1364, tag: div, level: 12" node_number="1364"><header class="valid" valid="valid" title="valid: True, node: 1365, tag: header, level: 13" node_number="1365"><h2 class="valid" valid="valid" title="valid: True, node: 1366, tag: h2, level: 14" node_number="1366">Tables</h2></header></div><div class="valid" valid="valid" title="valid: True, node: 1367, tag: div, level: 12" node_number="1367"><header class="valid" valid="valid" title="valid: True, node: 1368, tag: header, level: 13" node_number="1368"><h2 class="valid" valid="valid" title="valid: True, node: 1369, tag: h2, level: 14" node_number="1369">Share</h2></header><h3 class="valid" valid="valid" title="valid: True, node: 1370, tag: h3, level: 13" node_number="1370">Share</h3><div class="valid" valid="valid" title="valid: True, node: 1371, tag: div, level: 13" node_number="1371"><section class="valid" valid="valid" title="valid: True, node: 1372, tag: section, level: 14" node_number="1372"><h4 title="valid: False, node: 1373, tag: h4, level: 15" node_number="1373">Share article link</h4><div title="valid: False, node: 1374, tag: div, level: 15" node_number="1374"><a title="valid: False, node: 1375, tag: a, level: 16" node_number="1375">Copy Link</a><div title="valid: False, node: 1376, tag: div, level: 16" node_number="1376"><p title="valid: False, node: 1377, tag: p, level: 17" node_number="1377">Copied!</p><p title="valid: False, node: 1378, tag: p, level: 17" node_number="1378">Copying failed.</p></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1379, tag: section, level: 14" node_number="1379"><h4 title="valid: False, node: 1380, tag: h4, level: 15" node_number="1380">Share on social media</h4><div title="valid: False, node: 1381, tag: div, level: 15" node_number="1381">facebook<a title="valid: False, node: 1382, tag: a, level: 16" node_number="1382">twitter</a><a title="valid: False, node: 1383, tag: a, level: 16" node_number="1383">linkedin</a><a title="valid: False, node: 1384, tag: a, level: 16" node_number="1384">email</a></div></section></div></div></div></article><section class="valid" valid="valid" title="valid: True, node: 1385, tag: section, level: 10" node_number="1385"><div class="valid" valid="valid" title="valid: True, node: 1386, tag: div, level: 11" node_number="1386"><div class="valid" valid="valid" title="valid: True, node: 1387, tag: div, level: 12" node_number="1387"><div class="valid" valid="valid" title="valid: True, node: 1388, tag: div, level: 13" node_number="1388"><div class="valid" valid="valid" title="valid: True, node: 1389, tag: div, level: 14" node_number="1389"><h3 title="valid: False, node: 1390, tag: h3, level: 15" node_number="1390">Submit a Response to This Article</h3></div></div></div></div> <div class="valid" valid="valid" title="valid: True, node: 1391, tag: div, level: 11" node_number="1391"> <div class="valid" valid="valid" title="valid: True, node: 1392, tag: div, level: 12" node_number="1392"> <h2 class="valid" valid="valid" title="valid: True, node: 1393, tag: h2, level: 13" node_number="1393">(0)eLetters</h2> </div> <p class="valid" valid="valid" title="valid: True, node: 1394, tag: p, level: 12" node_number="1394">eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed. Please read our Terms of Service before submitting your own eLetter.</p> <a class="valid" valid="valid" title="valid: True, node: 1395, tag: a, level: 12" node_number="1395">Log In to Submit a Response</a> <p class="valid" valid="valid" title="valid: True, node: 1396, tag: p, level: 12" node_number="1396">No eLetters have been published for this article yet.</p> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 1397, tag: div, level: 10" node_number="1397"><a class="valid" valid="valid" title="valid: True, node: 1398, tag: a, level: 11" node_number="1398">View Full Text</a><a class="valid" valid="valid" title="valid: True, node: 1399, tag: a, level: 11" node_number="1399">Download PDF</a></div> </div></div></div></div><div class="valid" valid="valid" title="valid: True, node: 1400, tag: div, level: 6" node_number="1400"><div class="valid" valid="valid" title="valid: True, node: 1401, tag: div, level: 7" node_number="1401"><div class="valid" valid="valid" title="valid: True, node: 1402, tag: div, level: 8" node_number="1402"><div class="valid" valid="valid" title="valid: True, node: 1403, tag: div, level: 9" node_number="1403"><section class="valid" valid="valid" title="valid: True, node: 1404, tag: section, level: 10" node_number="1404"><div class="valid" valid="valid" title="valid: True, node: 1405, tag: div, level: 11" node_number="1405"><h4 class="valid" valid="valid" title="valid: True, node: 1406, tag: h4, level: 12" node_number="1406"> Current Issue </h4><div class="valid" valid="valid" title="valid: True, node: 1407, tag: div, level: 12" node_number="1407"><div class="valid" valid="valid" title="valid: True, node: 1408, tag: div, level: 13" node_number="1408"> <div class="valid" valid="valid" title="valid: True, node: 1409, tag: div, level: 14" node_number="1409"><div title="valid: False, node: 1410, tag: div, level: 15" node_number="1410"><article title="valid: False, node: 1411, tag: article, level: 16" node_number="1411"><div title="valid: False, node: 1412, tag: div, level: 17" node_number="1412"><div title="valid: False, node: 1413, tag: div, level: 18" node_number="1413"><h3 title="valid: False, node: 1414, tag: h3, level: 19" node_number="1414"><a title="valid: False, node: 1415, tag: a, level: 20" node_number="1415">Cell-by-cell dissection of phloem development links a maturation gradient to cell specialization</a></h3><ul title="valid: False, node: 1416, tag: ul, level: 19" node_number="1416"><li title="valid: False, node: 1417, tag: li, level: 20" node_number="1417">By<ul title="valid: False, node: 1418, tag: ul, level: 21" node_number="1418"> <li title="valid: False, node: 1419, tag: li, level: 22" node_number="1419">Pawel Roszak</li> <li title="valid: False, node: 1420, tag: li, level: 22" node_number="1420">Jung-ok Heo</li> <li title="valid: False, node: 1421, tag: li, level: 22" node_number="1421">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1422, tag: article, level: 16" node_number="1422"><div title="valid: False, node: 1423, tag: div, level: 17" node_number="1423"><div title="valid: False, node: 1424, tag: div, level: 18" node_number="1424"><h3 title="valid: False, node: 1425, tag: h3, level: 19" node_number="1425">The energetics of uniquely human subsistence strategies</h3><ul title="valid: False, node: 1426, tag: ul, level: 19" node_number="1426"><li title="valid: False, node: 1427, tag: li, level: 20" node_number="1427">By<ul title="valid: False, node: 1428, tag: ul, level: 21" node_number="1428"> <li title="valid: False, node: 1429, tag: li, level: 22" node_number="1429">Thomas S. Kraft</li> <li title="valid: False, node: 1430, tag: li, level: 22" node_number="1430">Vivek V. Venkataraman</li> <li title="valid: False, node: 1431, tag: li, level: 22" node_number="1431">et al.</li> </ul> </li></ul></div></div></article><article title="valid: False, node: 1432, tag: article, level: 16" node_number="1432"><div title="valid: False, node: 1433, tag: div, level: 17" node_number="1433"><div title="valid: False, node: 1434, tag: div, level: 18" node_number="1434"><h3 title="valid: False, node: 1435, tag: h3, level: 19" node_number="1435">Early giant reveals faster evolution of large body size in ichthyosaurs than in cetaceans</h3><ul title="valid: False, node: 1436, tag: ul, level: 19" node_number="1436"><li title="valid: False, node: 1437, tag: li, level: 20" node_number="1437">By<ul title="valid: False, node: 1438, tag: ul, level: 21" node_number="1438"> <li title="valid: False, node: 1439, tag: li, level: 22" node_number="1439">P. Martin Sander</li> <li title="valid: False, node: 1440, tag: li, level: 22" node_number="1440">Eva Maria Griebeler</li> <li title="valid: False, node: 1441, tag: li, level: 22" node_number="1441">et al.</li> </ul> </li></ul></div></div></article></div><div title="valid: False, node: 1442, tag: div, level: 15" node_number="1442">Table of Contents</div></div> </div></div></div></section><section class="valid" valid="valid" title="valid: True, node: 1443, tag: section, level: 10" node_number="1443"> <h4 class="valid" valid="valid" title="valid: True, node: 1444, tag: h4, level: 11" node_number="1444">LATEST NEWS</h4> <div class="valid" valid="valid" title="valid: True, node: 1445, tag: div, level: 11" node_number="1445"> <div class="valid" valid="valid" title="valid: True, node: 1446, tag: div, level: 12" node_number="1446"><div class="valid" valid="valid" title="valid: True, node: 1447, tag: div, level: 13" node_number="1447"> <article class="valid" valid="valid" title="valid: True, node: 1448, tag: article, level: 14" node_number="1448"> <div title="valid: False, node: 1449, tag: div, level: 15" node_number="1449"> <div title="valid: False, node: 1450, tag: div, level: 16" node_number="1450"> News<time title="valid: False, node: 1451, tag: time, level: 17" node_number="1451">30 Dec 2021</time> </div> <div title="valid: False, node: 1452, tag: div, level: 16" node_number="1452"> Airborne DNA from plants could reveal invasive species, impact of climate change </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1453, tag: article, level: 14" node_number="1453"> <div title="valid: False, node: 1454, tag: div, level: 15" node_number="1454"> <div title="valid: False, node: 1455, tag: div, level: 16" node_number="1455"> ScienceInsider<time title="valid: False, node: 1456, tag: time, level: 17" node_number="1456">29 Dec 2021</time> </div> <div title="valid: False, node: 1457, tag: div, level: 16" node_number="1457"> <a title="valid: False, node: 1458, tag: a, level: 17" node_number="1458"> Once a &#8216;crazy idea,&#8217; patent-pooling nonprofit will help bring COVID-19 pills to world&#8217;s poor </a> </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1459, tag: article, level: 14" node_number="1459"> <div title="valid: False, node: 1460, tag: div, level: 15" node_number="1460"> <div title="valid: False, node: 1461, tag: div, level: 16" node_number="1461"> ScienceInsider<time title="valid: False, node: 1462, tag: time, level: 17" node_number="1462">28 Dec 2021</time> </div> <div title="valid: False, node: 1463, tag: div, level: 16" node_number="1463"> The natural world loses two of its biggest advocates </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1464, tag: article, level: 14" node_number="1464"> <div title="valid: False, node: 1465, tag: div, level: 15" node_number="1465"> <div title="valid: False, node: 1466, tag: div, level: 16" node_number="1466"> ScienceInsider<time title="valid: False, node: 1467, tag: time, level: 17" node_number="1467">28 Dec 2021</time> </div> <div title="valid: False, node: 1468, tag: div, level: 16" node_number="1468"> <a title="valid: False, node: 1469, tag: a, level: 17" node_number="1469"> What the Charles Lieber verdict says about U.S. China Initiative </a> </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1470, tag: article, level: 14" node_number="1470"> <div title="valid: False, node: 1471, tag: div, level: 15" node_number="1471"> <div title="valid: False, node: 1472, tag: div, level: 16" node_number="1472"> ScienceInsider<time title="valid: False, node: 1473, tag: time, level: 17" node_number="1473">25 Dec 2021</time> </div> <div title="valid: False, node: 1474, tag: div, level: 16" node_number="1474"> NASA&#8217;s Webb telescope takes flight&#8212;a Christmas gift to astronomers everywhere </div> </div> </article> <article class="valid" valid="valid" title="valid: True, node: 1475, tag: article, level: 14" node_number="1475"> <div title="valid: False, node: 1476, tag: div, level: 15" node_number="1476"> <div title="valid: False, node: 1477, tag: div, level: 16" node_number="1477"> News<time title="valid: False, node: 1478, tag: time, level: 17" node_number="1478">23 Dec 2021</time> </div> <div title="valid: False, node: 1479, tag: div, level: 16" node_number="1479"> <a title="valid: False, node: 1480, tag: a, level: 17" node_number="1480"> More than a virus: Science&#8217;s areas to watch in 2022 </a> </div> </div> </article> </div></div> </div></section></div></div></div></div> </main> </div> </div> </div> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>